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SUMMARY 
 
Transcription of protein coding genes by RNA polymerase II (RNAPII) is an essential step 
in gene expression. Transcription elongation is a highly dynamic and discontinuous 
process that includes frequent pausing of RNAPII, backtracking, and arrest both in vitro 
and in vivo. Consequently, a multitude of transcription elongation factors are needed for 
efficient transcription elongation. When transcription elongation factors fail to “restart” 
RNAPII the persistently stalled RNAPII complex prevents transcription and thus has to be 
recognized and removed to free the gene for subsequent polymerases. Similarly, DNA 
damage causes stalling of RNAPII. In this case, the DNA damage is either repaired by 
Transcription-Coupled Repair (TCR) or RNAPII is degraded as a “last resort” mechanism 
by the ubiquitin proteasome system. In contrast to RNAPII degradation caused by DNA 
damage, the cellular pathway for removal of transcriptionally stalled RNAPII complexes 
has remained largely obscure. However, it was speculated that transcriptionally stalled 
RNAPII complexes are degraded by the same pathway as RNAPII stalled due to DNA 
damage. Here, it is shown that the pathway for degradation of transcriptionally stalled 
RNAPII is distinct from the DNA damage-dependent pathway, providing the first 
evidence that the cell distinguishes between RNAPII complexes stalled for different 
reasons. The novel cellular pathway for transcriptional stalling-dependent degradation of 
RNAPII is termed TRADE. Specifically, in the TRADE pathway a different yet 
overlapping set of enzymes is responsible for poly- and de-ubiquitylation of 
transcriptionally stalled RNAPII. Moreover, the catalytic 20S proteasome is recruited to 
transcribed genes indicating that Rpb1 of transcriptionally stalled RNAPII complexes is 
degraded at the site of transcription. Importantly, nucleotide starvation and temperature 
stress which might mimic natural conditions of transcription elongation impairment also 
lead to RNAPII degradation. Finally, this study provides the first evidence that the 
mechanism for the controlled degradation of the transcriptionally stalled RNA polymerase 
complex might also exist for transcription by RNAPI and RNAPIII. Taken together, the 
TRADE pathway elucidated in this study ensures continued transcription.  
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1. INTRODUCTION  
 
 
1.1.  THE CENTRAL DOGMA OF MOLECULAR BIOLOGY 
 
Gene expression is a fundamental cellular process through which a certain genotype 
results in the corresponding phenotype. In 1958 Francis Crick introduced the Central 
Dogma of Molecular Biology as the concept behind gene expression (Crick, 1970; 
Thieffry and Sarkar, 1998). The central dogma describes how the information-
containing deoxyribonucleic acid (DNA) is transcribed to the intermediate ribonucleic 
acid (RNA) which in turn becomes translated into proteins (Figure 1). 
 
 
 
 
 
 
Figure 1| The Central Dogma of Molecular Biology.  
 
 
The transcription from DNA to RNA is mediated by multiprotein complexes termed 
DNA-dependent RNA polymerases (RNAP). However, in 1970 it was discovered that 
reverse transcription can also take place in a reaction mediated by RNA-dependent DNA 
polymerases also known as reverse transcriptases (Baltimore 1970; Temin and Mizutani 
1970). Moreover, around the same time RNA replication was reported for RNA-viruses 
(Penhoet, Miller et al. 1971; Skehel 1971). The final step of gene expression for protein 
coding genes is the translation of the intermediate molecule RNA into proteins the 
molecules responsible for the phenotype. Translation is mediated by the ribosome, a large 
molecular weight complex made from RNAs and proteins.  
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1.2.  DNA-DEPENDENT RNA POLYMERASES 
 
Transcription in eukaryotes is performed by three DNA-dependent RNA polymerases 
(RNAPs), which are functionally and structurally related (Cramer, Armache et al. 2008). 
Each of them is a multisubunit complex responsible for the synthesis of different classes 
of RNA. Table 1 summarizes their subunit composition as well as the subunits shared in 
the yeast Saccharomyces cerevisiae (Archambault and Friesen 1993; Akira, Makoto et al. 
1998). 
 
 
Table 1| Subunit composition including subunits shared between S.cerevisiae RNA polymerases. 
Modified from (Cramer, Armache et al. 2008). Subunits which are unique to its enzyme are colored 
accordingly. 
 
 
 
RNA polymerase II (RNAPII) mediates transcription of protein-coding genes and many 
noncoding RNAs, including all spliceosomal small nuclear RNAs (snRNAs) except U6, 
small nucleolar RNAs (snoRNAs), microRNA (miRNA) precursors, and cryptic unstable 
transcripts (CUTs). RNA polymerase I (RNAPI) transcribes the abundant ribosomal 
RNAs (rRNAs), and RNA polymerase III (RNAPIII) transcribes noncoding RNAs such 
DNA-dependent RNA polymerase RNAPI RNAPII RNAPIII 
Enzyme Core  Rpa190 Rpb1  Rpc160 
Rpa135 Rpb2 Rpc128 
Rpc40 (AC40) Rpb3 Rpc40 (AC40) 
Rpa12 Rpb9 Rpc11 
Rpc19 (AC19) Rpb11 Rpc19 (AC19) 
Rpb5 (ABC27) Rpb5 (ABC27) Rpb5 (ABC27) 
Rpb6 (ABC23) Rpb6 (ABC23) Rpb6 (ABC23) 
Rpb8 (ABC14,5) Rpb8 (ABC14,5) Rpb8 (ABC14,5) 
Rpb10 (ABC10α) Rpb10 (ABC10α) Rpb10 (ABC10α) 
Rpb12 (ABC10β) Rpb12 (ABC10β) Rpb12 (ABC10β) 
Other subunits Rpa49 Rpb7 Rpc82 
Rpa43 Rpb4 Rpc53 
Rpa34  Rpc37 
Rpa14  Rpc34 
  Rpc31 
  Rpc25 
  Rpc17 
Total number of subunits 14 12 17 
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as transfer RNAs (tRNAs), 5S rRNA, and U6 spliceosomal snRNA. Recently, two 
additional types of RNAP were discovered in plants. These two RNAPII-related, plant-
specific enzymes, named RNAPIV and V, collaborate with proteins of the RNA 
interference machinery to generate long and short noncoding RNAs involved in 
epigenetic regulation (Till and Ladurner 2007; Matzke, Kanno et al. 2009).  
 
 
1.3.  MODIFICATION OF THE CARBOXYL-TERMINAL DOMAIN (CTD) OF 
RNAPII 
 
RNAPII is responsible for the transcription of all mRNA encoding genes. A unique 
feature of RNAPII that sets it apart from the other polymerases is the extended carboxyl-
terminal domain (CTD) of its largest subunit, Rpb1. The CTD of Rpb1 consists of a 
varying number of tandemly repeated heptapeptides with the consensus sequence Y1-S2-
P3-T4-S5-P6-S7 (Stiller and Hall 2002; Svejstrup 2004). The consensus repeat has been 
conserved in evolution although the number of repeats varies between different species. 
RNAPII of mammalian cells contains 52 copies of the consensus repeat, and S.cerevisiae 
contains 26–27 copies, whereas other eukaryotes contain an intermediate number of 
repeats (Stiller and Hall 2002). The CTD has modification-specific protein interactions 
through which RNAPII proceeds in the transcription cycle (see below). The CTD 
modifications include phosphorylation (mostly on Ser2 and Ser5), glycozylation, and 
cis/trans isomerization of prolines (Figure 2) (reviewed in (Lin, Tremeau-Bravard et al. 
2003)).   
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Figure 2| The CTD modifications. Most of the residues in the heptapeptide repeat of the CTD are 
subject to modification. Phosphorylation of the three serine residues and isomerization of the two proline 
residues are the main CTD modifications. Enzymes are colored according to their involvement in the 
modification of a specific site.  
 
 
Several proteins have been shown to regulate the phosphorylation status of the CTD 
(Bensaude, Bonnet et al. 1999). In S.cerevisiae Srb10 and Kin28 (CDK7 and CDK8 in 
mammals) phosphorylate the CTD at Ser5. Srb10 is also responsible for phosphorylating 
Ser2 (Hengartner, Myer et al. 1998; Sun, Zhang et al. 1998). The CTDK-I complex and 
the Bur1/2 complex (CDK9 in mammals) predominantly phosphorylate the CTD at 
Ser2 (Sterner, Lee et al. 1995; Cho, Kobor et al. 2001; Murray, Udupa et al. 2001). In 
S.cerevisiae, Ssu72 (SCP1 in mammals) is a Ser5 phosphatase and has been linked to all 
stages of transcription, from initiation to elongation and termination (Kim, Vasiljeva et 
al. 2006; Reyes-Reyes and Hampsey 2007). Another phosphatase, Fcp1 dephosphorylates 
both Ser2 and Ser5 in vitro (Cho, Kim et al. 1999; Lin, Marshall et al. 2002), although 
there are discrepancies as to whether there is preference towards one of these two sites 
(Sims, Belotserkovskaya et al. 2004). Upon termination, Fcp1 can recycle RNAPII 
molecules for new rounds of transcription (Cho, Kim et al. 1999).  
Furthermore, the CTD is also glycozylated by beta-O-linked GlcNAc on a subset of 
RNAPII molecules. Initially, it was hypothesized that the reason for this modification is 
the regulation of phosphorylation by sterically blocking sites of kinase action (Kelly, 
Dahmus et al. 1993). However, it was later discovered that the enzymes responsible for 
the glycozylation and phosphorylation of the CTD are mutually exclusive, suggesting 
that in vivo this could result in their differential association with the CTD at specific 
stages during the transcription cycle (Comer and Hart 2001).  
Finally, the phosphorylation-specific peptidyl-prolyl cis-trans isomerise Ess1 (PIN1 in 
mammals) was shown to regulate RNAPII transcription by altering the cis-trans ratio of 
proline-containing peptide bonds in the CTD (Verdecia, Bowman et al. 2000; Wu, 
Rossettini et al. 2003; Xu and Manley 2004)  
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Taken together, modification of the CTD most likely influences its conformation and 
thus its association with factors which function at different stages of transcription. 
Additionally, CTD modifications influence the recruitment of the mRNA processing 
machinery for capping, splicing, and polyadenylation of the message, to produce an 
export competent messenger ribonucleoprotein particle (mRNP) (reviewed in (Hirose 
and Ohkuma 2007)) . So there seems to be a "CTD code" that creates a differential 
scaffold for the enzymes that catalyse the next step of transcription. This code could 
ensure (i) the successful synchronization of the RNA processing reactions so that they 
occur in the correct order, (ii) the efficient transitions between the reactions, and (iii) the 
assurance that no step is omitted (Dahmus 1996; Orphanides and Reinberg 2002). 
Different CTD modifications are characteristic of the different transcription stages and 
are hence important for the progression through the transcription cycle.  
 
 
1.4.  THE TRANSCRIPTION CYCLE 
 
Gene transcription by RNAPII consists of different stages, whose recycling make up the 
transcription cycle (Figure 3). There are three main parts in the cycle, known as 
initiation, elongation and termination, and each of them is regulated by transcription 
factors (Bregman, Pestell et al. 2000; Panning and Taatjes 2008).  
During transcription initiation, non-phosphorylated RNAPII assembles at the core 
promoter together with several general transcription factors (GTFs) and coactivators 
(such as the Mediator) to form the preinitiation complex (PIC) (Bushnell, Westover et al. 
2004; Rani, Ranish et al. 2004; Chen, Warfield et al. 2007). In the PIC the dsDNA of 
the promoter is melted and thus becomes accessible to the polymerase. This results in the 
formation of a transcription bubble, i.e. the open complex (Brueckner, Ortiz et al. 2009). 
During transcription initiation the CTD is phosphorylated on Ser5 (Cho, Kobor et al. 
2001). It was shown that early in initiation the polymerase can produce abortive 
transcripts. These abortive cycles have been observed with a single RNAP releasing several 
transcripts without escaping the promoter (Venters and Pugh 2009). 
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Figure 3| The mRNA transcription cycle. There are three main parts in the cycle: initiation, elongation 
and termination. The transcribing complex, mostly through the CTD modifications, associates with 
different factors in the different stages. At the end of each cycle RNAPII is recycled and can enter a new 
round of transcription. 
 
 
 
RNAPII can then initiate template DNA-dependent mRNA synthesis. In the active site 
nucleotides are paired with the template and joined processively during elongation to 
produce the RNA transcript (Cramer, Bushnell et al. 2001). At the transition from 
promoter escape to processive transcription elongation, the levels of Ser5 phosphorylation 
are reduced and the CTD becomes mainly phosphorylated on Ser2 (Komarnitsky, Cho 
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et al. 2000). Termination of transcription involves the release of the RNA transcript and 
the dissociation of RNAPII from the DNA template (Richard and Manley 2009). Several 
studies showed that RNAPII termination is coupled to 3’-end processing of the pre-
mRNA (reviewed in (Buratowski 2005). The released RNAPII is then recycled and is 
able to enter a new round of transcription.  
 
 
1.5.  TRANSCRIPTION IS A HIGHLY DYNAMIC AND DISCONTINUOUS 
PROCESS  
 
Transcription is a fundamental step in gene expression and ensuring its continuation is 
important for the survival of the cell. Hence, it is one of the most regulated and complex 
processes requiring the function of numerous auxiliary factors (Arndt and Kane 2003; 
Hirose and Ohkuma 2007; Fuda, Ardehali et al. 2009). Most studies on transcriptional 
regulation have focused on promoter regulation and transcription initiation. Promoter-
proximal pausing is the phenomenon where RNAPII pauses at the 5’region of the open 
reading frame (ORF). It can then progress efficiently into productive elongation only in 
response to appropriate signals. Promoter-proximal pausing functions as a checkpoint 
before committing to productive elongation. Importantly, even though RNAPII can 
escape rapidly from the pause (Lis 1998) this escape continues to be a rate-limiting and 
regulatory step after gene induction (Giardina, Perez-Riba et al. 1992). 
However, there are more and more studies emerging suggesting that events subsequent to 
initiation could be tightly regulated. To that end, as demonstrated by in vitro studies 
with prokaryotic polymerases, the elongation step can be regulated by pausing for various 
times (Davenport, Wuite et al. 2000; Tadigotla, O'Maoileidigh et al. 2006). For 
eukaryotic cells, several studies attempted to shed light on the transcription rate of 
RNAPII. These included radioactive quantitative northern blot analysis (Thummel, 
Burtis et al. 1990), nuclear run-on assays (O'Brien and Lis 1993), chromatin 
immunoprecipitation (ChIP) of RNAPII on inducible genes (Mason and Struhl 2005), 
quantitative reverse transcription PCR (q-RT PCR) following induction of expression 
(Tennyson, Klamut et al. 1995), and in situ visualization of specific mRNAs (Femino, 
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Fay et al. 1998). In these studies, elongation was thought to be continuous with a 
calculated rate from 1,1-2,4 kb/min. However, recent studies in living mammalian cells 
gave new insights into the in vivo kinetics of RNAPII transcription and introduced the 
concept of frequent RNAPII pausing instead of continuous RNAPII transcription 
(Figure 4) (Darzacq, Shav-Tal et al. 2007; Pelechano, Jimeno-Gonzalez et al. 2009; 
Singh and Padgett 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4| Schematic representation of RNAPII pausing during transcription. 
RNAPII transcription was considered to be a continuous process (A). However, recent data showed that 
transcription is discontinuous (B) as it involves frequent pausing of the transcribing RNAPII across the 
ORF with a calculated maximum time of four minutes.  
 
 
 
Interestingly, it was shown that only a minor fraction of the polymerases assembling at 
the promoter ultimately produce a transcript. More importantly in about 4% of these 
polymerases that enter elongation there is frequent pausing and arrest of RNAPII. Based 
on the experimental data, RNAPII elongation was divided into two subclasses: rapid 
elongation occurring at a speed of 4,3kb/min (up to four times faster than once thought) 
A 
B 
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and probabilistic pausing that can last for up to four minutes. However, due to technical 
limitations it could not be distinguished whether a single polymerase was engaging in 
multiple short pauses or in one long arrest. Furthermore, another study that applied the 
same methodology found that transcription by RNAPI is also rather inefficient (Dundr, 
Hoffmann-Rohrer et al. 2002).  
A number of proteins facilitate paused RNAPII complexes to resume transcription 
(Awrey, Weilbaecher et al. 1997; Nesser, Peterson et al. 2006; Ardehali and Lis 2009). 
Nevertheless, it was suggested that the frequent pausing of RNAPII could lead to its 
irreversible arrest (Svejstrup 2007; Margaritis and Holstege 2008; Daulny and Tansey 
2009), an event that would prevent continuation of transcription and subsequently cell 
viability.   
 
 
1.6. TRANSCRIPTION ELONGATION FACTORS 
 
Transcription elongation by RNAPII is regulated at different stages by auxiliary protein 
factors (Saunders, Core et al. 2006). There are three main categories of transcription 
elongation factors. The first, a typical example of which is TFIIS, re-activates elongation 
complexes that have paused or arrested during elongation (Wind and Reines 2000). The 
second class, which includes among others the CTDK-I and the Bur1/2 kinase 
complexes, facilitates escape of the elongation complex from the promoter (Cho, Kobor 
et al. 2001; Jona, Wittschieben et al. 2001; Keogh, Podolny et al. 2003). Finally, in the 
third class, proteins such as Spt4/Spt5 and the THO complex have been shown to 
increase the general efficiency of elongation (Hartzog, Wada et al. 1998; Jimeno, Rondon 
et al. 2002; Strasser, Masuda et al. 2002; Rondon, Jimeno et al. 2003).  
 
 
1.6.1. The CTDK-I kinase complex 
 
The CTDK-I complex is composed of three subunits, Ctk1, Ctk2, and Ctk3. Ctk1, a 
cyclin-dependent kinase, is the catalytic subunit, Ctk2 is the cyclin, while Ctk3 shows no 
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similarity to other known proteins (Sterner, Lee et al. 1995). The assembly of those three 
subunits leads to an active protein kinase complex that phosphorylates the CTD of 
RNAPII on Ser2 of the heptapeptide YSPTSPS repetitive sequence (see Introduction 
1.3). Ctk1 is suggested to be the primary Ser2 kinase during transcription elongation 
(Cho, Kobor et al. 2001). Even though the CTK1 gene is not essential its deletion results 
in a severe growth defect (Ostapenko and Solomon 2005).  
The CTDK-I complex is involved in multiple steps of transcription. Ctk1 plays a role in 
(i) the release of basal transcription factors from RNAPII as it enters productive 
elongation (Ahn, Keogh et al. 2009), (ii) coupling transcription elongation to 3’ end 
processing and transcription termination (Ahn, Kim et al. 2004; Ni, Schwartz et al. 
2004), (iii) splicing (Morris and Greenleaf 2000), (iv) methylation of histones (Xiao, 
Shibata et al. 2007) and (v) DNA damage-induced transcription (Ostapenko and 
Solomon 2003). Furthermore, Ctk1 is most likely involved in the control of transcription 
elongation since it modulates the elongation efficiency of RNAPII in mammalian HeLa 
extracts (Lee and Greenleaf 1997) and interacts genetically with various factors that 
control transcription elongation (Jona, Wittschieben et al. 2001; Hurt, Luo et al. 2004).   
Surprisingly, Ctk1 was also found to play a role in RNAPI transcription (Bouchoux, 
Hautbergue et al. 2004) and in translation elongation by phosphorylation of the 
ribosomal protein Rps2 (Rother and Strasser 2007).   
 
 
1.6.2. The elongation cleavage factor TFIIS 
 
The elongation factor TFIIS (also called Dst1) is an RNA cleavage stimulatory factor that 
enables RNAPII to escape arrest during transcription elongation. Dst1 binds to the 
stalled complex and stimulates RNAPII’s intrinsic cleavage activity for the nascent RNA. 
This cleavage allows RNAPII to resume transcription by placing the 3’ end of the 
transcript in the active site of the enzyme (Wind and Reines 2000). By structural studies 
it became evident that the C-terminus of Dst1 is able to reach deeply into the RNAPII 
secondary channel, approaching the catalytic site of the polymerase (Kettenberger, 
Armache et al. 2003). This proximity between Dst1 and the nascent RNA may trigger 
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the endogenous nuclease activity of RNAPII, which permits the stalled complex to restart 
the elongation (Prather, Larschan et al. 2005). 
Mutations in the DST1 gene cause sensitivity to 6-Azauracil (6AU) (Mason and Struhl 
2005), a drug that depletes cellular GTP/UTP levels and is thus used as a phenotypic 
marker for transcription elongation impairment (Exinger and Lacroute 1992). Moreover, 
DST1 genetically interacts with various components of the transcription elongation 
machinery such as Spt4/Spt5 (Wind and Reines 2000; Lindstrom and Hartzog 2001) 
and references therein). Furthermore, upon stress conditions such as low temperature, 
heat shock, or the presence of 6AU in the growth medium, Dst1 was found to be 
recruited to the ORF of several genes (Pokholok, Hannett et al. 2002). In addition to its 
role in transcription elongation, some studies have indicated that Dst1 may also play a 
role in transcription initiation (Davie and Kane 2000; Malagon, Tong et al. 2004; 
Guglielmi, Soutourina et al. 2007). Finally, Dst1 was recently found to play a role in 
RNAPIII transcription (Ghavi-Helm, Michaut et al. 2008).  
 
 
1.6.3. The THO complex 
 
The THO complex is a nuclear protein complex conserved from yeast to human that is 
involved in the biogenesis of mRNP particles which are then exported from the nucleus 
(reviewed in (Jimeno and Aguilera 2010). In S.cerevisiae, the RNAPII-associated THO 
complex consists of the four proteins Mft1, Hpr1, Tho2 and Thp2. None of these THO 
components are essential for cell viability. However, deletion of each of these four genes 
results in similar phenotypes indicating that THO is a functional and physical unit. 
Specifically, it was shown that the THO complex is important for the formation of the 
correct mRNP particle since it prevents the nascent RNA from interacting with the DNA 
template (Huertas and Aguilera 2003). Such an interaction would lead to the formation 
of a DNA-RNA hybrid, also known as R-loop, which would prevent elongation by the 
next polymerase (Huertas, Garcia-Rubio et al. 2006). The formation of R-loops has been 
linked to hyper-recombination, a phenotype observed in all the deletion mutants of 
THO (Chavez, Beilharz et al. 2000; Jimeno, Rondon et al. 2002). Additionally, the 
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THO complex is present at actively transcribed genes over the entire length of the ORF 
(Strasser, Masuda et al. 2002; Zenklusen, Vinciguerra et al. 2002; Kim, Ahn et al. 2004) 
and is needed for efficient transcription elongation (Chavez and Aguilera 1997; Piruat 
and Aguilera 1998; Chavez, Beilharz et al. 2000; Strasser, Masuda et al. 2002; Rondon, 
Jimeno et al. 2003). Moreover, several studies showed that the THO complex is a 
conserved nuclear factor with a key function in mRNP biogenesis and export (Strasser, 
Masuda et al. 2002; Zenklusen, Vinciguerra et al. 2002; Huertas, Garcia-Rubio et al. 
2006; Rougemaille, Dieppois et al. 2008) as well as in development and cell 
differentiation (Wang, Chang et al. 2006; Wang, Chinnam et al. 2009). For its function 
in mRNA export, the THO complex interacts with Sub2 and Yra1 (mRNA export 
factors), Gbp2 and Hrb1 (SR-like proteins) and Tex1 to form the so called TREX 
complex that couples TRanscription to mRNA EX
 
port (Strasser and Hurt 2000; Strasser 
and Hurt 2001).  
 
1.6.4. The Bur1/Bur2 kinase complex 
 
The BUR kinase complex, which consists of the cyclin-dependent kinase Bur1, a protein 
essential for viability, and the corresponding cyclin Bur2 (Yao, Neiman et al. 2000) was 
shown to be important for efficient transcription elongation (Keogh, Podolny et al. 
2003). Deletion of BUR2 results in an impaired growth phenotype. The Bur1 kinase 
phosphorylates the CTD of RNAPII in vitro (Murray, Udupa et al. 2001) and in vivo 
(Qiu, Hu et al. 2009). Furthermore, Bur1 binds to initiating RNAPII since it copurifies 
with the Ser5 phosphorylated form of the enzyme (Lindstrom and Hartzog 2001). As 
another in vitro substrate of Bur1 the E2 ubiquitin-conjugating enzyme Rad6 was 
identified. Subsequently, the Rad6 phosphorylation leads to  the ubiquitylation of 
histone H2B on K123 (Wood, Schneider et al. 2005) which in turn is required for 
H3K4 methylation (a histone modification present at actively transcribed genes) by the 
COMPASS complex (Wood, Schneider et al. 2003; Wood, Schneider et al. 2005; Lee, 
Shukla et al. 2007).  Finally, a recent study identified the protein Spt5 as an in vivo 
substrate of the Bur1/2 kinase complex (Zhou, Kuo et al. 2009). Based on this finding 
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and since Spt5 promotes RNAPII transcription elongation (Hartzog, Wada et al. 1998) it 
was proposed that the effect of Bur1/2 in transcription elongation is partially mediated 
by the phosphorylation of Spt5 in its C-terminal region (CTR) (Zhou, Kuo et al. 2009). 
Furthermore, combining the deletion of the CTR of Spt5 with a C-terminal TAP-tag on 
RAD6 (the other Bur1 substrate) resulted in a severe growth phenotype. This synthetic 
sickness phenotype suggests that the requirement of the BUR1 gene for cell viability 
could be due to the fact that the kinase phosphorylates both Rad6 and the Spt5 (Zhou, 
Kuo et al. 2009).  
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1.7.  THE UBIQUITIN-PROTEASOME PATHWAY (UPP) 
 
The degradation of a protein is mediated through two distinct pathways. The first one 
involves the degradation of extracellular proteins that are taken up by the cell via 
endocytosis and are then transferred through a series of vesicles to primary lysosomes 
where they are degraded. This kind of degradation is not specific and all proteins that are 
taken up by the lysosomes are degraded at more or less the same rate (reviewed in 
(Todde, Veenhuis et al. 2009). The observation that the different intracellular proteins 
have different half-lives led to the prediction that there is another pathway for protein 
degradation, one that should have a high degree of specificity towards its substrate. The 
finding of the UPP verified this prediction (Etlinger and Goldberg 1977; Ciehanover, 
Hod et al. 1978). 
Protein degradation by the UPP comprises two successive steps. First, a polyubiquitin 
chain that consists of covalently linked ubiquitin molecules is attached to the target. 
Second, the polyubiquitylated substrate is degraded by the 26S proteasome complex in a 
reaction that recycles the ubiquitin molecules. A schematic representation of the pathway 
is shown in Figure 5.  
 
 
1.7.1. Polyubiquitylation of the substrate 
 
Ubiquitin is a 76 amino acid globular protein that is highly conserved throughout 
evolution. The attachment of the polyubiquitin chain to the substrate is a three-step 
process (Figure 5, left pannel) (Pickart 2004). The first step is an ATP-required reaction 
mediated by the ubiquitin-activating enzyme also known as E1. During this reaction the 
E1-S~intermediate is generated which contains a high-energy thiol-ester bond (S). Then 
one of the several ubiquitin-conjugating enzymes, called E2s, generates a high-energy 
thiol-ester E2-S~ubiquitin intermediate. The third step depends on the type of the 
ubiquitin-protein ligase E3 that is used for each specific substrate. There are two main 
types of E3 ligases (Ardley and Robinson 2005). In the first type the E3 of the RING-
finger/U-box family recognizes the substrate to allow ubiquitin transfer directly from the 
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E2. In the second type the E3 of the HECT domain E3 family recognizes the substrate 
directly and ubiquitylates it. Here, the ubiquitin transfer is from the E2 to the E3 and 
then to the substrate. In the case of the HECT E3s, a third high-energy thiol ester E3-
S~ubiquitin intermediate is generated, before the activated ubiquitin molecule is 
transferred to the E3-bound substrate. In any case, the final step is the covalent 
conjugation of ubiquitin to the substrate by the E3 enzyme.  
 
Figure 5| Schematic representation of the UPP. Degradation of a protein by the UPP is divided into 
two main steps; polyubiquitylation of the substrate (left panel) followed by its proteasome-mediated 
degradation (right panel.). See text for details  
 
Successive steps of this reaction result in the further addition of ubiquitin molecules on 
the substrate. A polyubiquitin chain is then formed and each ubiquitin is linked with the 
previous and the next molecule via an internal lysine residue of ubiquitin (reviewed in 
(Hochstrasser 1996; Hershko and Ciechanover 1998; Hochstrasser, Johnson et al. 1999; 
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Glickman and Ciechanover 2002).  In S.cerevisiae, all seven lysine residues (K6, K11, 
K27, K29, K33, K48 and K63) of ubiquitin can be used for chain formation, resulting in 
chains of different topologies. These lysines are used in the frequency order of K48>K63 
& K11>>K33, K27, K29 and K6 (Peng, Schwartz et al. 2003).  Of these chains, the best 
understood type is the polyubiquitin chain linked through K48 of ubiquitin. K48-linked 
chains with a length of four or more ubiquitins serve as the predominant proteasome-
targeting signal (Thrower, Hoffman et al. 2000; Pickart and Fushman 2004). K11- and 
K29-linked chains are also involved in proteasome dependent protein degradation 
(Baboshina and Haas 1996; Koegl, Hoppe et al. 1999; Jin, Williamson et al. 2008). In 
contrast, K63-linked chains and mono-ubiquitylation are generally thought to function 
in proteasome-independent processes such as DNA repair, signal transduction and 
receptor endocytosis in vivo (Hicke 2001; Pickart and Fushman 2004). However, a 
number of in vitro (Hofmann and Pickart 2001; Lee and Sharp 2004; Kim, Kim et al. 
2007) and in vivo studies (Saeki, Kudo et al. 2009) suggest that K63-linked chains also 
support the proteasomal degradation of the substrate. Much less is known about the 
functions of chains with other topologies (Figure 6). The polyubiquitin chain is then 
recognised by the downstream 26S proteasome complex.  
 
 
 
 
 
 
 
 
 
Figure 6| Lysine-specific ubiquitin chains serve different functions. Different lysine residues of 
ubiquitin can be used for chain formation, resulting in chains of different topologies. K48 and K63 are the 
two mostly used lysines. K48-specific chains serve mainly for degradation while K63-specific chains serve 
mainly for regulatory purposes as well as degradation. See text for details 
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1.7.2. Degradation by the 26S Proteasome  
 
The proteasome is a multicatalytic protease composed of a 20S core particle, which 
catalyses the degradation of polyubiquitylated proteins into small peptides, and two 19S 
regulatory particles (Figure 7). The catalytic component of the proteasome, the 20S 
particle, is a cylindrical chamber of 28 subunits that form two identical inner β-rings and 
two identical outer α-rings (Figure 7, green subunits) (reviewed in (Hanna and Finley 
2007; Tanaka 2009). The general structure is α7β7α7β7. Three of the β-subunits –β1, β2 
and β5– contain the six active sites of the particle. The active site is a single threonine 
residue that is located at the amino-terminus of the β subunits (Groll, Ditzel et al. 1997; 
Unno, Mizushima et al. 2002). The 20S core is capped at each end by a 19S particle. 
This particle has two multisubunit components: the “base”, which is composed of six 
ATPases and two non-ATPases, and the “lid”, which includes 8 non-ATPase subunits 
(Figure 7, black subunits) (Glickman, Rubin et al. 1998). The functions of the 19S 
component include: (i) recognition of polyubiquitylated proteins, (ii) formation of an 
opening in the α-ring by which the entry of the target protein into the proteolytic 
chamber is allowed, and (iii) presumably unfolding of the substrate and its introduction 
into the catalytic particle. The six different ATPase subunits provide the energy required 
for most of the 19S functions (Glickman, Rubin et al. 1999).   
After the degradation of the polyubiquitylated protein the proteasome releases small 
peptides derived from the substrate as well as reusable ubiquitin (Figure 5, right pannel). 
 
 
Figure 7| Schematic repre-
sentation of the 26S protea-
some.  
The 26S proteasome compri-
ses of (i) the barrel-like 20S 
catalytic core which is built by 
two β-rings and two α-rings 
and (ii) the two 19S particles, 
each consisting of the base and 
the lid, that cap either side of 
the barrel  
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1.7.3. Deubiquitylation of the substrate  
 
Polyubiquitylation of proteins is a reversible process. Deubiquitylation is mediated by 
specialized proteases that are called deubiquitylating enzymes (DUBs). DUBs belong to a 
large and diverse group of proteases that specifically cleave ubiquitin from ubiquitin-
conjugated protein substrates, ubiquitin precursors, ubiquitin adducts and polyubiquitin 
(reviewed in (Ventii and Wilkinson 2008). For deubiquitylation of a substrate, the DUB 
either hydrolyzes the amide bond between the terminal ubiquitin and the substrate or 
cleaves the isopeptide bond formed between two ubiquitin molecules (Pickart and Rose 
1985; Wilkinson 1997; D'Andrea and Pellman 1998). Based on their molecular size, 
sequence homology, and active site residues, DUBs are categorized as UCHs (ubiquitin 
COOH-terminal hydrolyses) or UBPs (ubiquitin-specific proteases). In S. cerevisiae, there 
are at least 17 different DUBs, 16 of which are of the UBP family. None of those is 
encoded by an essential gene, suggesting that they have overlapping functions 
(Hochstrasser 1996).  
Deubiquitylation has been implicated in numerous cellular functions, including cell cycle 
regulation (Song and Rape 2008), proteasome-and lysosome-dependent protein 
degradation (Guterman and Glickman 2004; Komada 2008), gene expression (Daniel 
and Grant 2007), DNA repair (Kennedy and D'Andrea 2005) and kinase activation 
(Adhikari, Xu et al. 2007; Komada 2008). Additionally, the DUBs are involved in 
maintaining the steady state levels of free ubiquitin and in affecting the stability of 
ubiquitylated proteins (Chung and Baek 1999; Wilkinson 2000). Finally, in S. cerevisiae 
two deubiquitylases, Rpn11 (POH1 in mammals) and Ubp6 (USP14 in mammals), have 
been shown to associate with the proteasome. These DUBs remove polyubiquitin chains 
from substrates during proteasomal degradation and upon inhibition of their function a 
monoubiquitylated substrate can transform into an efficient proteasome substrate 
(Guterman and Glickman 2004).  
Although some substrates have been identified for a handful of DUBs, the substrates and 
physiological roles of most DUBs are poorly defined.  
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1.7.4. Non-proteolytic roles of the UPP in transcription 
 
The proteasome is known to function in transcription independently of its proteolytic 
function. Initially, it was shown that the proteasomal ATPases of the 19S particle 
stimulate transcriptional initiation and elongation without engaging in protein 
degradation. Specifically, two 19S components, Sug1 and Sug2, were recruited to 
promoters but also to the entire ORF after gene activation, while components of the 20S 
particle were not (Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002; 
Gonzalez, Delahodde et al. 2002; Sulahian, Sikder et al. 2006). Moreover, mutations in 
19S components give rise to phenotypes consistent with an elongation defect (Ferdous, 
Gonzalez et al. 2001). Additionally, a genome-wide analysis of proteasome gene 
recruitment revealed that several hundred yeast genes had either the 20S or the 19S 
complex present but not both, suggesting  some degree of independent function for the 
proteasomal sub-complexes (Sikder, Johnston et al. 2006). This finding was further 
corroborated by another genome-wide study showing the existence of a 19S-independent 
20S complex and a 20S-independent ATPase-containing complex (Auld, Brown et al. 
2006). 
 
 
 
 
 
 
 
 
 
 
Figure 8| How the proteasome regulates transcription.  
The proteasome regulates many aspects of transcription through both proteolytic (red) and non-proteolytic 
mechanisms (green). The non proteolytic roles include (a) interaction between the proteasome and 
chromatin (d) non-proteolytic stimulation of a co-activator and (g) promoting of efficient transcription 
elongation by 19S base subunits. Figure taken from (Collins and Tansey 2006). 
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Furthermore, since components of 19S genetically interact with the FACT elongation 
complex, which remodels histones during elongation, it was speculated that the 
unfolding activity of the 19S complex could facilitate elongation by promoting histone 
ejection, movement or exchange (Collins and Tansey 2006). In another study it was 
shown that the 19S complex can use the energy of ATP hydrolysis to drive stable 
complex formation of the SAGA complex during transcription initiation, indicating that 
the 19S can act both in early and late steps in the transcription process (Lee, Ezhkova et 
al. 2005). Other aspects of transcription are also influenced by 19S proteins since H3 
methylation, a modification present in actively transcribed genes, requires proper 
function of the 19S components Rpt4 and Rpt6 (Ezhkova and Tansey 2004). Another 
non-proteolytic function of the UPP in transcription is the stimulation of transcription 
activators by monoubiquitylation (Salghetti, Caudy et al. 2001; Greer, Zika et al. 2003; 
Rajendra, Malegaonkar et al. 2004). However, there are data showing that this mono-
ubiquitylation may be coupled to polyubiquitylation events that result in their 
subsequent degradation by the proteasome ((Kodadek, Sikder et al. 2006) and references 
therein). This is also supported by observations where activators and other transcription 
factors must be recycled regularly in a proteasome-dependent fashion to achieve high 
level of gene expression (Lee, Ezhkova et al. 2005; Lipford, Smith et al. 2005). 
Taken together, it has become evident that non-proteolytic, as well as proteolytic, roles of 
the UPP are necessary for the transcription of many genes. 
 
 
1.8. UBIQUITYLATION AND PROTEASOME-MEDIATED DEGRADATION OF 
RNAPII UPON DNA DAMAGE 
 
 
The integrity of the genetic information, i.e. of cellular DNA, is constantly threatened by 
both endogenous and exogenous sources, including oxygen radicals within cells, 
environmental UV light, ionizing radiation and other genotoxic agents. All these sources 
can lead to DNA damage (Ljungman and Lane 2004). In turn, DNA damage can result 
not only in the inheritance of compromising genetic mutations, but it can also lead to 
significant and immediate changes of gene expression (Putnam, Jaehnig et al. 2009). 
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More importantly, bulky DNA adducts that occur within transcribed regions of the 
genome can cause the irreversible arrest of RNAPII, which blocks the expression of the 
damaged ORFs and consequently promotes cell death (Figure 9C) (Svejstrup 2003).  
More than 20 years ago it was recognized that DNA lesions in the transcribed strand of 
an active gene are removed at a much higher rate than those in the non-transcribed 
strand or in the genome overall (Bohr, Smith et al. 1985; Mellon, Spivak et al. 1987). 
The cellular mechanism responsible for this removal is called Transcription Coupled 
Repair (TCR). TCR –a highly conserved process from E. coli to human– is a type of 
nucleotide excision repair (NER) that uses transcribing RNAPII as a sensor of DNA 
damage and directs the NER machinery to damaged sites in the genome ((Hanawalt and 
Spivak 2008) and references therein). This process is most likely triggered by the arrest of 
RNAPII at the site of DNA damage (Svejstrup 2007) and it allows rapid removal of 
DNA adducts from active genes (Figure 9A). Thus, TCR is an important cellular 
response for ensuring continued transcription. In humans, TCR is mediated by 
Cockayne syndrome A and B proteins (CSA and CSB) (Bregman, Halaban et al. 1996), 
while in S. cerevisiae by Rad26, the homolog of human CSB (van Gool, Verhage et al. 
1994), and by Rpb9, a nonessential subunit of RNAPII (Li and Smerdon 2002).  
However, if TCR fails the stalled RNAPII is removed from the site allowing the more 
general Global Genome Repair (GGR) pathway to repair the DNA damage (Figure 9B). 
The removal of RNAPII from the site of DNA damage is mediated by the UPP (Somesh, 
Reid et al. 2005). Polyubiquitylation and degradation of RNAPII was first thought to 
occur specifically in response to DNA damage (Bregman, Halaban et al. 1996; Ratner, 
Balasubramanian et al. 1998), but in fact this degradation of RNAPII is a ‘‘last resort” 
mechanism, used in order to clear active genes from persistently arrested RNAPII 
elongation complexes (Woudstra, Gilbert et al. 2002; Somesh, Reid et al. 2005). 
Specifically, in S. cerevisiae the switch from repair to degradation is mediated by the TCR 
protein Rad26 and the Degradation factor protein Def1 (Figure 9). It is believed that 
Rad26 inhibits RNAPII ubiquitylation or degradation, enabling the transcription block 
to first be sampled by TCR factors. If repair of the DNA damage fails Def1 promotes 
ubiquitylation or degradation of arrested polymerase complexes (Woudstra, Gilbert et al. 
2002), so that repair can take place by GGR. Interestingly, in S.cerevisiae the positive 
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effect of Rad26 on RNAPII stability upon DNA damage is in contrast to the one 
observed in higher eukaryotes, where CSB (and CSA) are necessary for efficient RNAPII 
degradation upon DNA damage (Bregman, Halaban et al. 1996; Ratner, 
Balasubramanian et al. 1998).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 | DNA damage induces either TCR or UPP-mediated removal of RNAPII.   
Upon DNA damage the transcribing complex becomes irreversibly stalled. Blocking of transcription might 
lead to cell death (C). To ensure continuation of transcription, the damage is either repaired by TCR (A) 
or as a “last resort” mechanism RNAPII is polyubiquitylated and degraded by the UPP, an action which 
allows the GGR pathway to repair the damage (B). See text for details.    
A B 
C 
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The molecular mechanism for the polyubiquitylation of RNAPII upon DNA damage is 
well characterized by a number of studies in several different experimental systems 
(summarized in Figure 9B) (Bregman, Halaban et al. 1996; Beaudenon, Huacani et al. 
1999; Gillette, Gonzalez et al. 2004; Somesh, Reid et al. 2005; Somesh, Sigurdsson et al. 
2007; Kvint, Uhler et al. 2008; Yasukawa, Kamura et al. 2008; Harreman, Taschner et 
al. 2009). For degradation of RNAPII, its largest subunit Rpb1 is polyubiquitylated by 
the ubiquitin-conjugating enzymes (E2s) Ubc4 and Ubc5 and the ubiquitin ligases (E3s) 
Rsp5 and Elc1 (Beaudenon, Huacani et al. 1999; Reid and Svejstrup 2004; Somesh, Reid 
et al. 2005; Ribar, Prakash et al. 2007; Malik, Bagla et al. 2008; Harreman, Taschner et 
al. 2009).  Unlike many E2s, Ubc5 plays an active role in the recognition of its substrate 
and binds directly to Rpb1 via a region called the “switch 2” domain of RNAPII 
(Somesh, Sigurdsson et al. 2007). Critically, this domain only becomes structured when 
the polymerase is in its elongating form (Cramer, Bushnell et al. 2001). By recognizing a 
structural feature within RNAPII that is determined by its activity, Ubc5 can direct its 
ubiquitylation abilities preferentially to the DNA/RNAPII/RNA ternary complex. Along 
these lines, the HECT E3 ligase, Rsp5, can only bind RNAPII via the Ser2 
phosphorylated form of the CTD (Huibregtse, Yang et al. 1997; Somesh, Reid et al. 
2005). Thus, Rsp5 uses the phosphorylation state of the CTD of Rpb1 to sense the 
transcriptional status of RNAPII. The combined action of Ubc5 and Rsp5 in directing 
ubiquitylation of only elongating RNAPII ensures that DNA damage will not cause 
unnecessary degradation of cellular polymerase, but rather only of polymerase that needs 
to be cleared away to restore normal transcription. 
The E2s Ubc4 and Ubc5 function redundantly, whereas the E3s Rsp5 and Elc1 function 
sequentially, with Rsp5 mono-ubiquitylating Rpb1 and Elc1 adding a K48-linked 
polyubiquitin chain. In addition, Rsp5 produces non-functional K63-linked 
polyubiquitin chains (Harreman, Taschner et al. 2009). The polyubiquitin chain is 
attached in two distinct ubiquitylation sites on Rpb1, K330 and K695. These two sites 
are more than 125 Ǻ apart and their modification is coordinated in vitro as well as in 
vivo, suggesting that an E2/E3/RNAPII complex is assembled that depends on not only 
the RNAPII CTD but also on the Rpb1 ubiquitylation sites themselves (Somesh, 
Sigurdsson et al. 2007). 
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The polyubiquitylated Rpb1 is then degraded by the 26S proteasome. Rpb1 is the only 
RNAPII subunit degraded upon DNA damage (Malik, Bagla et al. 2008). Through the 
specific degradation of Rpb1, the stalled complex is most likely released from the site of 
the DNA damage and the damage becomes accessible for repair. However, when the 
DNA damage is repaired before Rpb1 is degraded, polyubiquitylated Rpb1 is 
deubiquitylated by the ubiquitin proteases Ubp2 and Ubp3 and spared from degradation 
(Kvint, Uhler et al. 2008; Harreman, Taschner et al. 2009). Rsp5 and Ubp2 interact 
with each other (Kee, Lyon et al. 2005; Lam, Urban-Grimal et al. 2009), and Ubp2 is 
capable of hydrolyzing K63 chains to produce mono-ubiquitylated RNAPII. In contrast 
to Ubp2, Ubp3 ‘rescues’ RNAPII from degradation by hydrolyzing K48-linked ubiquitin 
chains (Kvint, Uhler et al. 2008) and by producing completely de-ubiquitylated 
polymerase. Thus, Ubp2 and Ubp3 appear to have temporally distinct roles in the 
deubiquitylation of RNAPII upon DNA damage.  
Taken together, upon DNA damage there is an immediate cellular response to restore the 
genetic information via TCR. However, if this fails the cell employs the “last resort” 
mechanism of polyubiquitylation and degradation of the stalled RNAPII. This action 
enables the more general GGR pathway to repair the damage thus allowing efficient 
transcription of the gene (Figure 9B).  
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1.9. AIM OF THIS STUDY 
 
 
Continued transcription is important for the survival of the cell. Transcription is one of 
the most regulated and complex cellular processes. Regulation occurs via the function of a 
large number of proteins (Arndt and Kane 2003; Saunders, Core et al. 2006; Hirose and 
Ohkuma 2007; Panning and Taatjes 2008; Fuda, Ardehali et al. 2009). To that end it is 
not surprising that the causes of several human diseases have been attributed to 
transcriptional impairment (Conaway and Conaway 1999; Engelkamp 2000). 
Transcription elongation is a highly complex and discontinuous process including 
frequent pausing of the mRNA synthesizing enzyme RNAPII (Neuman, Abbondanzieri 
et al. 2003; Darzacq, Shav-Tal et al. 2007; Ardehali and Lis 2009; Pelechano, Jimeno-
Gonzalez et al. 2009). Interestingly, it became evident that RNAPII pausing and arrest is 
a common phenomenon observed in vivo in about 4% of the polymerases that enter 
elongation(Darzacq, Shav-Tal et al. 2007). In order to reduce the negative effects of such 
events and to prevent irreversible arrest of the transcribing complex, a number of proteins 
have been reported to allow RNAPII to resume transcription (Awrey, Weilbaecher et al. 
1997; Nesser, Peterson et al. 2006; Ardehali, Yao et al. 2009).  
But what if this fails? In this case the irreversibly stalled RNAPII would block 
transcription of the gene and compromise cell viability. So, the arrested RNAPII has to 
be recognized and degraded to free the gene for subsequent polymerases. The cellular 
pathway for removal of these RNAPII complexes is not known. 
The aim of this study was to elucidate the molecular mechanism employed by the cell 
upon transcriptional stalling of RNAPII. Initially, it should be assessed whether the 
transcriptionally stalled RNAPII complex is recognized and degraded by the UPP. 
Furthermore, for UPP-mediated degradation to take place a polyubiquitin chain has to 
be attached to RNAPII. To that end, this study aimed to identify which ubiquitin-
modifying enzymes are involved in the poly- and de-ubiquitylation of RNAPII. 
Moreover, since UPP-mediated degradation of RNAPII is also a cellular response to 
DNA damage it should be addressed whether the two pathways employed by the cell are 
identical, overlapping or completely different. In fact, since Ubc4 and Ubc5 are needed 
for polyubiquitylation of Rpb1 in response to transcriptional stalling (Somesh, Reid et al. 
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2005), it was speculated that transcriptionally stalled RNAPII complexes are degraded by 
the same pathway as RNAPII stalled due to DNA damage (Somesh, Reid et al. 2005; 
Daulny and Tansey 2009).  
More importantly, it is not known whether transcription elongation impairment in 
general, which has been proposed to increase the events of natural pausing, results in the 
UPP-mediated degradation of RNAPII. To that end, this study aimed to assess whether 
temperature stress as well as depletion of the nucleotide pool –two phenomena frequently 
observed in nature– result in RNAPII degradation similarly to the lack of functional 
auxiliary transcription elongation factors. 
Finally, since there is a functional and structural resemblance of the three major RNA 
polymerases –RNAPI, RNAPII and RNAPIII– (Archambault and Friesen 1993) this 
study aimed to address whether the specific degradation of the transcribing complex 
upon transcriptional stalling is also present in the other two major transcribing 
complexes, RNAPI and RNAPIII.  
Taken together, the aim of this study was to discover and elucidate the molecular 
mechanism used by the cell for removal of transcriptionally stalled RNAP complexes.  
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2. RESULTS 
 
Transcription elongation is a highly dynamic and discontinuous process that includes 
frequent pausing of RNAPII. Paused RNAPII complexes resume transcription with the 
help of transcription elongation factors. If transcription elongation factors fail to restart 
RNAPII, the persistently stalled RNAPII complex prevents transcription and has to be 
recognized and degraded by the cell. The cellular pathway for removal of these RNAPII 
complexes is not known.  
My goal was to study the transcriptional stalling-dependent degradation of RNAPII. To 
elucidate the molecular mechanism for this degradation, it was hypothesized that stalling of 
RNAPII and consequently degradation of Rpb1 is enhanced when transcription elongation 
is impaired. In order to impair transcription elongation 4 non-essential transcription 
elongation factors were deleted: Ctk1, Bur2, Tho2 and Dst1. Ctk1 is the kinase subunit of 
the CTDK-I complex that phosphorylates the CTD of Rpb1, Dst1 is the cleavage factor 
TFIIS, Tho2 is a subunit of the THO complex, and Bur2 is the cyclin of the Bur1-Bur2 
kinase complex. Deletions of all factors are viable but, except of ∆dst1, the mutants display 
an impaired growth phenotype under normal conditions (Figure 10). 
 
 
Figure 10 | Deletion of transcription elongation factors leads, except 
of ∆dst1, to an impaired growth phenotype.  
10-fold serial dilutions of wild-type (wt), Δctk1, Δdst1, Δtho2 and Δbur2 
cells were spotted onto YPD plates and incubated at 30°C for 3 days.  
 
 
 
2.1 IMPAIRMENT OF TRANSCRIPTION ELONGATION RESULTS IN THE 
DEGRADATION OF RPB1, THE LARGEST SUBUNIT OF RNAPII 
 
2.1.1 Transcription elongation impairment results in decreased RNAPII occupancy 
on the gene.  
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To assess the recruitment of RNAPII to genes in the transcription elongation mutants 
Chromatin ImmunoPrecipitation (ChIP) assays were performed using RPB3-TAP tagged 
strains. The recruitment was tested in three exemplary highly transcribed genes, ADH1, 
ACT1, and PMA1. In the case of ADH1 a set of 4 primers was used that span from the 
promoter to the 3’ region of the ORF, allowing the detailed analysis of RNAPII’s 
recruitment (Figure 11A). RNAPII occupancy decreases about 2-fold in the transcription 
elongation mutants on all three genes compared to the one observed in wild-type cells 
(Figure 11B). The observed reduction in the levels of RNAPII present on the gene is 
probably resulting from the fact that the proteins deleted in these mutants have been 
shown to be required for promoting efficient RNAPII transcription (see Introduction 1.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 | RNAPII occupancy on the gene is decreased in Δctk1, Δdst1, Δtho2 and Δbur2 cells.  
ChIP experiments were performed with an RPB3-TAP strain. A, The indicated primers were used to assess 
recruitment to the genes ADH1, ACT1, and PMA1. B, Enrichment of Rpb3 on these genes was quantified 
by RealTime-PCR with the primers shown in A. As a control, primers for a non-transcribed region (NTR) of 
chromosome V were used. PCR efficiencies (E) were determined with standard curves. Enrichment of Rpb3 
over the NTR was calculated according to [E^(CT Input – CT IP)]gene / [E^(CT Input – CT IP)]NTR. Columns 
and error bars represent the mean ± standard deviation from 3 independent experiments. 
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2.1.2 Transcription elongation impairment results in lower Rpb1 protein levels.  
 
Reduction in the occupancy of a protein on the gene might result from its inefficient 
recruitment to the site of transcription. To investigate whether the recruitment of RNAPII 
was responsible for its reduced presence on the gene, the protein levels of Rpb1 were 
assessed in the four transcription elongation mutants. Interestingly, deletion of any of these 
four transcription elongation factors results in reduced total cellular Rpb1 levels to about 
50% (Figure 12). Rpb1 levels were detected by quantitative western blot (qWB) analysis 
and normalised against the levels of the protein Pgk1 that served as a loading control. The 
observed reduction was independent of the specificity of the antibody used for detection of 
Rpb1 since the same extent of reduction was observed either with the 8WG16 antibody or 
the yN-18 antibody recognizing the C- or the N-terminus, respectively (Figure 12A and 
B). This indicates that the total cellular levels of Rpb1 are reduced upon deletion of these 
transcription elongation factors.  
 
 
 
 
 
 
 
 
 
 
Figure 12 | Total cellular levels of Rpb1 are specifically reduced.  
For quantification of the total cellular levels of RNAPII subunits, whole cell extracts of the indicated yeast 
strains were subjected to quantitative western blot analysis (qWB). Western blot signals were acquired using 
the Fujifilm Mini-LAS300 System (Fujifilm Life Sciences) and quantified using the MultiGauge 
ScienceLab2005Ver3 (Fujifilm Life Sciences). A, and B, Total cellular levels of Rpb1 are reduced in Δctk1, 
Δdst1, Δtho2 and Δbur2 cells as assessed by probing with the 8WG16 and yN-18 antibodies. C, Protein 
levels of Rpb3-TAP remain unaffected as assessed by probing with PAP. Levels of total Rpb1 and Rpb3 were 
normalized to Pgk1. Columns and error bars represent the mean ± standard deviation from 4 independent 
experiments (bottom panels). 
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To investigate whether the levels of Rpb3 are also affected upon transcription elongation 
impairment the total cellular levels of Rpb3 were quantified in wild-type and the four 
transcription elongation mutants. There was no observed reduction in the Rpb3 protein 
levels upon deletion of the four transcription elongation factors (Figure 12C). This 
indicates that RNAPII’s biggest subunit, Rpb1, is specifically degraded and through this 
degradation probably the entire enzyme is then disassembled. Consistently, in response to 
DNA damage there is specific degradation of Rpb1 but not of other subunits of elongating 
RNAPII (Malik, Bagla et al. 2008). 
Furthermore, deletion of a transcription elongation factor could affect the transcription of 
either RPB1 and/or RPB3 and thus indirectly lead to reduced Rpb1 levels. In order to 
exclude this, the mRNA levels of RPB1 and RPB3 were quantified and normalised to the 
mRNA levels of 2 housekeeping genes ADH1 and ACT1. To that end, total RNA was 
extracted from wt and ∆ctk1 cells –the mutant with the slowest growth rate– and after 
reverse transcription, the levels of each mRNA were quantified by Real-Time PCR. There 
was no specific reduction of either the RPB1 or the RPB3 mRNA in the ∆ctk1 cells (Figure 
13). This shows that the decrease in the protein levels of Rpb1 is not caused by reduced 
levels of RPB1 mRNA.   
 
 
 
 
 
 
 
 
Figure 13 | Levels of mRNAs encoding RPB1 and RPB3 are not reduced compared to mRNAs 
encoding the house-keeping proteins Adh1 and Act1 in ∆ctk1 cells  
Total mRNA levels encoding RPB1, RPB3, ACT1 and ADH1 mRNA were quantified by Real-Time PCR in 
wild-type and ∆ctk1 cells. Relative RPB1 and RPB3 mRNA levels were calculated using a standard curve 
method as the ratio of the RPB1 and RPB3 over the ADH1 or ACT1 mRNA amount. Columns and error 
bars represent the mean ± standard deviation from 3 independent experiments  
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2.1.3  Transcription elongation impairment does not result in the reduction of the 
protein levels of other transcription factors.  
 
During transcription a number of transcription factors are bound to the transcribing 
RNAPII complex. From the above experiments it became evident that upon transcriptional 
stalling there is specific degradation of Rpb1. To investigate whether there is also UPP-
mediated degradation of associated factors, the protein levels of Spt5, Med2 and Dst1 were 
quantified upon transcriptional stalling. 
Spt5 is part of the Spt4/Spt5 complex required for efficient transcription elongation and is 
bound to RNAPII throughout transcription elongation (Hartzog, Wada et al. 1998; 
Lindstrom and Hartzog 2001). Med2 is part of the Mediator complex which associates 
with RNAPII and is important for the transduction of activation signals from enhancer 
bound activators to general transcription factors (Guglielmi, Soutourina et al. 2007; 
Esnault, Ghavi-Helm et al. 2008; Fan and Struhl 2009). TFIIS is the general elongation 
factor that stimulates the intrinsic cleavage activity of RNAPII which then enables the 
arrested complex to backtrack (Awrey, Shimasaki et al. 1998; Kettenberger, Armache et al. 
2003; Wang, Bushnell et al. 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 32 
(previous page) 
Figure 14 | Protein levels of Spt5, Med2 and Dst1 remain are not reduced upon transcriptional 
stalling. Total cellular levels of Spt5, Med2 and Dst1 are not reduced upon deletion of Ctk1, Dst1, Tho2, 
and Bur2. Experiment as in Figure 12. Columns and error bars represent the mean ± standard deviation of 3 
independent experiments (bottom panels). 
 
 
As shown in Figure 14, there was no significant reduction in the protein levels of any factor 
observed.  This indicates that the associated transcription factors might also disassemble 
from the arrested complex after degradation of Rpb1 –similarly with the other polymerase 
subunits.   
 
 
 
2.1.4  Depletion of transcription elongation factors also leads to lower Rpb1 levels. 
 
As deletion of the transcription elongation factors Ctk1, Tho2 and Bur2 leads to an 
impaired growth phenotype (Figure 10), the observed decrease in the Rpb1 protein levels 
could be a secondary effect, caused by an accumulation of various defects. To exclude this 
possibility, a genomic depletion system for these genes was used based on a strain carrying 
a C-terminal TAP-tagged version of each protein (to be able to determine protein levels 
using the PAP antibody) driven by the GAL1 promoter (GAL1::GENE-TAP). In galactose-
containing media (YPG) the protein will be expressed, whereas in glucose-containing 
media (YPD) its expression will be repressed (Figure 15A).  
The growth rates between the wild-type and the GAL1::GENE-TAP strains were identical 
for the first 8 hours after shift from YPG to YPD, whereas after 8 hours some of the 
depleted strains started to deviate from wt growth (Figure 15B). More importantly after 
the 8 hour depletion in YPD media none of the 3 proteins were detectable by western 
blotting (Figure 15C). Therefore, the 8 hour depletion time point was selected for 
assessing the total cellular Rpb1 levels. As shown in Figure 15D, depletion of Ctk1, Tho2, 
or Bur2 resulted into the same reduction of total Rpb1 levels at a time point when (i) 
growth of the cells was not impaired and (ii) the proteins were not present in the cell. This 
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indicates that the observed reduction in the Rpb1 protein levels is a direct effect of 
transcription elongation impairment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 | Depletion of transcription elongation factors results in lower total levels of Rpb1. 
A, Schematic representation of the GAL depletion system. B, Growth curve of yeast cells depleted of Ctk1, 
Tho2, or Bur2. Growth is not impaired during the first 8 hours of depletion. C, Protein levels of Ctk1, 
Tho2, and Bur2 after different depletion times. Depletion of TAP-tagged versions of these proteins was 
assessed by western blotting using PAP antibody. D, Total levels of Rpb1 were reduced after 8 hours of 
depletion of Ctk1, Tho2, or Bur2. Columns and error bars represent the mean ± standard deviation from 3 
independent experiments.  
 
 
2.1.5 Treatment with the transcription elongation inhibitor 6AU results in lower 
Rpb1 levels.  
 
Treatment with 6AU, a drug that decreases cellular GTP/UTP levels, also leads to 
transcription elongation impairment of RNAPII (Exinger and Lacroute 1992). Treatment 
A B 
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of the yeast cells with 6AU hence allows a more short-term inhibition of transcription 
elongation and probably mimics natural conditions of starvation. To assess whether this 
inhibition results in decreased Rpb1 levels as observed upon deletion or depletion of the 
transcription elongation factors the cellular levels of Rpb1 were quantified before and after 
treatment with 6AU.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16 | Treatment with 6AU results in lower total levels of Rpb1.  
The indicated yeast cells were treated (+6AU) or not (+solv) with the transcription elongation drug 6AU. 
Experiment as in Figure 12.  A, 6AU leads to decreased total cellular levels of Rpb1 in wild-type and ∆dst1 
and ∆bur2 cells. B, Quantification of Rpb1 levels in cells treated with just the solvent of 6AU shows a similar 
reduction in the protein levels as observed in Figure 12. Columns and error bars represent the mean ± 
standard deviation from 3 independent experiments.  
 
 
 
Two hours incubation with the drug in wild-type cells reduced total cellular Rpb1 levels to 
about 50% (Figure 16A, compare first 2 lanes). Moreover, 6AU treatment of the deletion 
mutants resulted in an additional reduction of the Rpb1 levels for the ∆dst1 and ∆bur2 
cells but not for the other two mutants (Figure 16A). Such an observation indicates that 
probably there is a threshold of lower Rpb1 levels that is essential for viability, which was 
already reached in the ∆ctk1 and ∆tho2 cells. This hypothesis would explain why addition 
of 6AU could not cause any further reduction in the Rpb1 levels in these strains.  
Taken together, total cellular Rpb1 levels are specifically reduced upon transcription 
elongation impairment. 
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2.2 REQUIREMENT OF THE CTD OF RPB1 IN THE DEGRADATION OF 
TRANSCRIPTIONALLY STALLED RNAPII 
 
During transcription initiation RNAPII frequently stops and stalls. So, the transcribing 
complex should be protected from UPP-mediated degradation during this phase. Several 
lines of evidence point to the CTD of Rpb1 as being important to protect the complex 
during initiation. Specifically, it was found that (i) RNAPII with a CTD phosphorylated 
on Ser5, a hallmark of initiation, is not polyubiquitylated in vitro (Somesh, Reid et al. 
2005), (ii) the full-length CTD (26 repeats), but not a truncated 12-repeat CTD, allows 
the assembly of the ubiquitylation machinery for efficient Rpb1 polyubiquitylation, (iii) 
the inactivation of the Ser5-specific phosphatase Ssu72 significantly decreases damage-
induced RNAPII degradation (Somesh, Reid et al. 2005), (iv) hyperphosphorylated Rpb1 
is ubiquitylated in vitro in higher eukaryotes (Mitsui and Sharp 1999) and (v) α-amanitin 
causes degradation of hyperphosphorylated Rpb1 in vivo (Arima, Nitta et al. 2005). 
To investigate the requirement of the CTD in degradation of transcriptionally stalled 
RNAPII, the CTD of Rpb1 was either truncated or mutated in the transcription 
elongation mutants. In particular, a set of four truncations (with the shortest being 10 
heptapeptide repeats) and two mutations (affecting either Ser2 or Ser5 phosphorylation) of 
the CTD were used (West and Corden 1995). The viability of the transcription elongation 
mutants that also carried those CTD truncations or mutations varied (Table 2). As the 
CTD is responsible for the recruitment of different proteins and thus for the progression 
through the transcription cycle (see Introduction 1.3) the growth variations are probably 
reflecting the function of Ctk1, Dst1, Tho2 and Bur2 in different stages of transcription.  
If proper CTD function is a prerequisite for efficient ubiquitylation and degradation of 
Rpb1 of transcriptionally stalled RNAPII one would expect that mutating or truncating 
the CTD would affect total cellular Rpb1 levels. To that end, the Rpb1 levels were 
quantified in the combined mutant strains by qWB (Figure 17). 
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Table 2 | Growth analysis of the combination of the transcription elongation mutants with CTD 
mutations or truncations.  
Two types of CTD mutants (grey) and four types of CTD truncations (green) were introduced in the 
deletion mutants of Ctk1, Dst1, Tho2 and Bur2. For the CTD mutations, in the indicated number of 
repeats either the serine 5 or the serine 2 of the heptapeptide was mutated to alanine. Occasionally, the 
combination of both mutations resulted into a synthetic lethality phenotype (-). However, most double 
mutans were viable (+).  
Transcription 
CTD                     Factor 
Variant 
wt  ∆ctk1 ∆dst1 ∆tho2 ∆bur2 
7wt 7A5 repeats + − + − + 
9wt 6A2 repeats + − + + − 
26 wt repeats + + + + + 
14 wt repeats + + + + + 
13 3/7 wt repeats + − + + + 
11 2/7 wt repeats + + + + − 
10 5/7 wt repeats + + − + − 
 
 
 Figure 17 | Quantification of the total cellular Rpb1 levels in the transcription elongation mutants 
that also carry CTD mutations or truncations.  
Total cellular Rpb1 levels were assessed in the indicating strains. Experiment as in Figure 12. A specific 
requirement of the CTD in the degradation of transcriptionally stalled Rpb1 is not evident. Columns and 
error bars represent the mean ± standard deviation from 3 independent experiments.  
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Specifically, in the mutant that affected the Ser2 phosphorylation (9wt6A2) there was 
restoration of the Rpb1 protein levels in the ∆dst1 and ∆tho2 cells (Figure 17, compare 
lanes 13 & 14; 18 & 19).  
This could be explained by the fact that the elongating form of RNAPII (Ser2 
phosphorylated on the CTD) is the preferred substrate for polyubiquitylation. 
Unfortunately, in the ∆ctk1 and ∆bur2 cells this additional CTD mutation resulted in a 
synthetic lethal phenotype (Table 2) which might reflect the involvement of both the 
CTDK-I and the Bur1/2 complex in phosphorylating the CTD in vivo.  Additionally, in 
the ∆ctk1 cells that also carry the of the truncated CTD with either 14 or 13 and 3/7 wt 
repeats there were significantly higher Rpb1 levels (Figure 17, compare lanes 8-10). This 
could be a result of the loss of recruitment of transcription factors in these cells; a 
recruitment that could depend on the length of the CTD.   
Taken together the above experiment provides hints that the state of the CTD of Rpb1 
might be involved in the pathway for RNAPII ubiquitylation and degradation upon 
transcriptional stalling. However, further analysis is required for elucidating the molecular 
mechanism behind this involvement.   
 
 
2.3 TEMPERATURE STRESS LEADS TO DEGRADATION OF RNAPII. 
 
All organisms are exposed to changes in their environmental conditions. Increases or 
decreases of the ambient temperature are common and may take place seasonally, daily or 
just unexpectedly, depending on region, climate and environment. Several studies have 
investigated the response and adaptation of yeast cells to either a cold or a heat shock 
(Becerra, Lombardia et al. 2003; Aguilera, Randez-Gil et al. 2007; Auesukaree, 
Damnernsawad et al. 2009).  In order to mimic potential transcription elongation 
impairment in more natural conditions the levels of Rpb1 were tested in yeast cells 
growing at temperatures from 18 oC to 42 oC for one hour. As shown in Figure 18, 
elevated growth temperatures –37oC and 42oC– resulted in decreased total cellular Rpb1 
levels. The observed decrease was not as pronounced as upon deletion of the four 
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transcription elongation factors (Figure 12A) or upon nucleotide depletion (Figure 16A), 
but this probably reflects the ability of the cells to adapt to the elevated temperature.  
 
 
Figure 18 | Quantification of the total Rpb1 
levels upon temperature stress.  
Total cellular Rpb1 levels were assessed in wild-
type cells grown at the indicated temperatures for 
one hour. Only growth in higher temperatures 
resulted in decreased cellular Rpb1 levels. 
Experiment as in Figure 12. Columns and error 
bars represent the mean ± standard deviation 
from 3 independent experiments.  
 
 
The observed reduction in the Rpb1 levels might reflect the UPP-mediated degradation of 
the protein. To investigate whether proper proteasomal function is required for this 
reduction and how rapidly this is done, a time course experiment was performed. 
Specifically, the Rpb1 levels were quantified after 5, 10, 15 and 30 minutes after the 
temperature shift in the presence or absence of the proteasomal inhibitor MG132 (Figure 
19).   
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Figure 19 | Quantification of the total cellular Rpb1 levels upon growth at 37oC and 42oC in the 
presence or absence of MG132.  
Total cellular Rpb1 levels were assessed in wild-type cells grown at the indicated temperatures. For pre-
treatment with the proteasomal inhibitor MG132, 100µM of the drug were added to the culture one hour 
prior to the temperature shift. A, Western blot signals of total protein extracts from wild-type cells grown as 
indicated. B, Quantification plots of A. Experiment as in Figure 12. Symbols (squares and circles) and error 
bars represent the mean ± standard deviation of 4 independent experiments.  
 
 
Even after 10 minutes at 37oC and 5 minutes at 42oC there was a significant reduction in 
the levels of Rpb1 (Figure 19B, black symbols). More importantly, pre-treatment of the 
yeast culture with MG132, i.e. inhibition of proteasomal function prevented the reduction 
of Rpb1 levels observed after the temperature shift (Figure 19B, blue symbols). This 
suggests that indeed the proteasome is responsible for the degradation of Rpb1 after heat 
shock. However, after 30 minutes in both temperatures there is no difference observed in 
the Rpb1 levels of cells pre-treated or not with MG132.  
Taken together higher growth temperatures, which might lead to “more natural” 
transcriptional impairment, results in the degradation of RNAPII’s largest subunit. 
However, further analysis is required to assess whether the observed reduction is indeed 
specific UPP-mediated degradation after transcriptional stalling or is a result of the 
denaturation of the large Rpb1 protein after heat shock.  
 
 
2.4 TRANSCRIPTIONALLY STALLED RNAPII IS POLYUBIQUITYLATED AND 
DEGRADED BY THE UBIQUITIN-PROTEASOME PATHWAY (UPP) 
 
2.4.1 Transcriptionally stalled RNAPII is polyubiquitylated  
 
The specific reduction in the total cellular Rpb1 levels suggests a targeted cellular 
degradation of the protein by the UPP (see Introduction 1.7). The first step of this 
pathway is the attachment of a polyubiquitin chain to the targeted substrate. To test 
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whether Rpb1 is polyubiquitylated upon transcription elongation impairment, RNAPII 
was purified from wild-type and the four transcription elongation mutants. The samples 
were then subjected to western blotting using anti-ubiquitin antibodies. This allowed 
quantification of the levels of polyubiquitylated Rpb1. Wild-type cells displayed a low level 
of polyubiquitylated Rpb1, which increased about two to four fold when transcription 
elongation was impaired (Figure 20).  
 
 
 
 
Figure 20 | Polyubiquitylation of Rpb1 is 
increased in ∆ctk1, ∆dst1, ∆tho2, and 
∆bur2 cells. 
RNAPII was purified using Rpb3-TAP. 
Polyubiquitylation of Rpb1 was assessed by 
western blotting using α-ubiquitin specific 
antibody (upper panel). The approximate 
positions of Rpb1 (arrow) and 
polyubiquitylated Rpb1 (brackets) are 
indicated. Columns and error bars represent 
the mean ± standard deviation from 3 
independent experiments 
 
 
 
 
Consistently, Rpb1 ubiquitylation is increased in ∆dst1 cells and after treatment with 6AU 
(Somesh, Reid et al. 2005). To further corroborate this finding, Rpb1 was purified under 
denaturing conditions that allowed purification of single RNAPII subunits (Figure 21A) 
from wild type cells using RPB1-TAP tagged strains.  The polyubiquitylation level of the 
purified subunit was then assessed by western blotting with an anti-ubiquitin antibody. As 
shown in Figure 21B, treatment with 6AU resulted in a significant increase in the 
polyubiquitylation of Rpb1.  
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Figure 21 | Polyubiquitylation of Rpb1 is increased upon treatment with 6AU.  
A, RNAPII was purified under denaturing conditions using RPB1-, RPB2- and RPB3-TAP strains. Specific 
purification of polymerase subunits was assessed by western blotting with a PAP and an Rpb1 (8WG16) 
antibody. Rpb2- and Rpb3-TAP purification did not co-precipitate the Rpb1 subunit indicating that with 
this method single RNAPII subunits can be purified. The band observed with the 8WG16 antibody in the 
Rpb2-TAP is a result of the recognition of the TAP-tag by the secondary a-mouse IgG antibody used. B, 
Rpb1 was purified under denaturing conditions as in A from an RPB1-TAP strain. Polyubiquitylation of 
Rpb1 was assessed by western blotting using a-ubiquitin specific antibody (upper panel). The approximate 
positions of Rpb1 (arrow) and polyubiquitylated Rpb1 (brackets) are indicated.  
 
Taken together, impairment of transcription elongation leads to increased 
polyubiquitylation of Rpb1 of potentially transcriptionally stalled RNAPII.   
 
 
2.4.2  A slower polymerizing form of RNAPII has decreased Rpb1 
polyubiquitylation.  
 
Two point mutations in the RPB1 gene, rpb1-N488D and rpb1-E1103G result in a slower 
or faster polymerization rate of RNAPII, respectively (Malagon, Kireeva et al. 2006). The 
properties of the two mutants are summarized in Figure 22A. Both of the mutants are 
sensitive to 6AU, suggesting the involvement of the affected amino acid in transcription 
elongation. However, the slower polymerizing rpb1-N488D mutant is not synthetic lethal 
with DST1 and is thus probably less prone to transcriptional stalling whereas the faster 
polymerizing rpb1-E1103G mutant is synthetic lethal with DST1 and it was shown to 
result in an error-prone RNAPII (Walmacq, Kireeva et al. 2009).  
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Figure 22 | Slower polymerizing RNAPII results in decreased polyubiquitylation of Rpb1. 
A, Table summarizing the properties of the two point mutations in the RPB1 gene that alter the 
polymerization rate of RNAPII. B, RNAPII was purified from the corresponding yeast strains using Rpb3-
TAP. Experiment as in Figure 20. Columns and error bars represent the mean ± standard deviation from 3 
independent experiments. C, Total cellular Rpb1 levels are increased in the polymerizing mutants. 
Experiment as in Figure 12. Columns and error bars represent the mean ± standard deviation from 3 
independent experiments  
 
Interestingly, rpb1-N488D had lower Rpb1 polyubiquitylation levels compared to the 
wild-type and the rpb1-E1103G mutant enzyme (Figure 22B). However, the total cellular 
levels of Rpb1 in those mutants are increased (Figure 22C). Since both of the mutations 
are affecting the subunit, the increased protein levels could be a result of the over-
production of mutated RPB1 mRNA.  
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Taken together, the above experiment indicates that Rpb1 polyubiquitylation is caused by 
transcriptional stalling in wild-type cells.   
 
 
2.4.3  The 26S proteasome degrades Rpb1 of transcriptionally stalled RNAPII 
probably at the site of transcription  
 
The polyubiquitylated Rpb1 is most likely a substrate of the 26S proteasome. Thus, the 
potential association of the proteasome with RNAPII was examined by co-
immunoprecipitation experiments. RNAPII was purified from wild type and the four 
transcription elongation mutants and the samples were then subjected to western blotting 
using an antibody recognizing the 20S catalytic subunits of the 26S proteasome. As shown 
in Figure 23, RNAPII associated with the 20S proteolytic core of the proteasome in wild-
type cells (compare first two lanes). This suggests that in wild-type cells the proteasome is 
physically associated with the polymerase to possibly degrade it upon transcriptional 
impairment. Importantly, association of RNAPII with the proteasome increased about 
two-fold when transcription elongation is impaired (Figure 23, lower pannel).  
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Figure 23 | Association of RNAPII with the 20S catalytic proteasome is increased in ∆ctk1, ∆dst1, 
∆tho2, and ∆bur2 cells. 
RNAPII was purified using an RPB3-TAP strain. Levels of Rpb1 and co-purifying proteasome were detected 
with 8WG16 and anti-20S core anti-bodies, respectively. Columns and error bars represent the mean ± 
standard deviation from 4 independent experiments. 
 
 
If degradation of Rpb1 of transcriptionally stalled RNAPII complexes takes place at the site 
of stalling, one would expect that the proteasome is recruited to the site of transcription. In 
order to test this, ChIP experiments were performed with four subunits of the 20S core of 
the proteasome (Pre1, Pre2, Pre4, and Pup1) since the 19S regulatory particle has been 
implicated in transcription elongation independently of degradation (Kodadek 2010). 
Recruitment of the 20S core was assessed in three exemplary genes, ADH1, ACT1, and 
PMA1. In the transcription elongation mutants, RNAPII occupancy decreases about 2-fold 
compared to wild-type (Figure 11B) most likely reflecting the decrease in Rpb1 levels 
(Figure 12A). Importantly, recruitment of the proteasome relative to RNAPII is increased, 
especially to the middle (M) and 3’ region of the ADH1 gene and the middle (M) regions 
of ACT1 and PMA1 as expected for impaired transcription elongation (Figure 24A-D). 
This distribution pattern indicates elongation dependent recruitment of the proteasome. 
Consistently, elongating RNAPII complexes are the preferred substrate for degradation 
(Mitsui and Sharp 1999; Arima, Nitta et al. 2005; Somesh, Reid et al. 2005; Somesh, 
Sigurdsson et al. 2007).  
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Figure 24 | The proteasome is recruited to the middle and 3’ region of actively transcribed genes in 
∆ctk1, ∆dst1, ∆tho2, and ∆bur2 cells.  
ChIP experiments were performed with PRE1-, PRE2-, PRE4-, and PUP1-TAP strains. A-D, The 
enrichment of Pre1 (A), Pre2 (B), Pre4 (C) and Pup1 (D) relative to Rpb3 in wt cells was set to one. 
Enrichment of proteasomal subunits on these genes was calculated as in Figure 11. Columns and error bars 
represent the mean ± standard deviation from 3 independent experiments.  
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2.5 SUBUNITS OF THE 26S PROTEASOME INTERACT GENETICALLY WITH 
THE TRANSCRIPTION ELONGATION FACTORS 
 
The physical or functional interaction between two proteins can be indicated by a synthetic 
lethality phenotype. In general, two alleles are synthetically lethal if the combination of 
otherwise viable mutations in these genes leads to cell death (Figure 25).  
 
 
 
Figure 25 | Principle of Synthetic Lethality. 
When the combination of otherwise viable gene mutations results in the death of the yeast cells, then the two 
genes are synthetically lethal 
 
 
For the proteasome and the transcription elongation factors a synthetic lethality phenotype 
would reflect the need of proper proteasomal function for the removal of transcriptionally 
stalled RNAPII complexes. This means: if in the transcription elongation mutants the 
rescue mechanism for the degradation of stalled Rpb1 is impaired then the cells are not 
able to cope with increased transcriptional stalling. This inability would prevent further 
transcription and subsequently the cells could no longer survive. To test this, temperature-
sensitive (ts) mutations of two proteasomal proteins, Pre1 and Cim3, were combined with 
the deletions of the four transcription elongation mutants. Pre1 is a subunit of the 20S 
catalytic core and Cim3 is an ATPase of the 19S regulatory particle of the proteasome. The 
pre1-1 and the cim3-1 alleles of the proteasome were found to be synthetic lethal with 
CTK1, THO2 and BUR2 and in the presence of 6AU with DST1 (Figure 26). This result 
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further supports the finding that the 26S proteasome is responsible for Rpb1 degradation 
in the transcription elongation mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 | PRE1 and CIM3 are synthetic lethal with CTK1, DST1, THO2 and BUR2.  
The deletion mutants of the four transcription elongation factors were combined with the temperature 
sensitive alleles of PRE1 (shown in A) and CIM3 (shown in B), pre1-1 and cim3-1 respectively. The single 
mutations were viable but showed a growth defect. However, the double mutant strains were dead showing 
the genetic interaction of the genes.  For ∆dst1, 50 µg/mL of 6AU was added to the plates.   
 
 
Moreover, TAP tagging the 19S components CIM3 and CIM5 in the transcription 
elongation mutants resulted in an inviable phenotype, except for the case of Dst1 (Figure 
27). This genetic interaction is consistent with previous findings that the 19S regulatory 
particle of the proteasome is needed for efficient transcription elongation.  
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Finally, temperature-sensitive mutants of the proteasome were tested for their sensitivity to 
the transcription drugs 6AU and Mycophenolic Acid (MPA), both affecting the nucleotide 
pool inside the cell (Exinger and Lacroute 1992). Only the cim3-1 mutant was sensitive to 
both 6AU (Figure 28A) and MPA (Figure 28B) whereas the rest of the ts mutants tested 
were not. As a positive control the sensitivity of the transcription elongation mutants was 
tested under the same growth conditions (Figure 28A and B, lower panels). The sensitivity 
to both of the drugs was more pronounced for the ∆dst1 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 | CIM3- and CIM5-TAP are synthetic lethal with CTK1, THO2 and BUR2 and are not 
synthetic lethal not with DST1.  
The deletion mutants of the four transcription elongation factors were combined with TAP-tagged versions 
of CIM3 and CIM5. The combination of the three transcription factor deletions and the tagging of the 19S 
component resulted in a synthetic lethal phenotype. For ∆dst1, 50 µg/mL of 6AU was added to the plates.   
 
 
 
 
 
A 
B 
Results 
 
 49 
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Figure 28 | Sensitivity of proteasome and transcription elongation factor mutants to the 
transcription elongation drugs 6-Azauracil (6AU) and Mycophenolic Acid (MPA).  
10-fold serial dilutions of the indicated yeast strains were spotted onto SDC-ura plates supplemented 
with 6AU or MPA. The plates were incubated at 30°C for 3 or where indicated 4 days. The transcription 
elongation mutants ∆ctk1, ∆dst1, ∆tho2 and ∆bur2 and the proteasome mutant cim3-1 were sensitive to 
both transcription elongation drugs.  
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2.6 MOLECULAR MECHANISM FOR THE POLYUBIQUITYLATION OF 
TRANSCRIPTIONALLY STALLED RNAPII.   
 
The above experiments showed that upon transcriptional stalling there is 
polyubiquitylation of Rpb1. In general, polyubiquitylation is mediated by a series of 
ubiquitin modifying enzymes which are responsible for: (i) the production of a ubiquitin-
lysine specific polyubiquitin chain and (ii) the attachment of this chain in an internal lysine 
residue of the protein targeted for degradation.  
 
 
2.6.1  The polyubiquitin chains on Rpb1 are mainly K63-linked and are required 
for degradation.  
 
There are two major types of polyubiquitin chains formed. The one is formed through 
Lys48 of ubiquitin and it is the one present in most proteins which are targeted for 
degradation. The second one is formed through Lys63 of ubiquitin and has mainly 
regulatory purposes although recently it was shown to be involved in the degradation of 
proteins as well (Figure 6). To determine the nature of the polyubiquitin chain attached to 
Rpb1, antibodies directed against K48- (Apu2.07) or K63- (Apu3.A8) ubiquitin lysine-
specific chains were used (Newton, Matsumoto et al. 2008). To test the specificity of these 
antibodies chemically synthesized polyubiquitin chains of either type were subjected to 
western blot. Both antibodies recognized with a high specificity and with no cross-reaction 
only their type of lysine-specific chains (Figure 29). The high specificity of these antibodies 
allowed assessing the nature of the polyubiquitin chain attached on transcriptionally stalled 
Rpb1. To that end RNAPII was purified from wild-type and the four transcription 
elongation mutants and the samples were subjected to western blot with the lysine specific 
antibodies. As shown in Figure 30, the polyubiquitin chains attached to Rpb1 in the four 
transcription elongation mutants are mainly formed through K63 of ubiquitin. 
Consistently, polyubiquitin chains of transcriptionally stalled mammalian RNAPII formed 
in vitro are K63-linked (Lee and Sharp 2004).   
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Figure 29 | The Apu2.07 and Apu3.A8 antibodies specifically recognize only K48- or K63-linked 
polyubiquitin chains respectively.  
Chemically synthesized K48- or K63- polyubiquitin chains (Sigma) were subjected to western blotting with 
the Apu2.07 and Apu3.A8 antibodies. A, The Apu2.07 only reacted with the K48 chains and B, the 
Apu3.A8 only with the K63 chains, showing the high specificity of these antibodies. Subsequent to exposure, 
the membranes were stained with AmidoBlack for detecting loading of proteins.  
 
 
 
 
 
 
 
 
 
 
 
Figure 30 | Polyubiquitin chains formed on Rpb1 in ∆ctk1, ∆dst1, ∆tho2 and ∆bur2 cells are mainly 
K63-linked. 
A, RNAPII was purified from the indicated strains. Experiment as in Figure 20. The nature of polyubiquitin 
chains was assessed by western blotting using K48- and K63-ubiquitin specific antibodies and B, 
Quantification of relative levels of polyubiquitylated RNAPII. Columns and error bars represent the mean ± 
standard deviation from 4 independent experiments. 
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There is also a small amount of K48-linked chains observed indicating that there might be 
two pools of polyubiquitylated Rpb1 upon transcriptional stalling (Figure 30, lower 
pannel). Alternatively, the observed K63-linked polyubiquitin chains could be remodelled 
by deubiquitylases and a K48-linked chain added by a yet unknown E3 ligase for 
degradation of Rpb1 (also see below), which would be consistent with the observed small 
increase in K48-linked chains (Figure 30, lower pannel).  
Since proteins carrying K63-linked polyubiquitin chains can be degraded by the 
proteasome in vitro and in vivo (Kirkpatrick, Hathaway et al. 2006; Kim, Kim et al. 2007; 
Saeki, Kudo et al. 2009), K63-polyubiquitylated Rpb1 of transcriptionally stalled RNAPII 
might be the substrate for degradation. Consistently, K63-polyubiquitylated Rpb1 is 
readily degraded by the 26S proteasome in vitro whereas nonphysiological 
polyubiquitylated substrates (e.g., GFP) are not (Saeki, Kudo et al. 2009). In order to test 
directly whether K63-linked polyubiquitin chains are essential for degradation of Rpb1 in 
vivo, the total Rpb1 levels in an ubi-K63R strain were assessed. Deletion of DST1 leads to 
a decrease in total Rpb1 levels to about 70% compared to the corresponding wild-type 
strain (Figure 12A and 31). This decrease in Rpb1 levels does not occur when transcription 
elongation is impaired by deletion of DST1 in the K63R background (Figure 31) 
indicating that K63-linked polyubiquitin chains are needed in vivo for Rpb1 degradation 
caused by transcriptional stalling. 
 
 
 
 
Figure 31 | K63-linked linked chains on Rpb1 
are required for its degradation in vivo. 
Western blot analysis of total Rpb1 levels in the 
indicated strains. Rpb1 levels in wild-type and 
K63R strains were set to 100. Experiment as in 
Figure 12.  Columns and error bars represent the 
mean ± standard deviation from 4 independent 
experiments (bottom panels). 
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Taken together, the polyubiquitin chains attached to Rpb1 are formed mainly through 
K63 of ubiquitin and these chains are probably needed in vivo for the transcriptional 
stalling-dependent degradation of RNAPII.  
 
 
2.6.2 The polyubiquitin chain is attached on K330 and K695 of Rpb1.  
 
The polyubiquitin chain formed is attached to a lysine residue of the substrate targeted for 
degradation. However, there are several proteins known in which more than one lysine are 
needed for the polyubiquitylation of the protein (Peng, Schwartz et al. 2003). Rpb1 is a 
190 kDa protein with 93 lysine residues that are located throughout the surface of the 
protein (Figure 32, green residues). Upon DNA damage-dependent degradation of 
RNAPII the lysines of Rpb1 that serve as ubiquitylation sites have been mapped (see 
Introduction 1.8).  
 
 
 
 
Figure 32 | Localization of Lysine residues of Rpb1.  
Schematic representation of the localization of the 93 lysine residues (green) of Rpb1 in respect to the 
different domains of the protein. The characterized ubiquitylation sites K330 and K695 are colored magenta 
and blue respectively. 
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The first of them is K330 (Figure 32, magenta lysine) located in a protein domain that is 
unordered in free RNAPII, but ordered in the elongating form. The other one is K695 
(Figure 32, blue lysine) which is located >125 Ångstroms away from the first one. Both of 
these residues were shown to be involved in the polyubiquitylation of Rpb1 as mutation of 
either site affects ubiquitylation of the other, in vitro and in vivo. To determine whether 
these residues are involved in the transcriptional stalling-dependent degradation of Rpb1, 
the rpb1-K330R and rpb1-K695R mutations were introduced in wild-type cells and the 
four transcription elongation mutants. The Rpb1 mutations in combination with the 
transcription elongation mutants did not further affect the growth phenotype of the cells 
(Figure 33A).  
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Figure 33 | The polyubiquitin chain is attached on K330 and K695 of Rpb1.  
A, Growth analysis of the combination of the transcription elongation mutants with the RPB1 lysine mutants 
showed no synthetic lethality phenotype. B, RNAPII was purified from the indicated strains, experiment as 
in Figure 20. Polyubiquitylation of Rpb1 was assessed by western blotting with the K63-linkage specific 
antibody. The rpb1-K330R and rpb1-K695R mutations in Δctk1, Δdst1, Δtho2, and Δbur2 cells resulted in 
the reduction of polyubiquitylated Rpb1 compared to the one observed in each deletion mutant with wild-
type Rpb1. Columns and error bars represent the mean ± standard deviation from 3 independent 
experiments.  
 
 
 
RNAPII was purified from the cells and the samples were then subjected to western 
blotting using anti-ubiquitin antibodies to detect the polyubiquitylation levels of Rpb1. In 
wild-type cells both Rpb1 mutations did not affect the basal polyubiquitylation of the 
protein (Figure 33B, first panel in right).  
However, upon transcription elongation impairment either the rpb1-K330R or the rpb1-
K695R mutation resulted in reduced levels of polyubiquitylated Rpb1 compared to the one 
observed in each transcription elongation mutant with wild-type Rpb1 (Figure 33B). 
Nevertheless, since Rpb1 has several lysine residues one can not exclude the presence of a 
third ubiquitylation site on Rpb1. The ideal experiment with both of the identified sites 
mutated, in order to potentially abolish Rpb1 ubiquitylation completely, is not possible 
since the K330R and K695R mutations are synthetic lethal.  This synthetic lethality 
phenotype supports the idea that the two sites perform overlapping roles in RNAPII 
biology.  
Taken together, in the transcriptional stalling-dependent degradation of RNAPII the 
polyubiquitin chain is attached to two sites on Rpb1: K330 and K695.  
 
 
2.6.3  Ubiquitin modifying enzymes involved in polyubiquitylation of Rpb1.   
 
Ubiquitylation requires the cooperation of three enzymes: the ubiquitin-activating enzyme 
(E1), the ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase (E3) (see 
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Introduction 1.7.1). There is only one E1 in eukaryotic cells (Uba1 in S.cerevisiae), but 
several E2s and a lot more E3s. This study aimed to uncover the E2 and E3 enzymes 
responsible for the polyubiquitylation of Rpb1 of transcriptionally stalled RNAPII. To test 
the function of the candidate ubiquitin modifying enzymes in the transcriptional stalling-
dependent pathway the corresponding genes were deleted or mutated in the ∆dst1 genetic 
background. The ∆dst1 mutant was selected among the other three transcription 
elongation mutants since it is the one exhibiting wild-type like growth (Figure 10) and –
more importantly– it is not synthetic lethal with any of the enzymes tested (Figures 34A, 
35 and (Lee, Yu et al. 2001; Woudstra, Gilbert et al. 2002).   
 
 
2.6.3.1   Ubc4 and Ubc5 are the E2 conjugating enzymes. 
 
In S.cerevisiae, there are two housekeeping E2 enzymes, Ubc4 and Ubc5, with redundant 
function. Although these proteins are encoded by very similar genes (97% similar at the 
amino acid level) the expression of Ubc4 is much higher that the one of Ubc5. Deletion of 
Ubc4 leads to a mild growth defect and a weak sensitivity to diverse environmental stresses. 
In contrast, loss of Ubc5 has no effect probably due to the presence of high levels of Ubc4 
(Seufert and Jentsch 1990) (Figure 34A). It was shown that the E2s Ubc4 and Ubc5 are 
needed for polyubiquitylation of Rpb1 in response to transcriptional stalling but also in 
response to DNA damage (Somesh, Reid et al. 2005).  
To corroborate the function of Ubc4 and Ubc5 in polyubiquitylation of Rpb1 in the 
transcription dependent pathway, RNAPII was purified from strains lacking either Dst1 or 
the E2 enzyme or the combination of both. The samples were then subjected to western 
blotting using anti-ubiquitin antibodies. Ubc4 and Ubc5 are indeed involved in the 
polyubiquitylation of Rpb1: in the double deletion mutants (∆dst1 ∆ubc4; ∆dst1 ∆ubc5) 
there was approximately 50% less polyubiquitylated Rpb1 compared to the one observed 
in the ∆dst1 cells (Figure 34B). This is most likely due to the overlapping roles of the two 
enzymes.  
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Figure 34 | The E2 enzymes Ubc4 and Ubc5 are responsible for the polyubiquitylation of transcrip-
tionally stalled Rpb1.  
A, Growth analysis of the single and double deletion mutants of Dst1, Ubc4 and Ubc5 showed no synthetic 
lethality phenotype. B, RNAPII was purified from the indicated strains. Experiment as in Figure 20. 
Deleting the E2s UBC4 and UBC5 in Δdst1 cells resulted in the reduction of polyubiquitylated Rpb1 
compared to the one observed in ∆dst1. Columns and error bars represent the mean ± standard deviation 
from 3 independent experiments.  
 
 
 
2.6.3.2 Rsp5 but not Elc1 is the E3 ligase. 
 
For the efficient ubiquitylation of a substrate the function of the E2 enzyme is followed by 
the subsequent function of an E3 ligase. The E2 and the E3 form a transient complex, 
which recognizes and ubiquitylates the protein substrate. Upon DNA damage there are 
two E3s that have been identified to ubiquitylate Rpb1 (see Introduction 1.8). These are 
the HECT domain ligase Rsp5 (NEDD4 in humans) and the RING finger domain-
containing Elc1/Cul3 complex (Elongin/ /Rbx1/Cullin 5 complex in humans). It was 
recently shown that upon DNA damage the two enzymes function sequentially, with Rsp5 
mono-ubiquitylating Rpb1 and Elc1 adding a K48-linked polyubiquitin chain. In 
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addition, Rsp5 produces non-functional K63-linked polyubiquitin chains (Harreman, 
Taschner et al. 2009). So, these proteins were tested for a function in the transcriptional 
stalling-dependent pathway using one of the transcription elongation mutants, ∆dst1. The 
polyubiquitylation of Rpb1 was assessed in either the single or the double mutant strains 
(Figure 35A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35 | The E3 enzymes Rsp5 and Elc1 are not synthetic lethal with Dst1.  
A, Growth analysis of the single and double deletion mutants of DST1 and RSP5. To rescue the lethality of 
the ∆rsp5 mutation, the medium was supplemented with 0.2% NP40 and 2mM oleic acid. B, Growth 
analysis of the single and double deletion mutants of DST1 and ELC1.  
 
 
 
Interestingly, the additional deletion of RSP5 in the ∆dst1 background resulted in reduced 
levels of polyubiquitylated Rpb1 compared to the single ∆dst1 cells (Figure 36A). So, the 
E3 Rsp5 polyubiquitylates Rpb1 in response to transcriptional stalling. Importantly, 
however, the combinational deletion of ELC1 and DST1 resulted in even higher levels of 
polyubiquitylated Rpb1 (Figure 36B). This shows that the E3 Elc1 is not required for 
polyubiquitylation of Rpb1.   
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Figure 36 | Rsp5 and not Elc1 is the responsible E3 ligase.  
RNAPII was purified from the indicated strains. Experiment as in Figure 20. A, Deleting the E3 Rsp5 and in 
Δdst1 cells resulted in the reduction of polyubiquitylated Rpb1 compared to the one observed in ∆dst1 (cells 
were grown on oleic acid; see Figure 31A). B, Deleting the E3 Elc1 and in Δdst1 cells resulted in a significant 
increase of polyubiquitylated Rpb1 compared to the one observed in ∆dst1. Columns and error bars represent 
the mean ± standard deviation from 3 independent experiments.  
 
This increase might be explained by a function of Elc1 in promoting efficient transcription 
elongation ((LeJeune, Chen et al. 2009) and references therein). So, in contrast to the 
DNA damage-dependent pathway, Rsp5 but not Elc1 is required for polyubiquitylation of 
Rpb1 upon transcriptional stalling.  
 
 
 
2.6.3.3    Investigation of a possible novel E3 ligase.  
 
The polyubiquitin chains on Rpb1 of transcriptionally stalled RNAPII are mainly K63-
linked. However, in the four transcription elongation mutants there was also a slight 
increase in the K48-linked chains observed (Figure 30). These K48-linked chains could be 
the result from the function of a yet unknown E3 ligase that is required for efficient 
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degradation of Rpb1. To investigate this, two candidate E3 enzymes were tested for their 
role in polyubiquitylation of transcriptionally stalled RNAPII. Asr1 is a RING finger 
ubiquitin-ligase that was selected for analysis since it binds directly to RNAPII  via the 
CTD of Rpb1 (Daulny, Geng et al. 2008). Bre1 is another RING-finger E3 that forms 
heterodimer with Rad6p to monoubiquitylate histone H2B on K123 and was selected for 
analysis since it is synthetic lethal with CTK1 and is needed for efficient transcription 
(Wood, Schneider et al. 2003; Lee, Shukla et al. 2007; Xiao, Shibata et al. 2007).  
However, deletion of both did not affect polyubiquitylation of Rpb1 upon transcriptional 
stalling (Figure 37). Further analysis of additional E3 ligases is required to potentially 
identify the enzyme responsible for the K48-linked chains shown in Figure 30.  
 
 
 
 
Figure 37 | Asr1 and Bre1 are not required for 
Rpb1 polyubiquitylation.  
RNAPII was purified from the indicated strains. 
Experiment as in Figure 20. Deleting either Asr1 or 
Bre1 in the ∆dst1 strain did not affect the levels of 
polyubiquitylated Rpb1. Columns and error bars 
represent the mean ± standard deviation from 3 
independent experiments  
 
 
 
2.6.3.4 Involvement of the ubiquitylation promoting protein Def1 and the 
TCR factor Rad26.  
 
Upon DNA damage in the transcribed strand the cell attempts to repair the damage by 
TCR.  However, if this fails RNAPII becomes persistently stalled at the site of damage and 
thus has to be removed to allow continued transcription (see Introduction 1.8). The switch 
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from repair to degradation is mediated by a complex formation of the TCR protein Rad26 
and the ubiquitylation promoting protein Def1.  
To test whether these two proteins are involved in the Rpb1 polyubiquitylation upon 
transcriptional stalling the DEF1 and RAD26 genes were deleted in the ∆dst1 genetic 
background. Consequently, RNAPII was purified from the single and double mutant 
strains and the samples were subjected to western blotting with anti-ubiquitin antibodies. 
As shown in Figure 38A, there was a significant reduction in the levels of polyubiquitylated 
Rpb1 in the ∆dst1 ∆def1 cells as compared to the ones observed in the ∆dst1 cells. 
Moreover, the single deletion of DEF1 resulted in a dramatic increase in the 
polyubiquitylation of Rpb1 (Figure 38A). This observation could reflect another unknown 
function of Def1 in transcription elongation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38 | Def1 and not Rad26 is required for efficient Rpb1 polyubiquitylation.  
RNAPII was purified from the indicated strains. Experiment as in Figure 20. A, Deleting the ubiquitylation 
promoting protein Def1 in Δdst1 cells resulted in the reduction of polyubiquitylated Rpb1 compared to the 
one observed in ∆dst1. B, Deleting the TCR factor Rad26 in the ∆dst1 strain did not affect the levels of 
polyubiquitylated Rpb1. Columns and error bars represent the mean ± standard deviation from 3 
independent experiments  
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However, loss of Rad26 function does not affect polyubiquitylation of Rpb1 in the Δdst1 
background indicating that Rad26 is not involved in the transcription dependent pathway 
(Figure 38B). The increase in the levels of polyubiquitylated Rpb1 observed in the single 
∆rad26 mutated strain might come from the reported inhibitory role of Rad26 in RNAPII 
ubiquitylation or degradation which enables the transcription block to first be sampled by 
TCR factors (Woudstra, Gilbert et al. 2002).  
 
 
  
2.7 MOLECULAR MECHANISM FOR DE-UBIQUITYLATION OF 
TRANSCRIPTIONALLY STALLED RNAPII.  
 
After polyubiquitylation of the substrate targeted for degradation, the 26S proteasome is 
responsible for its proteolysis. However, in the case of transcriptional stalling it is possible 
that through the function of general transcription elongation factors the stalled complex 
escapes arrest and is then able to restart transcription. Since RNAPII is an important 
enzyme a rescue mechanism must exist to prevent unnecessary Rpb1 degradation in 
complexes that are not stalled any more. So, ‘‘proofreading’’ of Rpb1 ubiquitylation by 
deubiquitylases (DUBs) is crucial for cell viability. This “proofreading” could serve for 
delaying RNAPII degradation until transcription factors can help the stalled complex to 
resume transcription by maintaining short-length polyubiquitin chain. Additionally, 
deubiquitylation by the DUBs could serve for preventing degradation of a rescued from 
staling RNAPII complex by cleaving off the polyubiquitin chain from Rpb1 to produce 
completely deubiquitylated RNAPII. S.cerevisiae cells contain 17–20 DUBs, 16 of which 
belong to the specific ubiquitin protease (UBPs) family. The UBPs antagonize the 
ubiquitylation of proteins, playing a role analogous to that of the phosphatases in a 
kinase/phosphatase regulatory pathway (see Introduction 1.7.3).  
In the DNA damage-dependent pathway there are two deubiquitylases that have been 
described to be involved: Ubp2 deubiquitylates excess K63-linked polyubiquitin chains 
formed by Rsp5, whereas Ubp3 deubiquitylates Rsp5-mediated monoubiquitin and Elc1-
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mediated K48-linked polyubiquitin chains from Rpb1 (Kvint, Uhler et al. 2008; 
Harreman, Taschner et al. 2009). These two proteins along with 3 more enzymes (Ubp6, 
Ubp10 and Ubp12) were selected based on their sensitivity to 6AU (Kvint, Uhler et al. 
2008) to be tested for their possible function in deubiquitylating Rpb1 in response to 
transcriptional stalling. To this end, yeast strains were created that lacked each of these 
enzymes either alone or in combination with the deletion of DST1. All the double mutants 
were viable and no additive growth defects were observed (Figure 39A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 | The UBPs Ubp2, 3, 6, 10,12 do not affect the growth of ∆dst1 cells and the total cellular 
levels of Rpb1.  
A, Growth analysis of the single and double deletion mutants of DST1 and the different UBPs. No synthetic 
lethality phenotype was observed. B, Total cellular Rpb1 levels were quantified in the indicated strains. 
Experiment as in Figure 12. No significant change was observed in the double mutants. Columns and error 
bars represent the mean ± standard deviation from 3 independent experiments  
 
 
The UBPs are known to affect the stability of ubiquitylated proteins (Chung and Baek 
1999; Wilkinson 2000). To investigate the effect of the deletion of the UBPs in RNAPII 
levels, the protein levels of Rpb1 were quantified in the single and double deletion strains. 
As shown in Figure 39B, there was no increased degradation of Rpb1 in any of the UBPs 
tested. This indicates that deletion of the deubiquitylases does not reduce the half-life of 
polyubiquitylated Rpb1.  
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To investigate which of the candidate UBPs is involved in deubiquitylating RNAPII in the 
transcriptional stalling-dependent pathway the level of polyubiquitylated Rpb1 was 
assessed in the single and the double deletion mutants. Consistent with a function of Rsp5 
in ubiquitylating Rpb1 of transcriptionally stalled RNAPII complexes, Ubp2 is required 
for deubiquitylation of Rpb1 (Figure 40, compare lanes 2 and 6). However, Ubp3 is not 
required for deubiquitylating Rpb1 since additional deletion of the protein in the ∆dst1 
background did not result in an increase in polyubiquitylation of Rpb1 (Figure 40, 
compare lanes 2 and 8). Importantly, whereas Ubp10 and Ubp12 are not required (Figure 
40, compare lanes 2 with 10 and 12), Ubp6 was identified to be responsible for 
deubiquitylating Rpb1 upon transcriptional stalling (Fig. 40, compare lanes 1 to 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 | Ubp2 and Ubp6 are required for deubiquitylation of transcriptionally stalled Rpb1.   
RNAPII was purified from the indicated strains. Experiment as in Figure 20. Polyubiquitylation of Rpb1 is 
increased, i.e. deubiquitylation of Rpb1 is decreased in Δdst1 cells that also carry a deletion in the Ubp6 and 
Ubp2 deubiquitylases. However, there is no effect observed upon deletion of Ubp3, Ubp10 and Ubp12. 
Columns and error bars represent the mean ± standard deviation from 3 experiments.  
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Ubp6, a cysteine protease, is an abundant proteasome-associated protein, which associates 
with the base of the proteasome. Binding of Ubp6 to the proteasome activates Ubp6’s 
catalytic activity (Leggett, Hanna et al. 2002), indicating an intimate functional 
relationship between Ubp6 and the proteasome. Recently it was reported that Ubp6 delays 
the breakdown of proteins by the proteasome. During this degradation delay, substrate 
deubiquitylation proceeds on proteasomes, but with a different mode than the one 
observed in the absence of Ubp6 (Hanna, Hathaway et al. 2006). Overall, it was suggested 
that Ubp6 has a catalytic as well as a non-catalytic function. Specifically, it deubiquitylates 
ubiquitylated proteins before their degradation thereby recycling ubiquitin and it delays 
degradation of polyubiquitylated proteins by the proteasome in a mainly non-catalytic 
manner (Hanna, Hathaway et al. 2006). To determine whether the catalytic activity of 
Ubp6 is indeed needed for deubiquitylation of Rpb1 (Figure 40) we assessed Rpb1 
ubiquitylation in the catalytically inactive ubp6-C118A mutant that still inhibits the 
proteasome (Hanna, Hathaway et al. 2006). Rpb1 ubiquitylation levels are increased in 
ubp6-C118A Δdst1 cells to a similar extent as in Δubp6 Δdst1 cells showing that the 
deubiquitylase activity of Ubp6 is necessary for Rpb1 deubiquitylation (Figure 41).  
 
 
Figure 41 | The deubiquitylating 
activity of Ubp6 is required for Rpb1 
deubiquitylation.   
RNAPII was purified from the 
indicated strains. Experiment as in 
Figure 20. Polyubiquitylation of Rpb1 
is increased, i.e. deubiquitylation of 
Rpb1 is decreased in Δdst1 cells that 
also carry either a deletion or a catalytic-
inactive mutation of Ubp6. Columns 
and error bars represent the mean ± 
standard deviation from 3 independent 
experiments.  
 
 
 
Taken together, two proteins, Ubp2 and Ubp6, are responsible for deubiquitylating Rpb1 
of transcriptionally stalled RNAPII complexes.   
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2.8 SPECIFIC DEGRADATION UPON TRANSCRIPTIONAL IMPAIRMENT MIGHT 
OCCUR IN RNAPI AND RNAPIII TRANSCRIPTION.   
 
The eukaryotic RNA polymerases (RNAPI, II and III) are the central multiprotein 
machines that synthesize mainly ribosomal, messenger, and transfer RNA, respectively. All 
three polymerases are multisubunit enzymes. Ten subunits form a structurally conserved 
core, and additional subunits are located on the periphery (see Introduction 1.2). Since 
there is a high level of similarity among the three enzymes it could be that the pathway for 
the controlled RNAP degradation upon block of transcription also exists for RNAPI and 
RNAPIII.  
Several studies have shown that the transcription elongation factor Dst1 of RNAPII is 
homologous to the polymerase subunits Rpa12 of RNAPI and Rpc11 of RNAPIII 
(Prescott, Osheim et al. 2004; Huang, Intine et al. 2005). All three proteins contain a zinc-
beta ribbon domain in which four cysteine residues bind to the zinc ion. This domain was 
shown in the case of Dst1 to be required for stimulating the RNA cleavage activity of the 
polymerase complex (Jeon, Yoon et al. 1994; Kettenberger, Armache et al. 2003). This 
domain contains 3 β-sheets and 4 highly conserved cysteine residues which are required for 
the binding of the zinc ion (Figure 42A).  
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Figure 42 | Schematic representation of the structural alignment of Dst1, Rpa12 and Rpc11.  
A, Amino acid composition of the zinc-beta ribbon domain of Dst1 showing the highly conserved Cys 
residues that bind the zinc ion (left panel) and representation of the domain’s secondary structure (right 
panel). The zinc ion is shown as a blue sphere. Scheme modified from (Qian, Gozani et al. 1993) B, Protein 
sequence alignment of the zinc-beta ribbon domains of the homolog proteins Dst1, Rpa12 and Rpc11. 
Rectangulars indicate the highly conserved Cys residues. Identical amino acids (*) are shown in red, 
conservative substitutions (:) in blue and semi-conservative ones (.) in green.  Alignment was done with 
ClustalW2.  
 
Sequence alignment of the zinc-beta ribbon domains of the three homologous proteins –
Dst1, Rpa12 and Rpc11– reveals their high level of similarity (Figure 42B).  
In order to impair transcription elongation of RNAPI and III the Rpa12 and Rpc11 
subunits, respectively, were mutated in the cells. In the case of RNAPI the Rpa12 subunit 
was deleted and the resulting strain even though viable exhibited a growth defect and both 
the wild-type strain and the mutant had to be grown at lower temperatures (20oC) (Figure 
43A, top panel). For RNAPIII the Rpc11 subunit was mutated via random mutagenesis to 
produce a temperature sensitive (ts) mutant that had impaired Rpc11 function (Ben-
Aroya, Coombes et al. 2008).  
 
 
 
 
 
 
 
 
 
 
 
Figure 43 | Growth and subunit integrity of the “TFIIS-like” mutants of RNAPI and RNAPIII.  
A, Growth analysis of the “TFIIS-like” mutants, Δrpa12 and rpc11-ts. 10-fold serial dilutions of the indicated 
yeast strains were spotted onto YPD plates and incubated at different temperatures. B, RNAPI and RNAPIII  
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subunit composition upon transcriptional stalling. TAP-purification of the two enzymes in the Δrpa12 and 
rpc11-ts strains.  
 
 
The rpc11-ts mutant exhibited a growth defect at the non-permissive temperature (37oC) 
(Figure 43A, bottom panel). More importantly, in these mutants the subunit composition 
of both RNAPI and RNAPIII is not altered indicating that the multisubunit enzymes do 
not fall apart upon loss-of-function of Rpa12 and Rpc11, respectively (Figure 43B).  
To investigate whether RNAPI and III are degraded upon transcription elongation 
impairment the total cellular levels of their corresponding biggest subunits were quantified 
in the ∆rpa12 and rpc11-ts mutant strains. As shown in Figure 44, in both of the cases the 
deletion of the “Dst1-like” subunit resulted in a dramatic reduction in the total cellular 
levels of Rpa190 (for RNAPI) and of Rpc160 (for RNAPIII) as compared to wild-type 
cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 44 | Mutation of the ‘Dst1-like’ subunit of RNAPI and III results in the degradation of their 
corresponding largest subunit Rpa190 and Rpc160.  Total cellular levels of Rpa190-TAP and Rpc160-
TAP were assessed by western blot with the PAP antibody in the corresponding strains at the indicating 
temperatures. Experiment as in Figure 12. Columns and error bars represent the mean ± standard deviation 
from 3 independent experiments 
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Taken together, it seems that there is also transcriptional elongation impairment-
dependent degradation of RNAPI and RNAPIII. However, it is crucial to investigate 
whether the RPA190 and RPC160 mRNA levels are affected in the mutant cells. 
Additionally, to address if Rpa190 and Rpc160 are targeted for UPP-mediated degradation 
the polyubiquitylation levels of these two proteins should be assessed. Whether the 
molecular mechanism for the polyubiquitylation and degradation of Rpa190 and Rpc160 
is similar to the one employed in the case of Rpb1 remains to be uncovered.  
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3. DISCUSSION 
 
Transcription is the first step in gene expression. By being the first it is one of the most 
tightly regulated processes and it requires a plethora of associating factors which facilitate 
the efficient progression through the transcription cycle (Saunders, Core et al. 2006). The 
coordinated function of the transcribing complex with the numerous transcription factors 
results in the accurate and fast transcription of all protein coding genes and could be 
resembled with the function of a intricate machine performing a delicate yet highly 
productive task (Panning and Taatjes 2008). However, even though transcription was once 
considered to be a step-by-step it is now known that the different stages of transcription are 
inter- and intra-connected with proteins from one phase (e.g. initiation) functioning in the 
other two stages (e.g. elongation or termination) and vice versa (e.g., transcription 
elongation factors implicated in other stages of gene expression; see Introduction 1.6). 
Importantly, the study of transcription elongation revealed that it is also a highly dynamic 
and discontinuous process. It was discovered that about 4% of the polymerases that 
actively transcribe become arrested on the gene for times that can last up to four minutes. 
During transcript elongation RNAPII engages in pausing, arresting and backtracking both 
in vitro and in vivo (see Introduction 1.5). Given the thousands of mRNAs produced by 
the cell every minute an irreversible arrest of RNAPII on an essential gene could 
compromise cell viability. This study elucidates the molecular mechanism by which the cell 
copes with the irreversible arrest of the transcribing complex during transcription 
elongation. The newly identified pathway for the transcriptional stalling-dependent 
degradation of RNAPII was termed TRADE.  
 
 
3.1 TRANSCRIPTIONAL STALLING-DEPENDENT DEGRADATION OF RNAPII-THE 
TRADE PATHWAY  
 
3.1.1 Transcriptional impairment results in lower Rpb1 levels.   
 
In order to be able to elucidate the TRADE pathway, three different approaches were used 
to impair transcription elongation and thus to increase transcriptional stalling events. 
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These were: (i) deletion of four transcription elongation factors known to be required for 
efficient transcription elongation –which were used mainly throughout the study–, (ii) 
nucleotide depletion which mimics natural conditions of cell starvation and (iii) elevated 
growth temperature which mimics natural conditions of environmental changes. In all 
three conditions degradation of RNAPII’s largest subunit Rpb1 was observed (Figures 12, 
16, 18 and 19).  
Moreover, the recruitment of the transcribing complex to highly transcribed genes was also 
reduced (Figure 11B). This finding corroborated a number of studies showing the reduced 
RNAPII occupancy on the genes in transcription elongation mutant cells (Hartzog, Wada 
et al. 1998; Keogh, Podolny et al. 2003; Xiao, Shibata et al. 2007; Ahn, Keogh et al. 2009; 
Sigurdsson, Dirac-Svejstrup et al. 2010) and references therein). The reduced recruitment 
of Rpb3, and hence of RNAPII, across the gene (Figure 11B) most likely results from the 
lower protein levels of Rpb1 shown in Figure 12.   
Importantly, the reduction in the cellular protein levels of Rpb1 (Figure 12) were a result 
of the proteolytic degradation of the protein rather than of the reduction of its 
corresponding mRNA (Figure 13).  
Taken together, this study showed that transcriptional impairment leads in the proteolytic 
degradation of the largest subunit of RNAPII, Rpb1.  
 
 
3.1.2 Specific degradation of Rpb1 at the site of transcription probably leads to the 
disassembly of the stalled complex.  
 
The transcriptionally stalled RNAPII is targeted for UPP-mediated degradation since the 
levels of polyubiquitylated Rpb1 are significantly increased in the four transcription 
elongation mutants (Figure 20). The polyubiquitylated RNAPII is probably still bound to 
the transcribed strand of the DNA.  Degradation at the site where the RNAPII complex 
became stalled seems reasonable since only then the gene can be freed for transcription by 
subsequent polymerases. If the arrested RNAPII had the ability to go away and be released 
from the DNA then the mechanism elucidated in this study would not be necessary. 
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Consistently, RNAPII in a ternary complex with RNA and DNA is the preferred substrate 
for polyubiquitylation (Somesh, Reid et al. 2005). 
Supporting this idea, the recruitment of the catalytic core of the 26S proteasome is 
significantly increased in the mutant cells. Specifically, the proteasomal occupancy was 
much higher towards the middle and 3’ end of the ORF which most probably reflects the 
site of the transcriptional stalling (Figure 24). Additionally, the association of the 
proteasome with its substrate RNAPII is also increased (Figure 23). These two observations 
indicate that the proteasome is responsible for the degradation of the polyubiquitylated 
Rpb1 of irreversibly stalled RNAPII at the site of transcription.  
One important observation is that only the levels of Rpb1 are reduced in the mutant cells 
while the levels of another RNAPII subunit, Rpb3, remained unaffected (Figure 12C).  
Consistently, upon DNA damage-induced stalling only Rpb1 is degraded while the other 
11 subunits are not (Malik, Bagla et al. 2008). The specific degradation of RNAPII’s 
largest subunit indicates that this is probably sufficient for the release of the stalled 
complex from the site of transcription/stalling. Most probably, once the core Rpb1 subunit 
is degraded then the rest of the polymerase falls apart. Furthermore, the associated 
transcription factors most likely also disassemble from the transcribing complex (Figure 
14). Both the released RNAPII subunits and the transcription factors are probably recycled 
and used for another round of transcription.  
 
 
3.1.3 K63-linked polyubiquitylation of Rpb1 leads to its degradation in vivo.  
 
For a protein to be degraded by the proteasome a polyubiquitin chain has to be attached to 
it. However, addition of a short ubiquitin chain in a protein might also serve for regulatory 
purposes (see Introduction 1.7.1). In any case the nature of the polyubiquitin chain 
attached is an indication of whether the protein should be degraded or regulated.  In Rpb1 
of transcriptionally stalled RNAPII there are mainly K63-linked chains (Figure 30). 
Until recently it was believed that only K48-linked polyubiquitin chains are targeting a 
protein for degradation. However, it was reported that K63-linked chains can also serve for 
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degradation purposes. Specifically, it was shown that polyubiquitin chains of 
transcriptionally stalled mammalian RNAPII formed in vitro are also K63-linked (Lee and 
Sharp 2004). Moreover, proteins carrying K63-linked polyubiquitin chains could be 
degraded by the proteasome both in vitro and in vivo (Kirkpatrick, Hathaway et al. 2006; 
Kim, Kim et al. 2007; Saeki, Kudo et al. 2009). Therefore, the observed K63-
polyubiquitylated Rpb1 could lead to RNAPII degradation in the TRADE pathway. 
Consistent with this hypothesis, this study showed that K63-linked polyubiquitin chains 
are needed in vivo for Rpb1 degradation caused by transcriptional stalling (Figure 31).  
However, in the ∆ctk1, ∆dst1, ∆tho2, and ∆bur2 cells there is also a small increase in the 
K48-linked chains (Figure 30). So, it could be that there are two distinct populations of 
polyubiquitylated Rpb1 –one with K48- and the other K63-linked chains– inside the cell 
with one of them being more rapidly degraded than the other. In addition, it can not be 
excluded that the mainly found K63-polyubiquitin chains are remodelled by the function 
of deubiquitylases and K48-linked chains are added by a yet unknown E3 ligase for 
efficient degradation of Rpb1 (also see below).  
The polyubiquitin chain is attached to an internal lysine residue of the targeted substrate. 
In general more than one lysine residue within a protein can serve as ubiquitylation sites. 
In the TRADE pathway the polyubiquitin chain is attached to K330 and K695 of Rpb1. 
K330 (Figure 32, magenta lysine) lies in a protein domain that is unordered in free 
RNAPII, but ordered in the elongating form while K695 (Figure 32, blue lysine) is located 
more than 125 Å away from the first one. The location of the K330 residue –structured 
only upon transcription elongation– allows the explanation of the preferential 
ubiquitylation of the elongating form of RNAPII (also see below). 
Taken together, in the TRADE pathway Rpb1 of transcriptionally stalled RNAPII is 
polyubiquitylated on K330 and K695 via K63-linked chains which are necessary for its in 
vivo degradation.  
 
 
# 
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3.1.4 Components for the attachment of the polyubiquitin chain on Rpb1 
 
In general, polyubiquitylation is mediated by an ubiquitin-activating enzyme (E1), an 
ubiquitin-conjugating enzyme (E2), and an ubiquitin ligase (E3) (see Introduction 1.7.1). 
Since there is only one E1 enzyme (Uba1) in S.cerevisiae, aim of this study was to uncover 
the E2 and E3 enzymes. Additionally, this study aimed to identify further components that 
either promote or inhibit polyubiquitylation of Rpb1. To that end a candidate approach 
was used. Since RNAPII degradation is reported in response to DNA damage (see 
Introduction 1.8) the components of this pathway were tested for a function in the 
TRADE pathway. Indeed, the functional overlapping proteins Ubc4 and Ubc5 are the 
responsible E2 conjugating enzymes in the TRADE pathway (Figure 34). Moreover, Def1 
is promoting Rpb1 polyubiquitylation upon transcriptional stalling since its deletion in the 
∆dst1 background resulted in a significant reduction in the levels of polyubiquitylated 
Rpb1 observed in the single ∆dst1 strain (Figure 38A).  
Importantly and in contrast to the DNA damage dependent pathway, the E3 ligase Elc1 
does not ubiquitylate Rpb1 of transcriptionally stalled RNAPII (Figure 36B). Instead, 
polyubiquitylation of Rpb1 occurs mainly by the E3 Rsp5 (Figure 36A). This is consistent 
with the finding that in the TRADE pathway there are mainly K63-linked chains (Figure 
30) since Rsp5 is shown to produce K63-linked polyubiquitin chains on its substrates. 
(Saeki, Kudo et al. 2009). Additionally, it was shown that Rsp5-mediated K63-
polyubiquitylated Rpb1 is readily degraded by the 26S proteasome in vitro whereas 
nonphysiological polyubiquitylated substrates (e.g., Rsp5 and GFP) are not (Saeki, Kudo 
et al. 2009). Along these lines K63-linked polyubiquitin chains result in the degradation of 
transcriptionally stalled Rpb1 in vivo (Figure 31). The involvement of Rsp5 and not Elc1 
as well as the requirement of K63-linked chains for the degradation of Rpb1 further 
corroborate the distinction between the TRADE and the DNA damage dependent 
pathway.  
However, since there is a small increase in K48-linked chains also observed (Figure 30) it 
cannot be excluded the K63-linked polyubiquitin chains are remodelled by deubiquitylases 
and K48-linked chains are then added by a yet unknown E3 ligase. Asr1 and Bre1 were 
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tested as potential novel E3 enzymes but were not found to be responsible for 
polyubiquitylating Rpb1 of transcriptionally stalled RNAPII (Figure 37).   
Taken together, polyubiquitylation of Rpb1 of transcriptionally stalled RNAPII complexes 
is mediated by an overlapping but different set of enzymes than polyubiquitylation of 
Rpb1 in the DNA damage-dependent pathway. Importantly, this is the first evidence that 
the mechanism of polyubiquitylation of Rpb1 is dependent on the cause of stalling. 
 
 
3.1.5 Distinction and relationship between TRADE and the DNA damage-
dependent pathway 
 
The details of the two pathways are depicted in Figure 45. As mentioned above, this study 
shows that the cell probably distinguishes between RNAPII complexes arrested on the gene 
by different causes.  
However, there is also an amount of resemblance between the two pathways. The first 
steps of Rpb1 polyubiquitylation are mediated by Ubc4, Ubc5, and Def1 and are thus 
identical in both pathways. The two pathways then diverge maybe by the action of DNA 
repair factors that are only present in case of DNA damage dependent stalling and could 
e.g. recruit Elc1. Once RNAPII is recognized as transcriptionally stalled, ubiquitin moieties 
could be added by the E3 Rsp5.  
The involvement of only Rsp5 and not Elc1 in the TRADE pathway is also reflected in the 
main presence of K63-linked polyubiquitin chains since Rsp5 is shown to produce K63-
linked chains in vivo (Saeki, Kudo et al. 2009). In contrast to the DNA damage-dependent 
pathway, a slow addition of K63-linked ubiquitin moieties could be essential for the 
transcriptional stalling-dependent pathway, as transcriptional stalling is known to occur 
often. It is generally accepted that proteasomal destruction of a ubiquitylated substrate 
requires a chain with a length of at least four ubiquitin molecules attached (Daulny and 
Tansey 2009) and references therein). This threshold in the number of ubiquitins required 
for proteolysis sets a temporal limit for the lifetime of a polyubiquitylated substrate –from 
the time of addition of the first ubiquitin to at least the time of addition of the fourth. So, 
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it could be that Rsp5-dependent ubiquitylation of Rpb1 creates a defined time window in 
which transcription factors attempt to restart the transcribing complex before the arrested 
complex is disassembled. Slow polyubiquitylation of Rbp1 would ensure that only 
prolonged stalling will lead to degradation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45 | Models comparing the DNA damage-dependent and the TRADE pathways.  
The pathway for degradation upon DNA damage is shown on the left side and the pathway for 
transcriptional stalling-dependent degradation of Rpb1 is shown on the right side. See text for details.  
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However, one cannot exclude the presence of a second E3 ligase in the TRADE pathway. 
This E3 could be responsible for the slight increase in the levels of K48-linked chains 
observed in the four transcription elongation mutants (see Discussion 3.1.4).  
Another difference between the two pathways is the enzymes responsible for 
deubiquitylation of Rpb1 (Figure 40). Consistent with Elc1 not involved in the TRADE 
pathway, Ubp3, the deubiquitylase that removes ubiquitin added by Elc1 in the DNA 
damage dependent pathway, is also not responsible for deubiquitylating Rpb1 of 
transcriptionally stalled RNAPII (Figures 36B and 40). Importantly, in the TRADE 
pathway an additional DUB was identified, Ubp6 (see Discussion 3.2). 
Taken together there are both similarities and differences among the two pathways. Based 
on the data presented in this study it seems that the TRADE pathway is a distinct yet 
simpler version of the DNA damage dependent pathway. One hypothesis to explain this 
simplicity could be that the TRADE pathway was developed initially in order to cope with 
stalling occurring during transcription elongation and was then employed also when the 
transcription machinery became stalled after DNA damage. This could explain the 
additional enzymes involved upon DNA damage and more importantly the difference in 
the final “product” of the ubiquitylation reaction: K63-polyubiquitylated Rpb1 for 
TRADE and K48-linked chains for DNA damage. However, further analysis of the 
TRADE pathway might reveal a more complex pathway than the one presented here. This 
would indicate that the two pathways started as one but then became different to be able to 
distinguish the two types of stalled RNAPII. Moreover, different cellular pathways to 
eliminate stalled RNAPII dependent on the cause of stalling might be necessary: When a 
DNA damage on a transcribed gene cannot be repaired the stalled polymerase should be 
degraded quickly. In contrast, since transcriptional stalling occurs frequently (Darzacq, 
Shav-Tal et al. 2007) it is crucial that not every paused polymerase is immediately 
degraded. Additionally, in the two pathways the arrested transcribing complex depends on 
the action either of TCR factors (for DNA damage dependent) or of transcription 
elongation factors (for TRADE) for a “restart”. So, the difference in Rpb1 deubiquitylation 
between the two pathways seems reasonable since the rescue-from-arrest mechanism is also 
different. Thus, once RNAPII is recognized as transcriptionally stalled ubiquitin moieties 
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could be added slowly by Rsp5 (see above). However, when RNAPII is able to continue 
transcription –by the function of transcription elongation factors – the polyubiquitin chain 
is removed by one of the two deubiquitylases, Ubp2 and Ubp6, and Rpb1 spared from 
degradation. 
 
 
3.2 DEUBIQUITYLATION OF RPB1 OPENS A TIME WINDOW FOR DEGRADATION OF 
RNAPII.  
 
It is surprising that the proteasome interacts stably with its substrate RNAPII. As 
degradation of Rpb1 is potentially very deleterious, the proteasome might have to stay 
associated with RNAPII for some time before it can degrade Rpb1. This, along with the 
slow addition of the K63-linked chains (see Discussion 3.1.5), would open another time 
window for transcription elongation factors to rescue the stalled RNAPII complex. Along 
these lines, deubiquitylation of Rpb1 can also be used to control the fate of the modified 
protein. Ubiquitin chain “editing” and substrate deubiquitylation provide an additional 
level of regulation that could delay or promote the destruction of Rpb1. This fits very well 
to the newly identified Ubp6 being a deubiquitylase of Rpb1 to counteract degradation 
(Figure 40). Ubp6 is one of two proteasome-associated deubiquitylases (Hanna, Hathaway 
et al. 2006; Reyes-Turcu, Ventii et al. 2009) and references therein). In addition to its 
catalytic activity, Ubp6 delays proteasomal degradation directly by binding to the 
proteasome (Hanna, Hathaway et al. 2006). One function of Ubp6 is to recycle ubiquitin 
from polyubiquitylated substrates before their degradation (Leggett, Hanna et al. 2002). In 
addition, the proteasome inhibitory function of Ubp6 is thought to delay the decision to 
degrade a substrate (Hanna, Hathaway et al. 2006). Since Ubp6 progressively 
deubiquitylates the substrate protein during its delay of proteasomal degradation, the 
length of inhibition is crucial: When the polyubiquitin chain is shortened beyond a critical 
length the substrate will be released from the proteasome and thus spared from degradation 
(Hanna, Hathaway et al. 2006). Additionally, Ubp2 has been suggested to maintain short 
ubiquitin chains on Rsp5 substrates in order to spare them from degradation (Saeki, Kudo 
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et al. 2009). Thus, both deubiquitylases, Ubp2 and Ubp6, uncovered here to 
deubiquitylate Rpb1 upon transcriptional stalling could act as a “fail-safe mechanism” to 
spare Rpb1 from degradation, either when RNAPII resumes transcription after prolonged 
arrest or after erroneous ubiquitylation. This deubiquitylation of Rpb1 by Ubp2 and Ubp6 
could serve two purposes: to delay RNAPII degradation until transcription factors can help 
the stalled complex to resume transcription by maintaining short-length polyubiquitin 
chain and to prevent degradation of a rescued from staling RNAPII complex by cleaving 
off the polyubiquitin chain from Rpb1 to produce completely deubiquitylated RNAPII. 
 
 
3.3 SIGNIFICANCE OF THE TRADE PATHWAY UNDER PHYSIOLOGICAL CONDITIONS  
 
Since RNAPII stalls frequently and for prolonged times during transcription elongation 
(Darzacq, Shav-Tal et al. 2007) the TRADE pathway most likely has an essential function 
in wild-type cells. Consistently, as shown in Figure 23, the 20S catalytic core of the 
proteasome stably associates with RNAPII in wild-type cells. Based on this observation one 
would expect that the proteasome “travels” along with RNAPII during transcription. 
Indeed, the proteasome is recruited to transcribed genes in wild-type cells (Gillette, 
Gonzalez et al. 2004; Auld, Brown et al. 2006; Sikder, Johnston et al. 2006). Importantly, 
the basic level of polyubiquitylated Rpb1observed in wild-type cells is reduced in cells 
carrying rpb1-N488D, an allele causing a slower polymerization rate of RNAPII that is 
most likely less prone to stalling (Figure 22B). Thus, less frequent stalling of RNAPII than 
in a wild-type situation causes less polyubiquitylation of Rpb1. This observation indicates 
that Rpb1 is polyubiquitylated in wild-type cells upon transcriptional stalling. This is 
corroborated by the recent finding that cells in which RNAPII is unable to resume from 
pausing also exhibit increased levels of polyubiquitylated Rpb1 (Sigurdsson, Dirac-
Svejstrup et al. 2010). 
In addition, Rpb1 is degraded upon treatment with 6AU, a drug that causes increased 
transcriptional stalling due to depletion of nucleotide pools, a situation that might mimic 
natural conditions such as starvation (Figure 16). Moreover, degradation of Rpb1 is also 
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observed upon elevated growth temperatures (Figures 18 and 19). Thus, this pathway 
could be essential for survival under suboptimal growth conditions. 
 
 
3.4 THE TRADE PATHWAY IS PROBABLY CONSERVED IN HIGHER EUKARYOTES 
 
Transcription-coupled and DNA damage-dependent ubiquitylation and degradation of 
RNAPII are also reported for higher eukaryotes (Lee, Wang et al. 2002). Specifically, it was 
shown that transcriptional arrest induced by α-amanitin, an inhibitor of RNAPII 
elongation, resulted in polyubiquitylation of the largest subunit of RNAPII. For 
ubiquitylation to take place, RNAPII had to be engaged in transcription elongation since 
the hyper-phosphorylated form of RNAPII was the one to be ubiquitylated and addition of 
template DNA promoted the reaction (Lee, Wang et al. 2002). Moreover, human cells 
depleted of the Rsp5-homologue NEDD4 or of the Elc1-homologue Elongin C or some 
Elongin C-associated proteins were compromised for RNAPII ubiquitylation/degradation 
(Ribar, Prakash et al. 2006; Anindya, Aygün et al. 2007; Ribar, Prakash et al. 2007). 
Importantly, and consistently with the TRADE pathway, NEDD4 was found to 
polyubiquitylate the hRpb1 in vitro (Beaudenon, Huacani et al. 1999) and the 
polyubiquitin chains formed on hRpb1 upon α-amanitin treatment were also K63-linked 
(Lee, Wang et al. 2002; Lee and Sharp 2004; Arima, Nitta et al. 2005).  
Thus, the TRADE pathway is most likely evolutionarily conserved in higher eukaryotes. 
 
 
3.5 OPEN QUESTIONS AND FUTURE DIRECTIONS 
 
Following the identification of the TRADE pathway, a number of questions arise. The 
most important of which are mentioned below.  
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3.5.1 Recognition of the stalled complex 
 
Transcriptional stalling as well as DNA damage leads to the degradation of RNAPII. How 
stalled RNAPII is recognized by the cell in either pathway remains an open question. 
However, independent of the cause of stalling the proteins XPG/Rad2 and CSB/Rad26 
bind to the stalled RNAPII forming a so-called “supracomplex” (Sarker, Tsutakawa et al. 
2005). Rad26 in turn forms a stable complex with the ubiquitylation promoting protein 
Def1 (Woudstra, Gilbert et al. 2002). In vivo Rad26 is unlikely to be essential for 
recognition of transcriptionally stalled RNAPII as deletion of RAD26 does not affect 
polyubiquitylation of Rpb1 (Figure 38B). In contrast, Def1 could be involved in 
recognition of stalled RNAPII since it promotes ubiquitylation of Rpb1 in both pathways 
(Figure 38A and (Reid and Svejstrup 2004). Alternatively, a DNA-binding protein sliding 
on the DNA could be responsible for the identification of stalled transcribing complexes 
on the genes. As soon as this protein comes across an arrested RNAPII it could alert the 
cellular mechanism for its removal.  
 
 
3.5.2 Hints for the import/export of RNAPII 
 
It is still unknown how the RNAPII enzyme is assembled after translation of its individual 
subunits. Two possibilities exist: either RNAPII assembles in the cytoplasm –after 
translation of the 12 subunits– and is then imported to the nucleus through the nuclear 
pore complex (NPC) as a multi-protein complex (Figure 46A) or the individual subunits 
are being imported separately and then RNAPII assembles inside the nucleus (Figure 46B). 
However, since none of the subunits contain a nuclear localization signal (NLS) (Cramer, 
Bushnell et al. 2001) the assembly of RNAPII in the cytoplasm (Figure 46A) seems more 
likely to be true. 
This study shows that there is specific degradation of Rpb1 –and not of the other subunits- 
inside the nucleus. This would mean that the rest of the subunits are either exported from 
the nucleus and then reassembled as a functional RNAPII in the cytoplasm (Figure 46A) or 
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that they reassemble in the nucleus using Rpb1 from the pool already present there (Figure 
46B). Taken together, it would be interesting to identify which of these two pathways for 
the nuclear import of RNAPII is true.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46 | Schematic representation of the two possible ways for the nuclear import of RNAPII. 
A, Cytoplasmic RNAPII assembly and import of the assembled RNAPII complex. B, Import of individual 
RNAPII subunits and nuclear RNAPII assembly. See text for details.  
 
3.5.3 Molecular mechanism for the removal of transcriptionally stalled RNAPI and 
RNAPIII 
 
In this study, it is reported for the first time that inhibition of transcript cleavage by 
RNAPI and RNAPIII results in reduced protein levels of their corresponding largest 
subunit (Figure 44). It would be of great interest to investigate whether the observed 
reduction is a result of the UPP-mediated degradation of these proteins. If this is the case, 
it would be interesting to elucidate the molecular mechanism behind the ubiquitylation 
and degradation of Rpa190 and Rpc160 upon transcription elongation impairment of 
RNAPI and RNAPIII, respectively.   
A 
B 
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3.6 MODEL OF THE TRADE PATHWAY 
 
This study demonstrates the existence of a novel pathway for transcriptional stalling-
dependent degradation of RNAPII termed TRADE. A model for the TRADE pathway 
could be formulated as follows (Figure 47).  
Transcription elongation is a tightly regulated and discontinuous process including 
frequent pauses of RNAPII. Paused RNAPII complexes resume transcription with the help 
of transcription elongation factors (Saunders, Core et al. 2006). In the case that 
transcription elongation factors fail to restart RNAPII, the persistently stalled RNAPII 
complex prevents transcription and has to be recognized and degraded by the cell. The first 
step for this removal is mediated by the ubiquitylation promoting protein Def1, the E2 
conjugating enzymes Ubc4/Ubc5 and the E3 ligase Rsp5.  
 
 
 
Figure 47 | Model of the TRADE pathway.  
Persistently stalled RNAPII complexes are polyubiquitylated with K63-specific polyubiquitin chains by the 
E2s Ubc4 and Ubc5, the E3 Rsp5, and Def1. When transcription factors restart RNAPII, Rpb1 is 
deubiquitylated by Ubp2 and Ubp6 (lower panel) and RNAPII resumes transcription. Alternatively, as a  
failsafe mechanism when RNAPII remains persistently stalled, polyubiquitylated Rpb1 is recognized by the 
proteasome and degraded (upper panel) freeing the way for following RNAPII complexes. 
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The function of these proteins results in the attachment of a K63-linked polyubiquitin 
chain to the largest subunit of RNAPII, Rpb1. Then, the polyubiquitylated Rpb1 is 
degraded by the proteasome. The specific degradation of Rpb1 probably results in the 
disassembly of RNAPII from the site of stalling. This disassembly frees the gene and allows 
subsequent polymerases to efficiently transcribe the gene (Figure 47, upper panel).  
Since transcriptional stalling occurs frequently (Darzacq, Shav-Tal et al. 2007) it is crucial 
that not every paused polymerase is immediately degraded. Two time windows ensure that 
RNAPII degradation only takes place when it is absolutely necessary (see Discussion 3.1.5. 
and 3.2). The first one is the slow addition of K63-linked polyubiquitin chains on Rpb1 
by the E3 ligase Rsp5. The second one is the trimming of the expanding chains by Ubp2 
and the proteasome associated Ubp6 to maintain short ubiquitin chains that do not trigger 
proteasomal degradation. When transcription elongation factors succeed in “restarting” the 
stalled RNAPII within this time the polyubiquitin chain is completely removed by one of 
the two deubiquitylases, Ubp2 and Ubp6, and Rpb1 spared from degradation (Figure 47, 
lower panel). The “rescued” RNAPII is then able to resume transcription.  
In summary, the TRADE pathway elucidated in this study ensures continued 
transcription.  
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4. MATERIALS 
 
 
4.1. STRAINS 
 
 
4.1.1. Escherichia coli strains 
 
Table 3 | Esherichia coli strains used in this study.  
Name  Genotype Source 
DH5α F- φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, 
endA1,hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, 
relA1 
Stratagene 
BL21 DE3 F– ompT; hsdS(rB, mB); dcm+; Tetr; gal λ(DE3) endA; Hte 
[argU, ileY, leuW, Camr] 
Stratagene 
 
 
4.1.2.  Saccharomyces cerevisiae strains 
 
Table 4 | Saccharomyces cerevisiae strains used in this study.  
Nr. Name Parent Relevant Genotype Reference 
wild-type strains 
YKS1 RS453 (Mat a)  ura3-1 trp1-1 his3-11,15 leu2-3,112 
ade2-1 can1-100 GAL+ 
R. Serrano 
YKS2 RS453 (Mat alpha)  ura3-1 trp1-1 his3-11,15 leu2-3,112 
ade2-1 can1-100 GAL+ 
R. Serrano 
YKS8 W303 (Mat a)  leu2-3,112 trp1-1 can1-100 ura3-1 
ade2-1 his3-11,15 [phi+] 
(Wallis, 
Chrebet et al. 
1989) 
YKS184 W303 (Mat alpha)  leu2-3,112 trp1-1 can1-100 ura3-1 
ade2-1 his3-11,15 [phi+] 
(Wallis, 
Chrebet et al. 
1989) 
YKS23 BY4743 (Mat a)   his3Δ1  leu2Δ0  LYS2/lys2Δ0 
met15Δ0/MET15 ura3Δ0 
(Brachmann, 
Davies et al. 
1998) 
YKS24 BY4743 (Mat alpha)  his3Δ1  leu2Δ0  LYS2/lys2Δ0 
met15Δ0/MET15 ura3Δ0 
(Brachmann, 
Davies et al. 
1998) 
YKS265 S288C (Mat alpha)  can1Δ::MFA1pr-HIS3 lyp1Δ his3Δ1  
leu2Δ0  ura3Δ0 met15Δ0 LYS2+ 
(Mortimer 
and Johnston 
1986) 
YKS266 S288C (Mat a)  can1Δ::MFA1pr-HIS3 lyp1Δ his3Δ1  
leu2Δ0  ura3Δ0 met15Δ0 LYS2+ 
(Mortimer 
and Johnston 
1986) 
TAP-tagged strains  
YKS1619 RPB1-TAP W303 RPB1::TAP::TRP1 This study 
YKS1906 RPB2-TAP W303 RPB2::TAP::TRP1 This study 
YKS1138 RPB3-TAP W303 RPB3::TAP::TRP1 This study 
YKS1143 RPB3-TAP Δpdr5 W303 PDR5::HIS3 RPB3::TAP::TRP1 This study 
YKS981 RPB3-TAP CTK1 W303 CTK1::HIS3, RPB3::TAP::TRP1  This study 
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shuffle  pRS316-CTK1[URA3 CTK1] 
YKS1139 RPB3-TAP Δpdr5 
CTK1 shuffle 
W303 PDR5::HIS3 CTK1::HIS3, 
RPB3::TAP::TRP1 pRS316-
CTK1[URA3 CTK1] 
This study 
YKS1030 RPB3-TAP DST1 
shuffle  
W303 DST1::HIS3, RPB3::TAP::TRP1  
pRS316-DST1[URA3 DST1] 
This study 
YKS1140 RPB3-TAP Δpdr5 
DST1 shuffle 
W303 PDR5::HIS3 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1109 RPB3-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
RPB3::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1141 RPB3-TAP Δpdr5 
THO2 shuffle  
W303 PDR5::HIS3 THO2::KANMX6, 
RPB3::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1103 RPB3-TAP BUR2 
shuffle  
W303 BUR2::KANMX6, 
RPB3::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1142 RPB3-TAP Δpdr5 
BUR2 shuffle  
W303 PDR5::HIS3 BUR2::KANMX6, 
RPB3::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1649 RPB3-TAP Δubc4 W303 UBC4::HIS3 RPB3::TAP::TRP1 This study 
YKS1650 RPB3-TAP Δubc4 
DST1 shuffle 
W303 UBC4::HIS3 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1652 RPB3-TAP Δubc5 W303 UBC5::HIS3 RPB3::TAP::TRP1 This study 
YKS1653 RPB3-TAP Δubc5 
DST1 shuffle 
W303 UBC5::HIS3 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1654 RPB3-TAP RSP5 
shuffle 
W303 RSP5::HIS3 RPB3::TAP::TRP1 This study 
YKS1655 RPB3-TAP Δdst1 RSP5 
shuffle 
W303 RSP5::HIS3 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1656 RPB3-TAP Δdef1 W303 DEF1::KANMX6 
RPB3::TAP::TRP1 
This study 
YKS1657 RPB3-TAP Δdef1  
DST1 shuffle 
W303 DEF1::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1745 RPB3-TAP Δelc1 W303 ELC1::KANMX6 
RPB3::TAP::TRP1 
This study 
YKS1747 RPB3-TAP Δelc1  
DST1 shuffle 
W303 ELC1::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1834 RPB3-TAP Δasr1 W303 ASR1::KANMX6  
RPB3::TAP::TRP1 
This study 
YKS1835 RPB3-TAP Δasr1  
DST1 shuffle 
W303 ASR1::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1837 RPB3-TAP Δbre1 W303 BRE1::KANMX6 RPB3::TAP::TRP1 This study 
YKS1838 RPB3-TAP Δbre1  
DST1 shuffle 
W303 BRE1::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1840 RPB3-TAP Δrad26 W303 RAD26::KANMX6 This study 
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RPB3::TAP::TRP1 
YKS1841 RPB3-TAP Δrad26  
DST1 shuffle 
W303 RAD26::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1746 RPB3-TAP Δubp2 W303 UBP2::KANMX6 
RPB3::TAP::TRP1 
This study 
YKS1751 RPB3-TAP Δubp2  
DST1 shuffle 
W303 UBP2::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1665 RPB3-TAP Δubp3 W303 UBP3::HIS3 RPB3::TAP::TRP1 This study 
YKS1666 RPB3-TAP Δubp3  
DST1 shuffle 
W303 UBP3::HIS3 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1695 RPB3-TAP Δubp4 W303 UBP4::KANMX6 
RPB3::TAP::TRP1 
This study 
YKS1712 RPB3-TAP Δubp4  
DST1 shuffle 
W303 UBP4::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1696 RPB3-TAP Δubp6 W303 UBP6::KANMX6 
RPB3::TAP::TRP1 
This study 
YKS1714 RPB3-TAP Δubp6  
DST1 shuffle 
W303 UBP6::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1697 RPB3-TAP Δubp10 W303 UBP10::KANMX6 
RPB3::TAP::TRP1 
This study 
YKS1716 RPB3-TAP Δubp10  
DST1 shuffle 
W303 UBP10::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS1698 RPB3-TAP Δubp12 W303 UBP12::KANMX6 
RPB3::TAP::TRP1 
This study 
YKS1718 RPB3-TAP Δubp12  
DST1 shuffle 
W303 UBP12::KANMX6 DST1::HIS3, 
RPB3::TAP::TRP1 pRS316-
DST1[URA3 DST1] 
This study 
YKS982 PRE1-TAP CTK1 
shuffle  
W303 CTK1::HIS3, PRE1::TAP::TRP1  
pRS316-CTK1[URA3 CTK1] 
This study 
YKS1042 PRE2-TAP CTK1 
shuffle  
W303 CTK1::HIS3, PRE2::TAP::TRP1 
pRS316-CTK1[URA3 CTK1] 
This study 
YKS983 PRE4-TAP CTK1 
shuffle  
W303 CTK1::HIS3, PRE4::TAP::TRP1  
pRS316-CTK1[URA3 CTK1] 
This study 
YKS1041 PUP1-TAP CTK1 
shuffle  
W303 CTK1::HIS3, PUP1::TAP::TRP1  
pRS316-CTK1[URA3 CTK1] 
This study 
YKS1169 SUG1-TAP CTK1 
shuffle  
W303 CTK1::HIS3, SUG1::TAP::TRP1  
pRS316-CTK1[URA3 CTK1] 
This study 
YKS1167 SUG2-TAP CTK1 
shuffle  
W303 CTK1::HIS3, SUG2::TAP::TRP1  
pRS316-CTK1[URA3 CTK1] 
This study 
YKS1168 CIM5-TAP CTK1 
shuffle  
W303 CTK1::HIS3, CIM5::TAP::TRP1  
pRS316-CTK1[URA3 CTK1] 
This study 
YKS1033 PRE1-TAP DST1 
shuffle  
W303 DST1::HIS3, PRE1::TAP::TRP1  
pRS316-DST1[URA3 DST1] 
This study 
YKS1034 PRE2-TAP DST1 
shuffle  
W303 DST1::HIS3, PRE2::TAP::TRP1  
pRS316-DST1[URA3 DST1] 
This study 
YKS1035 PRE4-TAP DST1 
shuffle  
W303 DST1::HIS3, PRE4::TAP::TRP1  
pRS316-DST1[URA3 DST1] 
This study 
YKS1031 PUP1-TAP DST1 W303 DST1::HIS3, PUP1::TAP::TRP1  This study 
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shuffle  pRS316-DST1[URA3 DST1] 
YKS1172 SUG1-TAP DST1 
shuffle  
W303 DST1::HIS3, SUG1::TAP::TRP1  
pRS316-DST1[URA3 DST1] 
This study 
YKS1170 SUG2-TAP DST1 
shuffle  
W303 DST1::HIS3, SUG2::TAP::TRP1  
pRS316-DST1[URA3 DST1] 
This study 
YKS1171 CIM5-TAP DST1 
shuffle  
W303 DST1::HIS3, CIM5::TAP::TRP1 
 pRS316-DST1[URA3 DST1] 
This study 
YKS1110 PRE1-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
PRE1::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1111 PRE2-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
PRE2::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1112 PRE4-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
PRE4::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1113 PUP1-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
PUP1::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1176 SUG1-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
SUG1::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1175 SUG2-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
SUG2::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1174 CIM5-TAP THO2 
shuffle  
W303 THO2::KANMX6, 
CIM5::TAP::TRP1 pRS316-
THO2[URA3 THO2] 
This study 
YKS1104 PRE1-TAP BUR2 
shuffle  
W303 BUR2::KANMX6, 
PRE1::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1105 PRE2-TAP BUR2 
shuffle  
W303 BUR2::KANMX6, 
PRE2::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1106 PRE4-TAP BUR2 
shuffle  
W303 BUR2::KANMX6, 
PRE4::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1107 PUP1-TAP BUR2 
shuffle  
W303 BUR2::KANMX6, 
PUP1::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1164 SUG1-TAP BUR2 
shuffle  
W303 BUR2::KANMX6, 
SUG1::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1166 CIM5-TAP BUR2 
shuffle  
W303 BUR2::KANMX6, 
CIM5::TAP::TRP1 pRS316-
BUR2[URA3 BUR2] 
This study 
YKS1201 RPB3-TAP RPB1 
shuffle  
W303 RPB1::KANMX6 RPB3::TAP::TRP1 
pRP112 [URA3 RPB1] 
This study 
YKS1202 RPB3-TAP RPB1 
shuffle  
CTK1 shuffle 
W303 RPB1::KANMX6 CTK1::HIS3 
RPB3::TAP::TRP1 
pRP112 [URA3 RPB1] 
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1203 RPB3-TAP RPB1 
shuffle  
W303 RPB1::KANMX6 DST1::HIS3 
RPB3::TAP::TRP1 
This study 
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DST1 shuffle pRP112 [URA3 RPB1] 
pRS316-DST1 [URA3 DST1] 
YKS1204 RPB3-TAP RPB1 
shuffle  
THO2 shuffle 
W303 RPB1::KANMX6 THO2::KANMX6 
RPB3::TAP::TRP1 
pRP112 [URA3 RPB1] 
pRS316-THO2 [URA3 THO2] 
This study 
YKS1205 RPB3-TAP RPB1 
shuffle  
BUR2 shuffle 
W303 RPB1::KANMX6 BUR2::KANMX6 
RPB3::TAP::TRP1 
pRP112 [URA3 RPB1] 
pRS316-BUR2 [URA3 BUR2] 
This study 
  
YKS322 CTK1-TAP RS453 CTK1::TAP::URA3 (Rother and 
Strasser 
2007) 
YKS433 DST1-TAP RS453 DST1::TAP::TRP1 K.Sträßer 
(unpublished 
work) 
YKS45 THO2-TAP RS453 THO2::TAP::TRP1 K.Sträßer 
(unpublished 
work) 
YKS238 BUR2-TAP RS453 BUR2::TAP::TRP1 K.Sträßer 
(unpublished 
work) 
YKS551 pGAL1::CTK1-TAP RS453 HIS3::PGAL1::CTK1::TAP::URA3 (Rother and 
Strasser 
2007) 
YKS1616 pGAL1::DST1-TAP RS453 KANMX6::PGAL1::DST1::TAP::T
RP1 
This study 
YKS1617 pGAL1::THO2-TAP RS453 HIS3::PGAL1::THO2::TAP::TRP1 This study 
YKS1618 pGAL1::BUR2-TAP RS453 HIS3::PGAL1::BUR2::TAP::TRP1 This study 
YKS1642 RPC160-TAP  S288C RPC160::TAP::KANMX6 This study 
YKS1644 RPC160-TAP rpc11-4 S288C rpc11-4  RPC160::TAP::KANMX6 This study 
YKS1662 RPA190-TAP   RPA190::TAP::TRP1 This study 
YKS1663 RPA190-TAP Δrpa12  RPA12::LEU2 RPA190::TAP::TRP1 This study 
Single mutation or deletion strains  
YKS814 CTK1 shuffle W303 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
(Rother and 
Strasser 
2007) 
YKS1027 DST1 shuffle W303 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1108 THO2 shuffle W303 THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1101 BUR2 shuffle W303 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1076 RPB1  shuffle W303 RPB1::KANMX6  
pRS316-RPB1 [URA3 RPB1] 
This study 
YKS1188 UBC4  shuffle W303 UBC4::HIS3  
pRS316-UBC4 [URA3 UBC4] 
This study 
YKS1186 UBC5  shuffle W303 UBC5::HIS3  
pRS316-UBC5 [URA3 UBC5] 
This study 
YKS1191 RSP5  shuffle W303 RSP5::HIS3  
pRS316-RSP5 [URA3 RSP5] 
This study 
YKS1425 rsp5-2 DF5 RSP5::HIS3 ura3-52::rsp5-2::URA3 Gift from 
S.Jentsch 
YKS1603 Δubp3 W303 UBP3::HIS3  This study 
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YKS1601 Δubp3 W303 UBP3::KANMX6 This study 
YKS1743 Δubp2 W303 UBP2::KANMX6 This study 
YKS1687 Δubp4 W303 UBP4::KANMX6 This study 
YKS1689 Δubp6 W303 UBP6::KANMX6 This study 
YKS1691 Δubp10 W303 UBP10::KANMX6 This study 
YKS1693 Δubp12 W303 UBP12::KANMX6 This study 
YKS1741 Δelc1 W303 ELC1::KANMX6 This study 
YKS1813 Δasr1 W303 ASR1::KANMX6 This study 
YKS1815 Δbre1 W303 BRE1::KANMX6 This study 
YKS1817 Δrad26 W303 RAD26::KANMX6 This study 
YKS1118 Δpdr5 W303 PDR5::HIS3  This study 
YKS655 cim3-1 S288C cim3-1 Gift from 
S.Jentsch 
YKS656 cim5-1 S288C cim5-1 Gift from 
S.Jentsch 
YKS653 PRE1 shuffle DF5 PRE1::TRP1  
pDP83-PRE1 [URA3 PRE1] 
Gift from 
S.Jentsch 
YKS654 pre1-1  DF5 PRE1::TRP1  
pDP83-pre1-1 [URA3 pre1-1] 
Gift from 
S.Jentsch 
YKS1426 DEF1 shuffle W303 DEF1::KANMX6  
pRS316-DEF1 [URA3 DEF1] 
This study 
YKS1470 GRY3020  RPB1 (Malagon, 
Kireeva et al. 
2006) 
YKS1471 GRY3027  rpb1-N488D (Malagon, 
Kireeva et al. 
2006) 
YKS1472 GRY3028  rpb1-E1103G (Malagon, 
Kireeva et al. 
2006) 
YKS1466 Z24  rpb2∆297::HIS3  
pRP214 [URA3 RPB2] 
(Scafe, 
Martin et al. 
1990) 
YKS1467 Z422   rpb2∆297::HIS3  
pRP2-4L [URA3 rpb2-4] 
(Scafe, 
Martin et al. 
1990) 
YKS1468 Z425  rpb2∆297::HIS3  
pRP2-7L [URA3 rpb2-7] 
(Scafe, 
Martin et al. 
1990) 
YKS1469 Z428  rpb2∆297::HIS3  
pRP2-10L [URA3 rpb2-10] 
(Scafe, 
Martin et al. 
1990) 
YKS1639 rpc11-4 
(YDR045C/ts241-4) 
 rpc11-4 (Ben-Aroya, 
Coombes et 
al. 2008) 
YKS1660 NOY504  RPA12::LEU2 (Nogi, Yano 
et al. 1993) 
YKS1661 NOY505  RPA12 (Nogi, Yano 
et al. 1993) 
Double mutation or deletion strains 
YKS986 PRE1 shuffle Δctk1  DF5/
W303 
PRE1::TRP1 CTK1:: HIS3 
pDP83-PRE1 [URA3 PRE1] 
This study 
YKS1193 PRE1 shuffle Δdst1  DF5/
W303 
PRE1::TRP1 DST1:: HIS3 
pDP83-PRE1 [URA3 PRE1] 
This study 
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YKS1195 PRE1 shuffle Δtho2  DF5/
W303 
PRE1::TRP1 THO2::KANMX6 
pDP83-PRE1 [URA3 PRE1] 
This study 
YKS1197 PRE1 shuffle Δbur2  DF5/
W303 
PRE1::TRP1 BUR2::KANMX6 
pDP83-PRE1 [URA3 PRE1] 
This study 
YKS1120 Δpdr5 CTK1 shuffle W303 PDR5::HIS3 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1128 Δpdr5 DST1 shuffle W303 PDR5::HIS3 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1126 Δpdr5 THO2 shuffle W303 PDR5::HIS3 THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1124 Δpdr5 BUR2 shuffle W303 PDR5::HIS3 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1130 CTK1 shuffle cim3-1 S288C
/W303 
cim3-1 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1122 CTK1 shuffle cim5-1 S288C
/W303 
cim5-1 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1390 DST1 shuffle  
cim3-1 
S288C
/W303 
cim3-1 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1392 DST1 shuffle  
cim5-1 
S288C
/W303 
cim5-1 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1382 THO2 shuffle cim3-1 S288C
/W303 
cim3-1 THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1384 THO2 shuffle cim5-1 S288C
/W303 
cim5-1 THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1386 BUR2 shuffle cim3-1 S288C
/W303 
cim3-1 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1388 BUR2 shuffle cim5-1 S288C
/W303 
cim5-1 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1199 RPB1 shuffle CTK1 
shuffle 
W303 RPB1::KANMX6 CTK1::HIS3  
pRP112 [URA3 RPB1] 
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1200 RPB1 shuffle DST1 
shuffle 
W303 RPB1::KANMX6 DST1::HIS3  
pRP112 [URA3 RPB1] 
pRS316-DST1 [URA3 DST1] 
This study 
YKS1146 RPB1 shuffle THO2 
shuffle 
W303 RPB1::KANMX6 THO2::KANMX6 
pRP112 [URA3 RPB1] 
pRS316-THO2 [URA3 THO2] 
This study 
YKS1144 RPB1 shuffle BUR2 
shuffle 
W303 RPB1::KANMX6 BUR2::KANMX6 
pRP112 [URA3 RPB1] 
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1402 Δubc4 CTK1 shuffle W303 UBC4::HIS3 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1404 Δubc4 DST1 shuffle W303 UBC4::HIS3 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1406 Δubc4 THO2 shuffle W303 UBC4::HIS3 THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1408 Δubc4 BUR2 shuffle W303 UBC4::HIS3 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1410 Δubc5 CTK1 shuffle W303 UBC5::HIS3 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1412 Δubc5 DST1 shuffle W303 UBC5::HIS3 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1414 Δubc5 THO2 shuffle W303 UBC5::HIS3 THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
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YKS1416 Δubc5 BUR2 shuffle W303 UBC5::HIS3 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1424 Δubc4 Δubc5  DF5 UBC4::TRP1 UBC5::LEU2  Gift from S. 
Jentsch 
YKS1398 Δubc4 Δubc5 CTK1 
shuffle 
DF5/ 
W303 
UBC4::TRP1 UBC5::LEU2 
CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1399 Δubc4 Δubc5 DST1 
shuffle 
DF5/ 
W303 
UBC4::TRP1 UBC5::LEU2 
DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1400 Δubc4 Δubc5 THO2 
shuffle 
DF5/ 
W303 
UBC4::TRP1 UBC5::LEU2 
THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1419 RSP5 shuffle CTK1 
shuffle 
W303 RSP5::HIS3 CTK1::HIS3  
pRS316-RSP5 [URA3 RSP5] 
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1420 RSP5 shuffle DST1 
shuffle 
W303 RSP5::HIS3 DST1::HIS3  
pRS316-RSP5 [URA3 RSP5] 
pRS316-DST1 [URA3 DST1] 
This study 
YKS1421 RSP5 shuffle THO2 
shuffle 
W303 RSP5::HIS3 THO2::KANMX6 
pRS316-RSP5 [URA3 RSP5] 
pRS316-THO2 [URA3 THO2] 
This study 
YKS1423 RSP5 shuffle BUR2 
shuffle 
W303 RSP5::HIS3 BUR2::KANMX6 
pRS316-RSP5 [URA3 RSP5] 
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1428 Δdef1 CTK1 shuffle W303 DEF1:: KANMX6 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1430 Δdef1 DST1 shuffle W303 DEF1:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1432 Δdef1 THO2 shuffle W303 DEF1:: KANMX6 
THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1434 Δdef1 BUR2 shuffle W303 DEF1:: KANMX6 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1749 Δelc1 DST1 shuffle W303 ELC1:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1605 Δubp3 CTK1 shuffle W303 UBP3:: KANMX6 CTK1::HIS3  
pRS316-CTK1 [URA3 CTK1] 
This study 
YKS1607 Δubp3 DST1 shuffle W303 UBP3:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1609 Δubp3 THO2 shuffle W303 UBP3::HIS3 THO2::KANMX6  
pRS316-THO2 [URA3 THO2] 
This study 
YKS1611 Δubp3 BUR2 shuffle W303 UBP3::HIS3 BUR2::KANMX6  
pRS316-BUR2 [URA3 BUR2] 
This study 
YKS1753 Δubp2 ∆dst1 W303 UBP2:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1720 Δubp4 DST1 shuffle W303 UBP4:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1722 Δubp6 DST1 shuffle W303 UBP6:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1724 Δubp10 DST1 shuffle W303 UBP10:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1726 Δubp12 DST1 shuffle W303 UBP12:: KANMX6 DST1::HIS3  
pRS316-DST1 [URA3 DST1] 
This study 
YKS1826 SUB280 (wt) BY  (Spence, 
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4741 Sadis et al. 
1995) 
YKS1827 SUB413 (63R) BY 
4741 
 (Spence, 
Sadis et al. 
1995) 
YKS1856 DST1 shuffle SUB280 BY 
4741 
DST1::KANMX6 
pRS316-DST1 [URA3 DST1] 
This study 
YKS1857 DST1 shuffle SUB413 BY 
4741 
DST1::KANMX6 
pRS316-DST1 [URA3 DST1] 
This study 
 
 
4.2. PLASMIDS  
 
Table 5 | Plasmids used in this study.  
Nr. Name  Description 
Plasmids previously described 
pKS1  pBluescript II KS (+) (Alting-Mees, Sorge et al. 1992) 
pKS5 pRS313 (Sikorski and Hieter 1989) 
pKS6 pRS314 (Sikorski and Hieter 1989) 
pKS7 pRS315 (Sikorski and Hieter 1989) 
pKS8 pRS316 (Sikorski and Hieter 1989) 
pKS13 pASZ11 (Stotz and Linder 1990) 
pKS14 Ydp-L (Berben, Dumont et al. 1991) 
pKS15 Ydp-H (Berben, Dumont et al. 1991) 
pKS84 pBS1479 (Puig, Rutz et al. 1998) 
pKS85 pBS1539 (Puig, Rutz et al. 1998) 
pKS82 pFA6a-HIS3MX6-PGAL1 (Longtine, McKenzie et al. 1998) 
pKS595 pFA6a-KANMX6-PGAL1 (Longtine, McKenzie et al. 1998) 
pKS391 pRS315-CTK1 (Strasser and Hurt 2000) 
pKS491 pRS316-CTK1 (Rother and Strasser 2007) 
pKS621 pRS315-DST1 K. Sträßer (unpublished work) 
pKS622 pRS316-DST1 K. Sträßer (unpublished work) 
pKS181 pRS315-THO2 Gift from A. Aguilera 
pKS520 pRS316-THO2 K. Sträßer (unpublished work) 
pKS395 pRS315-BUR2 K. Sträßer (unpublished work) 
pKS431 pRS316-BUR2 K. Sträßer (unpublished work) 
pKS432   GHB232 [pRS315-
Rpb1_CTD(14)WT Repeats] 
(West and Corden 1995) 
pKS433 GHB 233 [pRS315-
Rpb1_CTD(7)WT(7)A5 Repeats] 
(West and Corden 1995) 
pKS434 GHB 234 [pRS315-
Rpb1_CTD(9)WT(6)A2 Repeats] 
(West and Corden 1995) 
pKS435 pRP112 (Nonet, Sweetser et al. 1987) 
pKS437  GHB83 [pRS315-Rpb1_CTD(13 
3/7)WT Repeats] 
(Nonet and Young 1989) 
pKS438  GHB84 [pRS315-Rpb1_CTD(11 
2/7)WT Repeats] 
(Nonet and Young 1989) 
pKS439  GHB200 [pRS315-Rpb1_CTD(10 
5/7)WT Repeats] 
(Nonet and Young 1989) 
pKS759 pSE362-PRE1 Gift from S. Jentsch 
pKS760 pSE362-pre1-1 Gift from S. Jentsch 
pKS768 pBSIIKS+-5'-Δctk1-HIS3-3’ (Rother and Strasser 2007) 
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pKS1341 YEP112-Met25promoter-UBI4-
6HIS 
Gift from Stephan Jentsch 
pKS 
1342 
YEP112-Adh1promoter-UBI4-
6HIS 
Gift from Stephan Jentsch 
pKS1343 YEP181-Met25promoter-UBI4-
6HIS 
Gift from Stephan Jentsch 
pKS1344 YEP181-Adh1promoter-UBI4-
6HIS 
Gift from Stephan Jentsch 
pKS1345 Ubi-HIs Gift from Stephan Jentsch 
pKS1379 pRP214 (RPB2wt) Plasmid was rescued from YKS1466 (Scafe, Martin 
et al. 1990) 
pKS1380 pRP2-4L (rpb2-4) Plasmid was rescued from YKS1467 (Scafe, Martin 
et al. 1990) 
pKS1381 pRP2-7L (rpb2-7) Plasmid was rescued from YKS1468 (Scafe, Martin 
et al. 1990) 
pKS1382 pRP2-10L (rpb2-10) Plasmid was rescued from YKS1469 (Scafe, Martin 
et al. 1990) 
pKS1383 pRS414-RSP5 (Wang, Yang et al. 1999) 
pKS1384 pRS414-rsp5-1 (Wang, Yang et al. 1999) 
pKS1391 pRS415-RPB1K330R (Chen, Ding et al. 2009) 
pKS1392 pRS415-RPB1K695R (Chen, Ding et al. 2009) 
pKS1569 pJH80 (Hanna, Meides et al. 2007) 
pKS1570 pJH81 (Hanna, Meides et al. 2007) 
pKS1571 pUB146 (Hanna, Meides et al. 2007) 
pRS Series  
pKS753 pRS314-CIM3 CIM3 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating BamHI 
and SalI sites and cloned into the same sites of 
pRS314; 
pKS754 pRS315-CIM3 CIM3 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating BamHI 
and SalI sites and cloned into the same sites of 
pRS315; 
pKS755 pRS316-CIM3 CIM3 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating BamHI 
and SalI sites and cloned into the same sites of 
pRS316; 
pKS756 pRS314-CIM5 CIM5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating BamHI 
and SalI sites and cloned into the same sites of 
pRS314; 
pKS757 pRS315-CIM5 CIM5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating BamHI 
and SalI sites and cloned into the same sites of 
pRS315; 
pKS758 pRS316-CIM5 CIM5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating BamHI 
and SalI sites and cloned into the same sites of 
pRS316; 
pKS1309 pRS314-UBC4 UBC4 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS314; 
pKS1310 pRS315-UBC4 UBC4 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
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XhoI sites and cloned into the same sites of pRS315; 
pKS1311 pRS316-UBC4 UBC4 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS316; 
pKS1312 pRS314-UBC5 UBC5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS314; 
pKS1313 pRS315-UBC5 UBC5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS315; 
pKS1314 pRS316-UBC5 UBC5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS316; 
pKS1315 pRS314-RSP5 RSP5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS314; 
pKS1316 pRS315-RSP5 RSP5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS315; 
pKS1317 pRS316-RSP5 RSP5 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS316; 
pKS1334 pRS315-PRE1 PRE1 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
SalI sites and cloned into the same sites of pRS315; 
pKS1335 pRS316- PRE1 PRE1 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
SalI sites and cloned into the same sites of pRS316; 
pKS1336 pRS314-PRE2 PRE2 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS314; 
pKS1337 pRS315-PRE2 PRE2 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS315; 
pKS1338 pRS316-PRE2 PRE2 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
XhoI sites and cloned into the same sites of pRS316; 
pKS1377 pRS316-RPA12 RPA12 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
SalI sites and cloned into the same sites of pRS316; 
pKS1385 pRS315-SUG2 SUG2 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
SalI sites and cloned into the same sites of pRS315; 
pKS1389 pRS314-PRE1 The EcoRI-SalI fragment of pKS759 was subcloned 
into the same sites of pRS314 (pKS6) 
pKS1390 pRS314-pre1-1 The EcoRI-SalI fragment of pKS760 was subcloned 
into the same sites of pRS314 (pKS6) 
pKS1397 pRS315-RPB1 The NotI-SalI fragment of pBSIIKS+-RPB1 
(pKS1393) was subcloned into the corresponding 
sites of pRS315 (pKS7) 
pKS1398 pRS315-RPB1K330R The NotI-SalI fragment of pBSIIKS+-RPB1K330R 
(pKS1394) was subcloned into the corresponding 
sites of pRS315 (pKS7) 
pKS1399 pRS315-RPB1K695R The NotI-SalI fragment of pBSIIKS+-RPB1K695R 
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(pKS1395) was subcloned into the corresponding 
sites of pRS315 (pKS7) 
pKS1400 pRS315-RPB1K330R_K695R The NotI-SalI fragment of pBSIIKS+-
RPB1K330R_K695R (pKS1396) was subcloned 
into the corresponding sites of pRS315 (pKS7) 
Disruption cassettes 
pKS1323 pBSIIKS+-5'-Δubc4-3' about 500 bp 5' and 3' of the UBC4 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1324 pBSIIKS+-5'-Δubc4-HIS3-3’ about 500 bp 5' and 3' of the UBC4 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the HIS3 marker was inserted; used for 
disruption of UBC4 with HIS3 marker; 
pKS1325 pBSIIKS+-5'-Δubc5-3' about 500 bp 5' and 3' of the UBC5 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1326 pBSIIKS+-5'-Δubc5-HIS3-3’ about 500 bp 5' and 3' of the UBC5 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the HIS3 marker was inserted; used for 
disruption of UBC5 with HIS3 marker 
pKS1327 pBSIIKS+-5'-Δrsp5-3' about 500 bp 5' and 3' of the RSP5 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1328 pBSIIKS+-5'-Δrsp5-HIS3-3’ about 500 bp 5' and 3' of the RSP5 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the HIS3 marker was inserted; used for 
disruption of RSP5 with HIS3 marker 
pKS1386 pBSIIKS+-5'-Δctk1-KANMX6-3’ the KANMX6 marker was inserted into this BamHI 
site of pKS766; 
used for disruption of CTK1 with KANMX6 
marker 
pKS1349 pBSIIKS+-5'-Δdst1-3' about 500 bp 5' and 3' of the DST1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1350 pBSIIKS+-5'-Δdst1-HIS3-3’ about 500 bp 5' and 3' of the DST1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the HIS3 marker was inserted; used for 
disruption of DST1 with HIS3 marker 
pKS1387 pBSIIKS+-5'-Δdst1-LEU2-3’ the LEU2 marker was inserted into this BamHI site 
of pKS1349; 
used for disruption of DST1 with LEU2 marker 
pKS1388 pBSIIKS+-5'-Δdst1-KANMX6-3’ the KANMX6 marker was inserted into this BamHI 
site of pKS1349; 
used for disruption of DST1 with KANMX6 marker 
pKS1351 pBSIIKS+-5'-Δtho2-3' about 500 bp 5' and 3' of the THO2 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1352 pBSIIKS+-5'-Δtho2-KANMX6-3’ about 500 bp 5' and 3' of the THO2 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
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BamHI site the KANMX6 marker was inserted; used 
for disruption of THO2 with KANMX6 marker 
pKS1353 pBSIIKS+-5'-Δtho2-KANMX6-3’ about 500 bp 5' and 3' of the THO2 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of THO2 with KANMX6 marker 
pKS1401 pBSIIKS+-5'-Δtho2-LEU2-3’ the LEU2 marker was inserted into this BamHI site 
of pKS1351; 
used for disruption of THO2 with LEU2 marker 
pKS1402 pBSIIKS+-5'-Δtho2-HIS3-3’ the HIS3 marker was inserted into this BamHI site 
of pKS1351; 
used for disruption of THO2 with HIS3 marker 
pKS1348 pBSIIKS+-5'-Δbur2-KANMX4-3’ Disruption cassette of the BUR2 ORF was amplified 
by PCR from genomic DNA of BUR2::KANMX4 
disrupted BY strain bought from Euroscarf 
pKS1403 pBSIIKS+-5'-Δbur2-HIS3-3’ the HIS3 marker was exchanged with the KANMX6 
cassette of pKS1348 using the BamHI site; used for 
disruption of BUR2 with HIS3 marker 
pKS1404 pBSIIKS+-5'-Δbur2-LEU2-3’ the LEU2 marker was exchanged with the 
KANMX6 cassette of pKS1348 using the BamHI 
site; used for disruption of BUR2 with LEU2 
marker 
pKS1357 pBSIIKS+-5'-Δpdr5-3’ about 500 bp 5' and 3' of the PDR5 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1346 pBSIIKS+-5'-Δpdr5-HIS3-3’ about 500 bp 5' and 3' of the PDR5 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the HIS3 marker was inserted; used for 
disruption of PDR5 with HIS3 marker 
pKS1368 pBSIIKS+-5'-Δrpa12-3' about 500 bp 5' and 3' of the RPA12 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1369 pBSIIKS+-5'-Δrpa12-HIS3-3’ about 500 bp 5' and 3' of the RPA12 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the HIS3 marker was inserted; used for 
disruption of RPA12 with HIS3 marker 
pKS1370 pBSIIKS+-5'-Δrpa12-KANMX6-3’ about 500 bp 5' and 3' of the RPA12 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of RPA12 with KANMX6 marker 
pKS1374 pBSIIKS+-5'-Δubp3-3' about 500 bp 5' and 3' of the UBP3 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1375 pBSIIKS+-5'-Δubp3-HIS3-3’ about 500 bp 5' and 3' of the UBP3 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the HIS3 marker was inserted; used for 
disruption of UBP3 with HIS3 marker 
pKS1376 pBSIIKS+-5'-Δubp3-KANMX6-3’ about 500 bp 5' and 3' of the UBP3 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
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creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of UBP3 with KANMX6 marker 
pKS1553 pBSIIKS+-5'-Δubp2-3' about 500 bp 5' and 3' of the UBP2 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1554 pBSIIKS+-5'-Δubp2-KANMX6-3’ about 500 bp 5' and 3' of the UBP2 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of UBP2 with KANMX6 marker 
pKS1555 pBSIIKS+-5'-Δubp4-3' about 500 bp 5' and 3' of the UBP4 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1556 pBSIIKS+-5'-Δubp4-KANMX6-3’ about 500 bp 5' and 3' of the UBP4 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of UBP4 with KANMX6 marker 
pKS1557 pBSIIKS+-5'-Δubp6-3' about 500 bp 5' and 3' of the UBP6 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1559 pBSIIKS+-5'-Δubp6-KANMX6-3’ about 500 bp 5' and 3' of the UBP6 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of UBP6 with KANMX6 marker 
pKS1560 pBSIIKS+-5'-Δubp10-3' about 500 bp 5' and 3' of the UBP10 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1562 pBSIIKS+-5'-Δubp10-KANMX6-3’ about 500 bp 5' and 3' of the UBP10 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of UBP10 with KANMX6 marker 
pKS1563 pBSIIKS+-5'-Δubp12-3' about 500 bp 5' and 3' of the UBP12 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1565 pBSIIKS+-5'-Δubp12-KANMX6-3’ about 500 bp 5' and 3' of the UBP12 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of UBP12 with KANMX6 marker 
pKS1551 pBSIIKS+-5'-Δelc1-3' about 500 bp 5' and 3' of the ELC1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1552 pBSIIKS+-5'- Δelc1-KANMX6-3’ about 500 bp 5' and 3' of the ELC1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of ELC1 with KANMX6 marker 
pKS1576 pBSIIKS+-5'-Δrad26-3' about 500 bp 5' and 3' of the RAD26 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
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pKS1577 pBSIIKS+-5'- Δ rad26-KANMX6-3’ about 500 bp 5' and 3' of the RAD26 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of RAD26 with KANMX6 marker 
pKS1578 pBSIIKS+-5'-Δasr1-3' about 500 bp 5' and 3' of the ASR1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1579 pBSIIKS+-5'- Δasr1-KANMX6-3’ about 500 bp 5' and 3' of the ASR1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of  ASR1 with KANMX6 marker 
pKS1580 pBSIIKS+-5'-Δbre1-3' about 500 bp 5' and 3' of the BRE1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them" 
pKS1581 pBSIIKS+-5'- Δbre1-KANMX6-3’ about 500 bp 5' and 3' of the BRE1 ORF were 
amplified by PCR and cloned into pBluescriptIIKS+ 
creating a BamHI site "between them"; into this 
BamHI site the KANMX6 marker was inserted; used 
for disruption of BRE1 with KANMX6 marker 
pBluescript Series 
pKS1329 pBS1479minusALL pBS1479 (pKS84) was digested with  SmaI and 
KpnI; the ~3.4kb fragment was blunt ended and 
then ligated 
pKS1330 pBS1479HIS3 pBS1479minusALL (pKS1329) was digested with  
PstI; the linearised plasmid was blunt ended and 
then dephosphorylated with CIAP; the HIS3 
cassette was isolated from YDp-H after a  BamHI 
digestion and was also blunt ended; the two 
fragments were then ligated to create pBS1479HIS3 
pKS1331 pBS1479KANMX6 pBS1479minusALL (pKS1329) was digested with  
PstI; the linearised plasmid was blunt ended and 
then dephosphorylated with CIAP; the KANMX6 
cassette was isolated from pKS935 after a  BamHI 
digestion and was also blunt ended; the two 
fragments were then ligated to create 
pBS1479KANMX6 
pKS1332 pBS1479LEU2 pBS1479minusALL (pKS1329) was digested with  
PstI; the linearised plasmid was blunt ended and 
then dephosphorylated with CIAP; the LEU2 
cassette was isolated from YDp-L after a  BamHI 
digestion and was also blunt ended; the two 
fragments were then ligated to create pBS1479LEU2 
pKS1333 pBS1479LEU2 pBS1479minusALL (pKS1329) was digested with  
PstI; the linearised plasmid was blunt ended and 
then dephosphorylated with CIAP; the LEU2 
cassette was isolated from YDp-L after a  BamHI 
digestion and was also blunt ended; the two 
fragments were then ligated to create pBS1479LEU2 
pKS1393 pBSIIKS+-RPB1 RPB1 + ca. 500 bp promoter and ca. 300 bp 
terminator was amplified by PCR creating NotI and 
SalI sites and cloned into the same sites of 
pBSIIKS(+); Midi was extensively sequenced 
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pKS1394 pBSIIKS+-RPB1K330R a Lysine Arginine Mutation at aa 330 in Rpb1 
was introduced by quick change mutagenesis into 
pBSIIKS+-RPB1 (pKS1393); Midi was extensively 
sequenced 
pKS1395 pBSIIKS+-RPB1K695R a Lysine Arginine Mutation at aa 695 in Rpb1 
was introduced by quick change mutagenesis into 
pBSIIKS+-RPB1 (pKS1393); Midi was extensively 
sequenced 
pKS1396 pBSIIKS+-RPB1K330R_K695R An additional Lysine Arginine Mutation at aa 695 
in Rpb1 was introduced by quick change 
mutagenesis into pBSIIKS+-RPB1K330R 
(pKS1394); Midi was extensively sequenced 
Miscellaneous  
pKS1339 pASZ11-PRE1 The EcoRI-SalI fragment of pKS759 was subcloned 
into the same sites of pASZ11 (pKS13) 
pKS1340 pASZ11-pre1-1 The EcoRI-SalI fragment of pKS760 was subcloned 
into the same sites of pASZ11 (pKS13) 
pKS1347 pYM46-NatNT3 The NcoI-EcoRV fragment of pYM21 (pKS689) 
was inserted into the corresponding sites of pYM46 
(pKS712) 
 
 
4.3. OLIGONUCLEOTIDES  
 
Table 6 | Oligonucleotides used in this study.  
Purpose Name Sequence (5’-3’) 
Gene disruptions 
Disruption 
of DST1 
5’_NotI_Dst1_prom gggGCGGCCGCGCATTCACACCGCTCTGCCTATTCA 
3’_BamHI_Dst1_prom gggGGATCCGATGAATGCTCTTATGCGGACTGAC 
5’_BamHI_Dst1_term gggGGATCCGATGAGAGTAGCCACGGACAGAGC 
3’_XhoI_Dst1_ term  gggCTCGAGACTCCTGGTGTGATTAGTGGTAGA 
Disruption 
of THO2 
5’_NotI_Tho2_prom gggGCGGCCGCCAGTCCGATGTACTTTTGTT 
3’_BamHI_Tho2_prom gggGGATCCAAAGTCCTGAAAATGTATAC 
5’_BamHI_Tho2_term gggGGATCCTTACTAGTACTTAACATACC 
3’_XhoI_Tho2_ term gggCTCGAGTATTCGCATTAGTACCATTT 
Disruption 
of BUR2 
5’_EcoRV_Bur2_prom ggg GATATCCTCGGATAAAACTTCCTTAAC 
3’_XhoI_Bur2_ term gggCTCGAGCCGAAGATAATGACTGTTC 
Disruption 
of PDR5 
5’_NotI_Pdr5_prom gggGCGGCCGCTTCCGCGGAATCGCTCATGCCGCG
G 
3’_BamHI_Pdr5_prom gggGGATCCGTCTAAAGTCTTTCGAACGAGC 
5’_BamHI_Pdr5_term gggGGATCCTGGTTAAGAAAAGAAACTTACCA 
3’_XhoI_Pdr5_ term gggCTCGAGCACGTTCGTTGTACTTCCAGTCG 
Disruption 
of UBC4 
5’_NotI_Ubc4_prom gggGCGGCCGCAGGGTAACTGCACTATTCAT 
3’_BamHI_Ubc4_prom gggGGATCCGTTTTTTTGGATGCTTGTTT 
5’_BamHI_Ubc4_term gggGGATCCACAGAAGTCCTTACTCAGCT 
3’_XhoI_Ubc4_ term  gggCTCGAGCTCCATACTGTTCGAGGAAA 
Disruption 
of UBC5 
5’_NotI_Ubc5_prom gggGCGGCCGCTATATGAAATCATCTGCAAC 
3’_BamHI_Ubc5_prom gggGGATCCTTTTAGTTTAGTTGAGGGTG 
5’_BamHI_Ubc5_term gggGGATCCTTAATTTGGGCTAACGGATA 
3’_XhoI_Ubc5_ term  gggCTCGAGCCCATCGTGAGTGCTTTGTT 
Disruption 
of RSP5 
5’_NotI_Rsp5_prom gggGCGGCCGCATCGCATCTGCTAATTGATA 
3’_BamHI_Rsp5_prom gggGGATCCCTTTTTTCTTTCCTTTCTGTTAC 
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5’_BamHI_Rsp5_term gggGGATCCTTATTCCGCACCAATTTTTT 
3’_XhoI_Rsp5_ term gggCTCGAGGGTATCATGCTCCTTTTGAA 
Disruption 
of UBP3 
5’_NotI_Ubp3_prom gggGCGGCCGCTATGCCATTGAAGGGCGGCT 
3’_BamHI_Ubp3_prom gggGGATCCTTTTTTTAATGATGATGGAA 
5’_BamHI_Ubp3_term gggGGATCCGACGGGGGGTGGTATTATAG 
3’_XhoI_Ubp3_ term gggCTCGAGATTCCATTGTTGCCAAAGGC 
Disruption 
of UBP2 
5’_NotI_Ubp2_prom gggGCGGCCGCATCTAGACACCGCTATCAAG 
3’_BamHI_Ubp2_prom gggGGATCCTTCCTTATACCTTCTTAACC 
5’_BamHI_Ubp2_term gggGGATCCTCTTAGTCAATGAAGAG 
3’_XhoI_Ubp2_ term gggGTCGACCGACGTTATTGCTGATTTGC 
Disruption 
of UBP4 
5’_NotI_Ubp4_prom gggGCGGCCGCGGTTGGACACTTTGGAACAC 
3’_BamHI_Ubp4_prom gggGGATCCAACTTAAGCATGTATCAAATAG 
5’_BamHI_Ubp4_term gggGGATCCTTCATTTGAATAAATAACTG 
3’_XhoI_Ubp4_ term gggCTCGAGGATGATGACTGGGAATGAGTG 
Disruption 
of UBP6 
5’_NotI_Ubp6_prom gggGCGGCCGCCGGTGGTGTCTTAATGGTTTC 
3’_BamHI_Ubp6_prom gggGGATCCATTTTAACACAAGGATAGGTAG 
5’_BamHI_Ubp6_term gggGGATCCGTCCATTTTTCATTTTTTC 
3’_XhoI_Ubp6_ term gggCTCGAGGGCAGCATTTCTATAAAGGC 
Disruption 
of UBP10 
5’_NotI_Ubp10_prom gggGCGGCCGCGTAGTGAAGAATTGTCCTG 
3’_BamHI_Ubp10_pro gggGGATCCAGTCTGTGATTGTGATATGAC 
5’_BamHI_Ubp10_term gggGGATCCAAAAACTCGATATTCCTGG 
3’_XhoI_Ubp10_ term gggCTCGAGGTACCGTCAATTTCGAGAA 
Disruption 
of UBP12 
5’_NotI_Ubp12_prom gggGCGGCCGCCAATGTCACTGCCATCTCTAAAG 
3’_BamHI_Ubp12_pro gggGGATCCTTTCGAATGAAGAAACCTTCG 
5’_BamHI_Ubp12_term gggGGATCCTGACATGAGTTTATATGATAG 
3’_SalI_Ubp12_ term gggGTCGACCTAGTGGTAAGAAGAAGATC 
Disruption 
of ELC1 
5’_NotI_Elc1_prom gggGCGGCCGCAGTTGGCCATTTTAATTCGC 
3’_BamHI_ Elc1_prom gggGGATCCTTAGTTATGGTTTTTTATTC 
5’_BamHI_ Elc1_term gggGGATCCGTACAGGAAAAACAAAAAAG 
3’_SalI_ Elc1_ term gggGTCGACATTCTTACATTTTATGCGGC 
Disruption 
of RAD26 
5’_NotI_Rad26_prom gggGCGGCCGCGAATCGTCGACATGACTAAG 
3’_BamHI_ Rad26_pro gggGGATCCCACTGATGTATGTTTCTCTG 
5’_BamHI_ Rad26_term gggGGATCCAAACTTAGAATGGACAGAGTAC 
3’_XhoI_ Rad26_ term gggCTCGAGCAACGGGTATCTCTACTATC 
Disruption 
of RPA12 
5’_NotI_Rpa12_prom gggGCGGCCGCGCACTTTTCGTAACTTTATC 
3’_BamHI_Rpa12_prom gggGGATCCTCTTATAAGTACTAACCTGG 
5’_BamHI_Rpa12_term gggGGATCCTTGGGTTGTGTTCGCACATATTAC 
3’_SalI_Rpa12_term gggGTCGACGTTTGTAGCTCTTTATCACGC 
Disruption 
of ASR1 
5’_NotI_Asr1_prom gggGCGGCCGCACAGCCATCTTTATCTTTAC 
3’_ BamHI_Asr1_prom gggGGATCCCTTTTTATATGATATTTGG 
5’_BamHI _Asr1_term gggGGATCCTAATGCAATATAACATTAAAACAAG 
3’_ XhoI _Asr1_term gggCTCGAGGGAACTCATATATTATCTCTTC 
Disruption 
of BRE1 
5’_NotI_Bre1_prom gggGCGGCCGCTAGTTGATTATGTATGGCAG 
3’_ BamHI_Bre1_prom gggGGATCCATCTGATTATTATCAGCTAG 
5’_BamHI_Bre1_term gggGGATCCTACTAATTATTCTACCAC 
3’_ SalI_Bre1_term gggGTCGACATATATCTTGAACAAGC 
Checking 
for correct 
integra-
tion after 
gene 
disruption 
5’_HIS_del_down CTATACGTGTCATTCTGAACGAGGCGC 
3’_HIS_del_up GGGAAAGGACTGTGTTATGACTTCC 
5’_Kan_del_down GCAGTTTCATTTGATGCTCGATGAG 
3’_Kan_del_up GAAACGTGAGTCTTTTCCTTACCC 
5’_Ctk1_600_up_del CCAAAGATTTACGACAACTA 
5’_DstI_600_up_del CGAACATCATTTTCAAATTGATCA 
3’_DstI_400_down_del TCTGCACCTTTATGTGTGCATCTA 
5’_Pdr5_600_up_del ACGATTATCACGACACAACCTTGC 
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3’_Pdr5_400_down_del GTATGTCAGCCTGCCGTATGTCA 
5’_Ubc4_600_up_del GCTACTGTTTTAGTCAACAT 
3’_Ubc4_400_down_del AGGTACGGTTAACGTTGACG 
5’_Ubc5_600_up_del TCTTAGATTATGTTGGGCAA 
3’_Ubc5_400_down_del ATTTAGCTAGATGAATCAGA 
5’_Rsp5_600_up_del AAAGACCAAATTGCAGTGAT 
3’_Rsp5_400_down_del TATGGTTGTAAAAAGCAGGG 
5’_Tho2_600_up_del ATGAAACGTACTCCAAAGAT 
3’_Tho2_400_down_del ATGAAACATGGGGTCGTATC 
5’_Ubp3_600_up_del ATGCATTGCACATCTGAGAT 
3’_Ubp3_400_down_del GCTAAATTTGGATGATTAC 
5’_Ubp2_600_up_del CAATTTAGAAAGAACAGATGG 
3’_Ubp2_400_down_del GTATCATCATTTCCATTGAC 
5’_Ubp4_600_up_del CTTTCTCAATCGTCACTAGG 
3’_Ubp4_400_down_del CGAAAGTTGCTGTGTCTCAAG 
5’_Ubp6_600_up_del GCATTGTGTTTAAATAATCCAC 
3’_Ubp6_400_down_del CAAATCGAGTCGTTGAAC 
5’_Ubp10_600_up_del CAATAGTGTTGAAGACCCAC 
3’_Ubp10_400_down_d GGCATAGTTTATTGGAGATG 
5’_Ubp12_600_up_del AGAAGTTGGTGACAAGCTTG 
3’_Ubp12_400_down_d GCAGCCATTCTTACATCCTAC 
5’_Elc1_600_up_del TTCACAATTTTGATGGAGC 
3’_Elc1_400_down_del AATTGAAAAGGCACAGACAG 
5’_Rad26_600_up_del ACCCTCAAGAATGTCTTGAC 
3’_Rad26_400_down_d GAATCATCGGAGAAGCCA 
5’_Rpa12_600_up_del CTTTCTTAGTAACATAAGG 
3’_Rpa12_400_down_d ACAATGGCGTTCGACAGAT 
5’_ Asr1_600_up_del AGTACCATGGGTTATAAATG 
3’_ Asr1_400_down_del AAAGGGTTGTCGACATGTAG 
5’_ Bre1_600_up_del TTGATAAACCTGTTCAAC 
3’_ Bre1_400_down_del CAGTAGAAGAGTTATGTTAC 
TAP-tagging 
Carboxyl-
Terminal 
TAP 
tagging of 
proteins 
Pre1 primer 1 AAATCGTGGATAAAGATGGCATAAGACAAGTAGATG
ACTTCCAGGCACAGTCCATGGAAAAGAGAAG 
Pre1 primer 2 ATTTAATTTTATGAACGAGGAAGATAATTACTTTAG
TATATCATTAGCAATACGACTCACTATAGGG 
Pre2 primer 1 TATTTTGGAAGGTCAAGGAAGAGGAAGGATCTTTCA
ACAACGTTATTGGCTCCATGGAAAAGAGAAG 
Pre2 primer 2 GGACTTCCTTCATAATTCTATGGGAAGCCATATTGG
ATCCTTGAAGAGAATACGACTCACTATAGGG 
Pre4 primer 1 TGAAATGGGACTTCGCCAAGGATATTAAAGGCTACG
GTACTCAAAAAATTTCCATGGAAAAGAGAAG 
Pre4 primer 2 GAAGAGAGAAGAGTGATGATATTATGAATTGAAAAA
TAAAAATAAAATGATACGACTCACTATAGGG 
Pup1 primer 1 ATTGTCAATATTTGTGACATACAAGAAGAACAAGTC
GATATAACGGCTTCCATGGAAAAGAGAAG 
Pup1 primer2 TATGTAAATAGTTTTGCGGTTAGTTTTTGACTTCCT
TTATCACATTTTGTTACGACTCACTATAGGG 
Sug1 primer 1 TTATGAACAAGAACCAAGAAACGGCCATTTCTGTCG
CCAAGCTGTTCAAGTCCATGGAAAAGAGAAG 
Sug1 primer 2 GTATATCCAGCGGTATAATTTTGCCTCTTAGTTAAT
GCTAAACTATGATATACGACTCACTATAGGG 
Sug2 primer 1 AAGTAGCTGAAGTTAAGAAATTGGAAGGCACTATAG
AATACCAAAAATTATCCATGGAAAAGAGAAG 
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Sug2 primer 2 CTAGAGTTCAATAGCCATTTCGAGCTTAAATAAGGC
AAGCTTTCTCGCATTACGACTCACTATAGGG 
Cim5 primer 1 TTAGCGGATACAAGAAGTTTAGTTCCACATCGCGTT
ATATGCAATATAATTCCATGGAAAAGAGAAG 
Cim5 primer 2 GAGGGGATACTCTCGTATCCTTTTTATCTCGATAGT
TGTAGTTGTACTTGTACGACTCACTATAGGG 
Rpb1 primer 1  
 
CTCCAAAGCAAGACGAACAAAAGCATAATGAAAATGA
AAATTCCAGATCCATGGAAAAGAGAAG 
Rpb1 primer 2 
 
CCCTATCCCTACCATAATGCTATGAAAAATAATGGT
ATATTTGGTATACGTACGACTCACTATAGGG 
Rpb2 primer 1 GGCTATGAACATTACACCACGTTTATATACCGATCG
TTCGAGAGATTTTTCCATGGAAAAGAGAAG 
Rpb2 primer 2 GAAATGCTTCATTCTTATTTTATTACTATTGCCTAC
TTGTTTACCCTACGACTCACTATAGGG 
Rpb3 primer 1 ATGCATCTCAAATGGGTAATACTGGATCAGGAGGG
TATGATAATGCTTGGTCCATGGAAAAGAGAAG 
Rpb3 primer 2 TAAAGCTTTTTTTCTCTTATTATTTTCGGTTCGTTC
ACTTGTTTTTTTTCTACGACTCACTATAGGG 
Rpa190 primer 1 ATGTTGGTACGGGTTCATTTGATGTGTTAGCAAAG
GTTCCAAATGCGGCTTCCATGGAAAAGAGAAG 
Rpa190 primer 2 AATGGCGCTACCCATTGTGCATTTTTCTCTCTTTTC
TTCTGACCTTCTCCTACGACTCACTATAGGG 
Rpc160 primer 1 GCGATGTCTATTTGAAAGTCTCTCAAATGAGGCAGC
TTTAAAAGCGAACTCCATGGAAAAGAGAAG 
Rpc160 primer 2 GGTTTTTATCATGTAGTTTTATATGTATAAATACGT
TAAATGACTGTGGTAGTACGACTCACTATAGGG 
Gene Cloning 
Cloning of 
genes into 
the 
pRSseries 
5’_BamHI_Cim3_500   gggGGATCCCCACAGCCAAACTGGTCAATTGG 
3’_SalI_Cim3_300 gggGTCGACAGGCTGAGTGGTCGTTTGCTGTG 
5’_NotI_Sug2_500   gggGCGGCCGCAGGTCTATTACCGATGGGCAAAA 
3’_SalI_Sug2_300 gggGTCGACGGATTCTTCATTAGTTGGGACGA 
5’_BamHI_Cim5_500   gggGGATCCCGCCATTGTTGCACTATAAGGCG 
3’_SalI_Cim5_300 gggGTCGACCAATTAGAGAATGAGATTGAGGG 
Gene Sequencing 
Rpb1 Rpb1_seq1 CTGAAATCATATCTGTGTTG 
Rpb1_seq2 CACCTGAAGAAGTTAGAGCA 
Rpb1_seq3 TCTGAAGATGATCCTACTCA 
K330R_Rpb1_seq 1 GGAAACACTAGAGCATAACG 
Rpb1_seq5 GCCCACAGAGTAAAAGTTAT 
K695R_Rpb1_seq 1  GTTTGTGCTAAGTTGTTTGG 
Rpb1_seq7 CGTGAAGGTCTTATCGATAC 
Rpb1_seq8 ATTAGTGTTGCGTGGTAAGA 
Rpb1_seq9 TCTCATTATTGGATGAAGAG 
Rpb1_seq10 ATGTTATTGCTTCTGATGGT 
Rpb1_seq11 ACATCTCCCGGATTTGGAGT 
Rpb1_seq12 TTCTCCAAAGCAAGACGAAC 
Ubi4 Ubi4_seq1 TTAATGCGCCGCTACAGGGC 
Ubi4_seq2 ACTACCAACGCAATATGGAT 
Ubi4_seq3 ATCGATAACGTTAAGTCGAA 
Ubi4_seq4 GAACCTTGTCTGACTACAAC 
Rsp5 Rsp5_seq1 GATACTGCTACATCGAGTGG 
Rsp5_seq2 CACGTGTATATTTCGTTGAC 
Rsp5_seq3 GTATAGATGGTGTCTTGG 
Ubp6 Ubp6_seq1 ATACGAGATTTCGTTCTC 
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Ubp6_seq2 AGCGATTCTAAATTAC 
Ubp6_seq3 TTGAATCTTTAGCCGGTG 
Generation of GAL-Depletion Strains 
GAL1 
promoter 
insertion 
Dst1 F4 TCACTCGATGATGGGACTACGTATTGAAAAATATTG
AATGAAAAATTACTGAATTCGAGCTCGTTTAAAC 
Dst1 R2 TTGTTCTTTTCTAGATTCTTAACATGTACCAGTACT
TCCTTACTATCCATTTTGAGATCCGGGTTTT 
Tho2 F4 AATTATAGGGCTGTGATTTTATCGTCTTTATCTAAA
GCATAATAGGGTGAGAATTCGAGCTCGTTTAAAC 
Tho2 R2 ACTTTTTGAGAAAGAGCGTTCAATTTGGAAAGTAGC
GTCTGTTCTGCCATTTTGAGATCCGGGTTTT 
Bur2 F4 TATTTCTGTTAGAAAGCAAGTAGCTATTTTGATTGG
TAATTATATACACAGAATTCGAGCTCGTTTAAAC 
Bur2 R2 GGTACAGCTTGAAATTTTTTCACGTCACCACTTGAA
GATGTAGCAGACATTTTGAGATCCGGGTTTT 
Checking 
for correct 
insertion 
of pGAL1 
5’_colPCR_Gal1P TGTAAAGAGCCCCATTATCT 
3’_Gal1P_Bur2_colPC TGCACTCAAAAACCCACTGG 
3’Gal1P_Ctk1_colPCR TGAGAAGATATATTGTCCAT 
3’Gal1P_Dst1_colPCR GTTTGCTGATCTCTACATTA 
3’Gal1P_Tho2_colPCR TTGACTCCAGTGCAGTGAAA 
Real Time PCR primers 
RNApolII 
mRNA 
levels  
5’_Rpb1_RT1 GTGTGGATTTTTCGGCAAGAA 
3’_Rpb1_RT1 TGGAACACCGACTTGGTCTAATT 
5’_Rpb3_RT1 CGAAGGTGACCCCTTCGAT 
3’_Rpb3_RT1 CGGGAATAGACCCCACAGATT 
5'_Adh1_M_RT2 AGCCGCTCACATTCCTCAAG 
3'_Adh1_M_RT2 ACGGTGATACCAGCACACAAGA 
5’_Actin_RT3 TCAGAGCCCCAGAAGCTTTG 
3’_Actin_RT3 TTGGTCAATACCGGCAGATTC 
ChIP 
qPCR 
primers 
5’_Adh1_prom_RT1 ACGACAAAGACAGCACCAACA 
3’_Adh1_prom_RT1 ACCCCTCATCAGCTCTGGAA 
5’_Adh1_5’gene_RT1 GTTGTCGGCATGGGTGAAA 
3’_Adh1_5’gene_RT1 GGCGTAGTCACCGATCTTCC 
5'_Adh1_M_RT2 AGCCGCTCACATTCCTCAAG 
3'_Adh1_M_RT2 ACGGTGATACCAGCACACAAGA 
5’_Adh1_3’gene_RT1 TTGGACTTCTTCGCCAGAGG 
3’_Adh1_3’gene_RT1 GCCGACAACCTTGATTGGAG 
5'_Pma1_M_RT2 AAATCTTGGGTGTTATGCCATGT 
3'_Pma1_M_RT2 CCAAGTGTCTAGCTTCGCTAACAG 
5’_Actin_RT3 TCAGAGCCCCAGAAGCTTTG 
3’_Actin_RT3 TTGGTCAATACCGGCAGATTC 
5'_YERTIR_RT TGCGTACAAAAAGTGTCAAGAGATT 
3'_YERTIR_RT ATGCGCAAGAAGGTGCCTAT 
 
 
4.4. ANTIBODIES   
 
Table 7 | Antibodies used in this study.  
Name  Source Dilution Company 
Primary Antibodies 
anti-Ser2P (H5) mouse 1:500 MMS-129R; Covance 
anti-Ser5P (H14) mouse 1:500 MPY-127R; Covance 
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anti-RPB1 (8WG16) mouse 1:500 MMS-126R; Covance 
anti-RPB1 (yN-18) goat 1:1000 sc-8952; Santa Cruz 
anti-PGK1 mouse 1:20000 A-6457, Molecular Probes 
Peroxidase Anti-Peroxidase (PAP) rabbit 1:5000 P1292, Sigma 
anti-DST1 goat 1:200 sc-26335; Santa Cruz 
anti-MED2 goat 1:1000 sc-28058; Santa Cruz 
anti-SPT5 goat 1:400 sc-26355; Santa Cruz 
anti-mono/polyubiquitin (FK2) mouse 1:1000 PW8810; Biomol 
anti-polyubiquitin (FK1) mouse 1:500 PW8805; Biomol 
anti-ubiquitin (P4D1) mouse 1:1000 #3936;Cell Signalling Tech. 
anti-polyubiquitin (Apu2.07; K48-
specific chains) 
human 1:2000 (Newton, Matsumoto et al. 2008) 
anti-polyubiquitin (Apu3.A8; 
K63-specific chains) 
human 1:2000 (Newton, Matsumoto et al. 2008) 
Secondary Antibodies 
anti-mouse-HPRO (IgG H+L) goat 1:3000 #170-6516; Biorad 
anti-goat-HPRO (IgG) rabbit 1:5000 A5420; Sigma 
anti-mouse-HPRO (IgM) goat 1:300 A8786; Sigma 
anti-human-HPRO (IgG) goat 1:2000 #55220; Cappel 
 
 
4.5. CHEMICALS & CONSUMABLES 
 
Table 8 | Chemicals and consumables used in this study.  
Name  Source 
Standard chemicals and consumables 
Standard chemicals and 
consumables were purchased 
from the companies listed 
Acros Organics; Applichem; Applied Biosciences; Apollo Scientific 
Limited; Axon; Becton Dickinson; Beckman Coulter; Biaffin; Biomol; 
Biorad; Biozym; Fermentas; Formedium; GE Healthcare; Gilson; 
Invitrogen; Lake Placid Biologicals; Macherey&Nagel; Medac;  
Membra Pure; Merck Biosciences; Millipore; Mobitec; MP Biomedical; 
NEB; Neolab; Nunc; Peske; Promega; Qiagen; Roche; Roth; Santa 
Cruz; Sarstedt; Semadeni; Serva; Sigma-Aldrich; Stratagene; VWR 
Enzymes & Proteins & Standards 
Calf Intestine Alkaline 
Phosphatase 
Fermentas 
DNase-free RNase Roche 
DNA Standards Fermentas 
Glycogen Roche 
  
Lysozyme VWR 
Moloney Murine Leukemia 
Virus (M-MuLV) Reverse 
Transcriptase 
Fermentas 
Phusion Flash® High Fidelity Finnzymes 
Protein Standards Fermentas 
Proteinase K Sigma-Aldrich 
Pronase Sigma-Aldrich 
Restriction Endonucleases  Fermentas; New England BioLabs 
RNasin® Plus RNase Inhibitor Promega 
T4 DNA Ligase Fermentas 
T4 DNA Polymerase Fermentas 
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Taq Polymerase Fermentas; Axon 
TEV protease This study 
VentR® DNA polymerase  New England BioLabs 
Zymolase 20T Medac 
Zymolase 100T Medac 
Antibiotics & Drugs 
6-Azauracil Sigma-Aldrich 
Ampicillin Roth 
Chloramphenicol Sigma-Aldrich 
Chloronaphtol Sigma-Aldrich 
Clasto-Lactacystin Boston Biochemicals; Stratagene 
Cycloheximide Sigma-Aldrich 
Geneticin Serva 
Kanamycin Roth 
MG-132 proteasomal inhibitor Biomol 
MycoPhenolic Acid (MPA) Sigma-Aldrich 
N-ethylmaleimide (NEM) Sigma-Aldrich 
Commercially available kits 
ECL kit Applichem 
DC Protein Assay kit  Biorad 
Nucleobond AX PC100 Macherey & Nagel 
Nucleospin Mini Macherey & Nagel 
Nucleospin extract Macherey & Nagel 
RNeasy MinElute Cleanup Kit Qiagen 
West Dura ECL kit  Thermo 
 
 
4.6. GROWTH MEDIA & GENERAL BUFFERS 
 
Table 9 | Media and buffers used in this study.  
Name Description 
Growth media 
LB (Luria-Bertani Broth) 1% (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) NaCl 
(+2%(w/v) agar for selective media plates) 
Yeast Full Media (YPD or YPG) 2% (w/v) peptone; 2% (w/v) glucose (or galactose); 1% (w/v) yeast 
extract (+2% (w/v) agar for selective media plates) 
Synthetic Dextrose Complete 
(SDC)  
0.67% (w/v) yeast nitrogen base; 0.06% (w/v) complete synthetic 
mix of amino acids; drop out as required; 2% (w/v) glucose; when 
required 0.1% (w/v) 5’-FOA was added; (+2% (w/v) agar for 
selective media plates) 
Synthetic Galactose Complete 
(SGC)  
0.67% (w/v) yeast nitrogen base; 0.06% (w/v) complete synthetic 
mix of amino acids; drop out as required; 2% (w/v) galactose; when 
required 0.1% (w/v) 5’-FOA was added; (+2% (w/v) agar for 
selective media plates) 
Sporulation Media (YPA)  1%(w/v) yeast extract; 2% (w/v) peptone; 1% (w/v) potassium 
acetate; (+2% (w/v) agar for selective media plates) 
General Buffers, dyes & solutions 
4x Stacking gel buffer  0.5M Tris; 0.4% (w/v) SDS; pH 6.8 at 25°C 
4x Separation gel buffer 3 M Tris; 0.4% (w/v) SDS; pH 8.8 at 25°C 
10x Tris glycine electrophoresis 
buffer 
250 mM Tris; 1% (w/v) SDS; 1.9 mM glycine  
4x Sample loading buffer 0.2 M Tris pH 6.8 at 25°C; 40% (v/v) glycerol; 8% (w/v) SDS; few 
grains Bromophenol Blue; 0.1M DTT  
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Coomassie staining solution 0.25% (w/v) Coomassie Brilliant Blue R-250; 30% (v/v) Ethanol; 
10% (v/v) acetic acid 
Coomassie destaining solution 30% (v/v) Ethanol; 10% (v/v) acetic acid 
AmidoBlack staining solution 0.2% AmidoBlack; 10% methanol; 2% acetic acid 
AmidoBlack destaining solution 90% methanol; 3% acetic acid 
Ponceau staining solution 0.1% (w/v) PonceauS; 5% acetic acid 
1x Wet transfer buffer 25mM Tris; 192mM glycine; 10% methanol 
1x Semi-Dry transfer buffer 48mM Tris; 38mM glycine; 1.28mM SDS; 10% methanol 
10x Phosphate-buffered saline 
(PBS) 
1.37M NaCl; 27mM KCl; 20mM KH2PO4; 10mM Na2HPO4·2 
H2O; when required 0.1% (w/v) Tween-20® was added 
10x Tris-buffered saline (TBS) 1.37M NaCl; 27mM KCl; 125mM Tris-HCl pH 7.4 at 25°C 
50x TAE 2M Tris; 100mM EDTA pH 8.0; 1M Acetic Acid  
6x DNA loading dye 40% (w/v) sucrose; 0.25% Bromophenol Blue; 0.25% Xylene cyanol 
FF 
TBE 90mM Tris-borate; 2mM EDTA 
TE 1mM EDTA; 10mM Tris-HCl pH 8.0 at 25°C 
100x Protease Inhibitors 0.028 mg/ml Leupeptin; 0.137 mg/ml Pepstatin A; 0,017 mg/ml 
PMSF; 0.33 mg/ml benzamidine; in 100% EtOH p.a. 
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5. METHODS 
 
5.1. MOLECULAR BIOLOGY METHODS 
 
5.1.1. Agarose gel electrophoresis 
The method is described in detail in (Voytas 2001). In this study it was performed in 1% 
(w/v) agarose gels containing 0.2μg/mL ethidium bromide, with 1xTAE as electrophoresis 
buffer. DNA standard (200ng) was used for determining the length of the fragments. 
 
5.1.2. Molecular cloning 
Cloning procedures such as digestion of DNA fragments with restriction endonucleases, 
dephosphorylation and ligation of DNA fragments and transformation of newly generated 
vectors in Escherichia coli were done according to Sambrook & Russell, 2001. 
Commercially available kits for purification of DNA fragments from agarose gels and for 
preparation of plasmid DNA were used according to manufacturer’s instructions. 
 
 
5.1.3. Polymerase Chain Reaction (PCR) 
 
5.1.3.1. Amplification of yeast genes or TAP-tags 
Reactions were done in 50-100 μl final volume using 0.5 μM primer1, 0.5 μM primer2, 
0.2mM of each dNTP, 1x KNOP buffer (50mM Tris-HCl pH 9.2, 16mM (NH4)2SO4, 
2.25mM MgCl2), 0.3 μl genomic DNA or 1 μl 1:20 diluted plasmid Midiprep and 1μl 
KNOP mix polymerase (2U Taq, 0.56 U Vent).  
In general, the following amplification protocol was used: 2 min 94°C, [1 min 94°C, 30 s 
at the respective °C, 1 min / 1000 bp 68°C] for 35 cycles and 10 min 68°C. 
5.1.3.2. Yeast colony PCR 
Reactions were done in 25 μl final volume using 1 μM primer1, 1 μM primer2, 
62.5μM of each dNTP, 750μM MgCl2 and 1x Taq buffer (Fermentas). Freshly growing 
yeast cells were picked with a yellow tip and added to the reaction. The reaction was boiled 
for 15min, before 1.5U Taq polymerase were added. Amplification was then performed 
using the following protocol: [30sec 95°C, 30sec 45°C, 60sec 72°C] for 25 cycles and 2 
min 72°C. 
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5.1.3.3. Proof-reading PCR for cloning 
Point mutations were inserted by quick change mutagenesis using Pfusion Flash® High 
fidelity polymerase (Finnzymes). Reactions were performed according to the provided 
protocol. The PCR product was then digested with 10U DpnI for 2 hours at 37°C. Then, 
50μl of the reaction were transformed into E. coli DH5α. Point mutations or plasmids were 
sent for sequencing to Eurofins MWG-Operon in a concentration of 150ng/μL. 
 
5.1.4. Extraction and Ethanol Precipitation of DNA  
Digested DNA fragments from plasmids or PCR products were brought to 100μL final 
volume. Then, 60 μl of  phenol:chloroform:isoamylalcohol (25:24:1) were added to the 
DNA solution. After 10 min centrifugation at 16000g, the upper phase was removed, 
mixed with an equal volume of chloroform and centrifuged for 5min at 16000g. The 
upper phase was then removed, mixed with 1/10 of the volume of 3M sodium acetate pH 
5.2 as well as 2 volumes of 100% ethanol. After incubation for 1 h at -20°C, the DNA was 
precipitated and washed with 70% ethanol. The pellet was dried and resuspended in 10μl 
of TE buffer and used for subsequent reactions.  
 
 
5.2. YEAST SPECIFIC METHODS 
 
5.2.1. Cell density of a yeast culture  
The cell density of a yeast culture was determined in a spectrophotometer at a wavelength 
of 600nm. One Optical Density at 600 nm (1 OD600) corresponds to 2.5x107 cells.  
 
5.2.2. Transformation of yeast cells 
For the transformation 50 ml of yeast were grown to an OD600 of 0.5 to 0.8 and harvested 
by centrifugation for 3 min at 3600rpm using a Rotanda 46R centrifuge. After washing 
with 10 ml H2O, the pellet was resuspended in 500μl of Solution I. After centrifugation, 
the pellet was resuspended in 250μl Solution I. Every reaction consisted of 1μl of Midi-
prep DNA or 5μl of Mini-Prep DNA, 5μl of single strand carrier DNA (DNA of salmon 
or herring testis, 2mg/ml), 50μl of cells in Solution I and 300μl of Solution. The reaction 
was incubated for 30min on a turning wheel at 25°C. The transformations were then heat-
shocked for 10min at 42°C, followed by 3min incubation on ice. Then, 1ml of ddH2O 
was added and the cells were pelleted by centrifugation. The cell pellet was resuspended in 
50μl H2O and plated on drop-out selective plates according to the selection marker of the 
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transformed DNA fragment. For genomic integrations, that required homologous 
recombination to take place, the cells were allowed to recover. Specifically, the cell pellets 
were resuspended in 1ml of full yeast media and incubated for at least 1h at 25°C on a 
turning wheel prior to plating. To transform yeast cells grown on plate, 1 loop of freshly 
restreaked yeast cells was resuspended in 100mM Li-acetate and mixed well.  The 
transformation reaction was prepared as described above. After the 30min incubation at 
25°C, 35μl of DMSO were added prior to heat shock. Afterwards the reactions were 
treated as described above.  
 
 
 
 
 
 
5.2.3. Preparation of yeast genomic DNA 
For this purpose, 10ml of an overnight saturated yeast culture with an OD600>1 were 
centrifuged (3min, 3600rpm) and washed with 10ml H2O. The cells were resuspended 
with 500μl H2O. To the cell suspension 200μl Lysis buffer, 300μl glass beads and 300μl 
phenol:chloroform:isoamylalcohol (25:24:1) were added.  The mixture was then vortexed 
at full speed for 3min. After centrifugation for 10min at 16000g the upper phase was 
removed and extracted with an equal volume of chloroform. Genomic DNA was 
precipitated by addition of 1.2ml of 100% ethanol and incubation of the solution for 
10min at -20°C. After centrifugation for 30min at 4°C and 16000g, the pellet was dried 
and resuspended in 400μl TE . To degrade the RNA, 20μl RNaseA (10mg/ml) were added 
and incubated for 40min at 37°C. Genomic DNA was then precipitated by addition of 
40μl 3M Na-acetate pH 5.2 and 800μl of 100% ethanol and incubation of the mixture for 
10min at -20°C. After centrifugation (16000g, 4°C, 30min) the pellet was washed with 
80% ethanol, dried and resuspended in 30μl TE. 
 
Lysis Buffer 
2% Triton X-100 
1% SDS 
100mM NaCl 
10mM Tris-HCl pH 8.0 
1mM EDTA 
Solution II 
10 mM Tris-HCl pH 7.5 
1 mM EDTA 
100 mM Li-acetate 
40% PEG-4000 
Solution I  
10 mM Tris-HCl pH 7.5 
1 mM EDTA 
100 mM Li-acetate 
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5.2.4. Dot spot test 
Dot spot test was used to assay the growth of yeast clones on different conditions e.g. 
selective media; drugs and temperatures. For this, 1 loop of freshly growing cells was 
resuspended in 1ml water. After performing five 10-fold serial dilutions, 10-15μl of the cell 
suspensions were spotted onto the corresponding plate (YPD, SDC-X with or without the 
addition of drugs). Plates were then incubated upside down to the desired temperature.  
 
5.2.5. Epitope tagging of proteins 
In yeast, tagging of genes by chromosomal integration of PCR-amplified cassettes is a 
standard method to label proteins in vivo. This ‘one-step tagging’ strategy directs the 
amplified tags to the desired chromosomal loci due to flanking homologous sequences 
provided by the PCR-primers. These tags are combined with different selectable marker 
genes, resulting in PCR amplificable cassettes. For the genomic integration of a Tandem 
Affinity Purification (TAP) tag to the N- or the C-terminus of the targeted protein, the 
method described in (Puig, Caspary et al. 2001) was essentially followed. The created 
PCR-product was extracted and ethanol precipitated. The purified DNA was then 
transformed into the yeast cells to achieve integration into the genome by homologous 
recombination. Transformants were tested for the presence of the tag by western Blotting.  
 
5.2.6. Single gene deletions 
In order to disrupt a gene, its coding sequence has to be replaced by an auxotrophy marker. 
This is achieved by homologous recombination using a construct carrying overlapping 
regions in the promoter and terminator region of the respective gene, separated by an 
auxotrophy marker. The geneX::MARKER construct was cloned by PCR amplifications of 
a 500bp RestrictionEnzyme(RE)I-BamHI promoter and a 300bp BamHI-REII terminator 
fragment of GeneX, which were ligated into the REI-REII sites of the pBluescriptIIKS(+) 
plasmid resulting in pBSKS-5’-ΔgeneX-3’. The BamHI MARKER fragment from the YDp 
series of plasmids (Berben, Dumont et al. 1991) was then inserted into the BamHI site of 
pBS-5’-ΔgeneX-3’. The GeneX shuffle strain was generated by transformation of the REI-
REII geneX::MARKER fragment in a diploid W303 strain and selection for MARKER+ 
transformants. Deletion of geneX was assessed by colony PCR using primers that anneal in 
the promoter of geneX and in the MARKER gene sequence. Positive heterozygous 
transformants were transformed with pRS316-GENEX. Cells were sporulated and tetrads 
dissected using a tetrad dissection microscope. Correct deletion process was confirmed by a 
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2:2 ratio of two spores growing and two spores dying on SDC-Marker plates. Haploid 
geneX::MARKER spores were selected for further experiments.  
 
5.2.7. Mating of yeast strains 
In order to combine two or more gene deletions, the single deletion strains were mated. 
For mating, haploid parental strains carrying opposite mating types were mixed onto YPD 
plates. After several hours, the characteristic diploid cells were selected using a dissection 
microscope onto YPD plates. The next day, the grown colonies –derived from the single 
diploids- were restreaked on the necessary plates.  
 
5.2.8. Sporulation and tetrad dissection 
For sporulating a diploid strain, freshly grown diploid cells were restreaked onto 
sporulation plates. On these plates, the diploid cells undergo meiosis and the genetic 
information is divided in four haploid spores, enclosed in a tetrad. Sporulation was 
monitored on a light microscope. The outer cell wall of the tetrad was destroyed by 
incubating 1 loop of cells in 10μl Zymolase20T. The destruction was stopped by addition 
of 30μl of 1xTE, and the spores could be dissected using the tetrad microscope. Tetrads 
with four growing spores were then restreaked onto YPD and the respective drop out plates 
to check for segregation of markers. Double knock out strains were selected by checking 
for the correct 2:2 auxotrophy marker distribution. 
 
5.2.9. Depletion of genes by glucose repression  
A genomic depletion system for the targeted geneX was designed based on a strain carrying 
a C-terminal TAP-tagged version of geneX (allowing determination of protein levels using 
the PAP antibody) driven by the GAL1 promoter (GAL1::geneX-TAP). Cells were grown 
in galactose-containing media (YPG, GeneX expressed) to mid-log phase. Cells were then 
centrifuged (3min, 3600rpm), washed with H2O and resuspended in glucose containing 
medium (YPD), where the expression of geneX was repressed. A small amount of cells (5 
OD600) was taken every 2h to monitor by western blot for the reduction in the protein 
levels of ProteinX.  
 
5.2.10. Growth curve analysis  
In order to analyse the growth of different yeast strains, a growth curve analysis was 
performed. For this, the optical density of three independent yeast cultures was assessed 
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every hour and documented. The cultures were always kept in mid-log phase and so were 
diluted to an OD600 of 0.3 as soon as they reached an OD600≥1.  
 
5.2.11. Yeast Whole Cell Extracts (WCE) 
 
5.2.11.1. Glass beads preparation 
For analytical WCEs a 2ml culture was inoculated with one loop of freshly grown cells and 
grown over night to saturation. Cells were harvested (3min, 3600rpm), resuspended with 
95°C hot 100μl 1x Sample Buffer (1xSB) and vortexed with 100μl glass beads as following: 
3 x [1min vortexing, 3 min 96°C]. After 5min spin at 16000g, the supernatant was isolated 
from the glass beads and was used for further experiments. For native WCEs, cells were 
grown to mid-log phase and 10 OD600 were harvested and washed with 1ml 1x TAP buffer 
(for recipe see below). The pellet was resuspended in an equal volume of 1x TAP buffer 
and lysed with the double volume of glass beads (4x2min vortex, 2min ice). After a low 
spin (3min, 1500g, 4°C), the supernatant was centrifuged for 30min at 16000g and 4°C. 
The protein concentration was determined using the DC Protein Assay kit.   
 
5.2.11.2. Denaturing protein extraction 
Denaturing protein extraction from yeast cells was carried out essentially as described 
(Knop, Finger et al. 1996). Briefly 5 OD600 of cells were resuspended in 500μl of ddH2O, 
150μl of pre-treatment solution were added and the mixture was incubated for 20min on 
ice. After addition of 150μl of 55% (v/v) Trichloroacetic acid (TCA) and a further 20min 
incubation on ice, the tubes were centrifuged for 20min at 16000g and 4°C. The 
supernatant was removed and the pellets were resuspended with 100μl of 1xSB and 20μl of 
1M Tris base. The samples were then incubated for 2min at 95°C. After 5min 
centrifugation at full speed the supernatant was ready for use in further experiments.  
Pre-treatment solution 
7.5% (v/v) β-mercaptoethanol 
1.85M NaOH 
 
 
5.2.12. Long-term storage of yeast cultures 
To store yeast cultures for longer periods, freshly growing cells (approximately 100μL) 
were resuspended in 1mL of 50% (v/v) sterile glycerol. Cell suspensions were quick freeze 
in liquid N2 and stored at -80°C.  
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5.3. SDS-PAGE & WESTERN BLOTTING 
 
5.3.1. SDS-PAGE 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out 
according to Laemmli using the Mini-Protean II system (Biorad). Routinely, 6% to 15% 
polyacrylamide mini gels were used. For separation of purified complexes occasionally pre-
cast 4-12% Bis-Tris gradient gels were used. After electrophoresis, separated proteins were 
either transferred to a membrane (western blot) or directly stained with Coomassie.  
 
 
5.3.2. Western Blotting 
 
5.3.2.1. Protein transfer 
In order to detect a specific protein in a given sample of an extract, proteins were separated 
by SDS-PAGE and then transferred to a nitrocellulose of a PVDF membrane.  Briefly the 
stacking gel was removed after the run and the gel was equilibrated for 1min in 1x Semidry 
or Wet blotting buffer. The PVDF membrane was previously activated (in methanol) and 
washed with 1xSemidry or Wet blotting buffer. A sandwich consisting of (from bottom to 
top) three layers of  Whatman®-paper soaked in 1x blotting bufer, nitrocellulose or PVDF 
membrane, polyacrylamide gel and another three soaked Whatman®-papers was assembled 
in a Semidry or Wet blotting device. Semidry devices were mostly used for transfer of low 
molecular weight proteins onto nitrocellulose membranes while Wet blotting devices were 
used for transfer of high molecular weight proteins onto PVDF membranes. Proteins were 
transferred either at 7V for 45min (Semidry) or at 100V for 1h (Wet). Successful transfer 
was monitored by PonceauS or AmidoBlack reversible staining of the membrane. 
 
5.3.2.2. Protein detection 
After transfer, the membrane was blocked with blocking buffer (see below) for at least 1h. 
The blot was then incubated overnight at 4°C with the primary antibody dissolved in 
blocking buffer. Excess of primary antibody was removed by washing the membrane 3 
times for 15min with blocking buffer at 25°C. The membrane was incubated with 
secondary antibody diluted in blocking buffer for 2h at 25°C. Signals were detected using a 
chemiluminescence kit, followed either by exposure of the membrane to either light-
sensitive films and subsequent developing using a Kodak X omat M35 developing 
machine, or by exposure to a fluorescent image reader. In the latter case the images were 
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acquired using the Fujifilm Mini-LAS300 System (Fujifilm Life Sciences) and quantified 
using the MultiGauge ScienceLab2005Ver3 (Fujifilm Life Sciences).  
 
Blocking buffers 
2% (w/v) milk in 1x PBS 
5% (w/v) milk in 1x TBS-Tween20 
2% (w/v) BSA in 1x TBS-Tween20 
 
 
5.4. TANDEM AFFINITY PURIFICATION (TAP) 
 
TAP purification allows a rapid and clean purification of native protein complexes using a 
combination of two different tags, Protein A and calmodulin binding protein (CBP), 
separated by a TEV-cleavage site. 
 
 
 
 
 
 
 
5.4.1. Cell harvest and lysis  
For purification of native protein complexes of S. cerevisiae (Puig, Caspary et al. 2001), a 2 
l culture of an OD600 of 3,5 was harvested (2min, 5000rpm). Cells were washed with 
ddH2O, followed by a second washing step with 25ml 1xTAP buffer  supplemented with 
1xProteaseInhibitor (1xPI) cocktail (for recipe see below). Cells were then frozen in liquid 
N2. An equal volume of 1xTAP buffer (also containing 1 mM DTT) and a double volume 
of glass beads were mixed with the cells in a bead mill, and lysed by the following milling 
protocol: 3x [4min, 500rpm, 2min break]. The glass beads were removed and washed once 
with 1xTAP buffer, so that the final volume of the lysate was 25ml. After centrifugation for 
10min at 4°C and 4000rpm, the supernatant was subjected to ultracentrifugation for 1h at 
100000g and 4°C using an SW32 rotor. The top fatty phase was removed by aspiration 
and the clear lysate was collected. For storage, 5% (v/v) glycerol was added to the lysate 
and the lysate was frozen in liquid N2. 
 
1x Elution Buffer 
10mM Tris-HCl pH 8.0  
5mM EGTA 
1x TAP Buffer 
100mM NaCl 
50mM Tris-HCl pH 7.5 
1.5mM MgCl2 
0.15% NP-40 
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1xProteaseInhibitor (1xPI) cocktail 
0.028 mg/ml Leupeptin 
0.137 mg/ml Pepstatin A 
0,017 mg/ml PMSF 
0.33 mg/ml benzamidine 
Dissolved in 100% EtOH p.a. 
 
5.4.2. Purification and TCA precipitation 
For purification, 0.4ml IgG-sepharose were washed 3x in 1xTAP buffer (2min, 1800rpm, 
4°C) and were then added to the lysate. After incubation for 1h at 4°C, the beads were 
centrifuged down and transferred to a mobicol column, containing a 35μm filter. The 
beads were washed by gravity flow with 10ml 1xTAP buffer containing 0.5mM DTT. To 
cleave off the protein complex from the IgG beads, 6μl of TEV protease and 150μl 1xTAP 
buffer plus 0.5 mM DTT were added to the mobicol and incubated for 1h and 20min at 
19°C. For elution, the column was centrifuged for 1min at 2000rpm. During the TEV 
cleavage, 0.5ml of calmodulin beads were washed 3x with 1xTAP buffer containing 1mM 
DTT and 4mM CaCl2. After removal of surplus buffer, the beads were incubated with 
150μl 1xTAP buffer containing 1 mM DTT and 2 mM CaCl2 on ice. For calmodulin 
binding, the 150μl TEV eluate were added to the activated calmodulin beads and 
incubated for 1h at 4°C. The reaction was then washed with 7.5ml of 1xTAP buffer plus 
1mM DTT and 2mM CaCl2. To elute the protein complex, the beads were incubated in a 
thermomixer at 37°C for 2x; each 7.5min in 1xElution Buffer. The eluate was obtained by 
centrifugation for 1min at 2000rpm. To concentrate the samples, TCA was added to a 
final concentration of 10% (v/v) and the samples were incubated for 20min on ice. After 
20 min centrifugation at 16000g and 4°C, the pellet was resuspended in 60μl 1xSB. The 
resulting solution was neutralized by the addition of 1M Tris-Base, denatured and 
subjected to SDS-PAGE. 
 
 
5.5. CHROMATIN IMMUNOPRECIPITATION (CHIP) 
 
For analyzing the occupancy of RNApolII and the proteasome on the genes, ChIP was 
performed essentially as described (Kuras and Struhl 1999; Strasser, Masuda et al. 2002).  
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5.5.1. Cell preparation and lysis 
An over night saturated culture was diluted to 0.2 OD600. The culture was grown at 30°C 
and 120rpm until it reached mid-log phase (OD600 0.7-0.8). Protein crosslinking was 
achieved by the addition of 1% (v/v) formaldehyde to the culture and slowly shaking at 
room temperature for 15min. The crosslinking reaction was stopped by addition of 
375mM Glycine and further incubation for 20min. Cells were harvested by centrifugation 
(4000g, 5min, 4°C) and washed 2x with cold 1xTBS and 1x with 1xFA lysis buffer 
supplemented with 1xPI cocktail. Cell pellets were frozen in liquid N2 and stored at -80°C. 
For lysis, the crosslinked cells were resuspended in 1ml of 1xFA lysis buffer and mixed with 
an equal volume of glass beads. The mixture was vortexed at full speed for 6x [3min vortex, 
3min on ice]. The lysate was sonicated in a BioruptorTM UCD-200 (Diagenode) using 
25x30 sec cycles with 30sec breaks at an output of 200W to produce chromatin fragments 
of average size 200bp. Cell debris were removed with a 16000g centrifugation at 4ºC. 
Protein concentration was assessed by measuring absorbance of the lysate at 280nm (A280).  
 
5.5.2. Immunoprecipitation, elution, protein degradation and DNA purification 
For precipitation, 3A280 units (for RNApolII) or 18A280 units (for Proteasome) were 
incubated with 15μL IgG-coated Dynabeads M280 in a total volume of 1.2mL 1xFA lysis 
buffer for 3.5h at 20 ºC or O/N at 4ºC, respectively. After immunoprecipitation, the 
samples were washed as previously described (Kuras and Struhl, 1999). 
1x FA lysis buffer 
50mM HEPES-KOH pH to 7.5 
150mM NaCl 
1mM EDTA 
1% Triton X-100 
0.1% sodium deoxycholate 
0.1% SDS 
 
1x FA (high NaCl) lysis buffer 
50mM HEPES-KOH pH to 7.5 
0.5M NaCl 
1mM EDTA 
1% Triton X-100 
0.1% sodium deoxycholate 
  
1xTLEND 
10mM Tris-HCl pH 8.0 
0.25M LiCl 
1mM EDTA 
0.5% Nonidet P-40 
0.5% SDS 
 
ChIP elution buffer 
50 mM Tris·Cl pH 7.5 
10 mM EDTA 
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Immunoprecipitated material was eluted from the beads with 1xChIP elution buffer by 
incubating the samples for 20min at 65 °C and reversal of the crosslink was achieved by 
incubation with 400μg pronase O/N at 65°C. The DNA was purified using the 
Nucleospin extract II (Macherey & Nagel) kit with a final elution volume of 50μL. 
Immunoprecipitated DNA was subjected to PCR analysis.  
 
5.5.3. Amplification of precipitated DNA by PCR 
 
For determining the amount of the purified protein in a specific genomic region, the 
precipitated chromatin was subjected to quantitative Real-Time PCR (qPCR) with primers 
directed against specific genomic regions. Briefly, qPCR was performed on an ABI Prism 
7000 machine (Applied Biosystems). The PCR reactions were carried out in 20μL 
containing 1xPolymerase buffer (Axon), 1.5mM MgCl2, 0.2mM dNTPs, 0.5μM each 
primer, 1:50.000 diluted SYBR Green I Nucleic Acid dye (Roche) and 1U of Taq 
polymerase (Axon). Relative quantification using a standard curve method was performed 
and the occupancy level for a specific fragment was defined as the ratio of 
immunoprecipitated DNA over total DNA. The NTR ChrV 174137-174447 region was 
used as a negative control. Primers used are listed in Table 6.  
 
5.5.4. Coupling of beads 
Coupling of Tosyl-Activated Dynabeads M280® (Invitrogen) to IgG antibody was done 
according to the manufacturer’s protocol.  
 
 
5.6. ANALYSIS OF RNA POLYMERASE II UBIQUITYLATION 
 
For assessing the ubiquitylation of RNApolII, strains that carried a TAP-tagged version of 
Rpb3 were used to purify RNApolII. Briefly, 100 OD600  of logarithmically grown cells 
were pelleted and resuspended in 1xLysis Buffer. Cells were lysed in an equal volume of 
glass beads by vortexing at full speed for 5x [3min vortex, 3min on ice]. After 
centrifugation for 30min at 16000g and 4ºC, the clear lysate was collected for 
immunoprecipitation. For each reaction, 50μL of IgG slurry (pre washed 3x with 1xLysis 
buffer) was incubated with the lysate for 2h at 4ºC. The samples were then washed at least 
4x with 1xLysis Buffer and proteins bound were eluted by addition of equal volume of 2X 
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SB and incubation for 3min at 65 ºC. The precipitated proteins were subjected to western 
blotting and blots were probed with anti-ubiquitin (see Table 7) antibodies.  
 
 
 
 
 
 
 
 
 
5.7. QUANTIFICATION OF mRNA LEVELS  
 
5.7.1. RNA extraction  
RNA was extracted from yeast as previously described (Köhrer and Domdey, 1991).  
 
5.7.2. cDNA synthesis and qPCR 
The extracted RNA was subjected to first strand cDNA synthesis using oligo-dT as primer 
and the M-MuLV Reverse Transcriptase (Fermentas). Reaction was carried out according 
to the Fermentas instructions. The cDNA was then analyzed by Real-Time PCR on an 
ABI Prism 7000 machine (Applied Biosystems). Reactions were performed as mentioned 
above for the ChIP. Relative quantification using a standard curve method was performed 
and the relative mRNA level of Rpb1 or Rpb3 was defined as the ratio of the Rpb1 or 
Rpb3 mRNA over the Adh1 or Act1 mRNA. Primers used are listed in Table 6. 
 
 
1x Lysis Buffer 
100mM NaCl 
50 mM Tris-HCl pH 7.5 
1.5 mM MgCl2 
0.15% NP-40 
 
2mM N-ethylmaleimide 
20μM lactocystine 
1x PI cocktail 
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7. ABBREVIATIONS  
 
6AU 6-Azauracil 
Ǻ Angstrom 
ATP adenosine triphosphate 
bp basepair 
°C degree centigrade 
ChIP Chromatin Immuno Precipitation 
CTD C-Terminal Domain of the largest RNAPII subunit 
d  day 
Da  dalton 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleosid triphosphate 
E. coli Escherichia coli 
ECL enhanced chemoluminiscence 
et al. et alli (Latin and others) 
5’-FOA 5-Fluoorotic Acid 
g gram 
GGR Global Genome Repair 
h hours 
kDa Kilo Dalton 
L litre 
LB Luria-Bertani 
M molar 
min minute 
MDa Mega Dalton 
mRNA messenger RNA 
NER Nucleotide Excision Repair 
nt nucleotide 
OD optical density 
ORF Open Reading Frame 
PAGE polyacrylamide gelelectrophoresis 
PBS Phosphate-buffered saline 
PBST PBS with 0.1 % Tween 20 
PCR Polymerase Chain Reaction 
pH potential of hydrogen 
RNA ribonucleic acid 
RNAP RNA Polymerase  
qPCR quantitative PCR 
rpm  rotation per minute 
rRNA ribosomal RNA 
RT room temperature 
RT-PCR Reverse Transcription PCR  
S Svedberg 
SDS Sodium Dodecyl-Sulphate 
SL Synthetic Lethal 
snoRNP small nucleolar RNP 
TAP Tandem Affinity Purification 
TBS Tris-buffered saline 
TBST TBS with 0.1 % Tween 20 
TCA Trichloroacetic Acid 
TCR Transcription Coupled Repair 
TEV Tobacco Etch Virus 
TREX Transcription/Export complex 
tRNA transfer RNA 
ts temperature sensitive 
UPP Ubiquitin Proteasome Pathway 
μ micro 
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